var title_f27_38_28256="Hulka uterine manipulator";
var content_f27_38_28256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hulka uterine manipulator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This type of manipulator does not allow injection of dye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28256=[""].join("\n");
var outline_f27_38_28256=null;
var title_f27_38_28257="Scorpion fluorescence";
var content_f27_38_28257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scorpion exhibiting fluorescence under ultraviolet light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28257=[""].join("\n");
var outline_f27_38_28257=null;
var title_f27_38_28258="Bronchiectasis CT II";
var content_f27_38_28258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiectasis with marked airway dilatation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HRCT shows clustering of markedly dilated airways in both upper lobes (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Barker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28258=[""].join("\n");
var outline_f27_38_28258=null;
var title_f27_38_28259="Gadoteridol: Patient drug information";
var content_f27_38_28259=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gadoteridol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/15/4341?source=see_link\">",
"     see \"Gadoteridol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ProHance&reg;;",
"     </li>",
"     <li>",
"      ProHance&reg; Multipack&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, this drug may cause a very bad health problem. Call your doctor right away if you have joint stiffness, muscle weakness, very bad bone pain in the hips or ribs, yellow eyes, or very bad skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during an MRI (magnetic resonance imaging) test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gadoteridol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain in the hips or ribs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11744 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-E320E62127-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28259=[""].join("\n");
var outline_f27_38_28259=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175126\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029177\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029179\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029178\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029182\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029183\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029185\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029181\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029187\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/15/4341?source=related_link\">",
"      Gadoteridol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28260="Neostigmine: Patient drug information";
var content_f27_38_28260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neostigmine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     see \"Neostigmine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/38/44644?source=see_link\">",
"     see \"Neostigmine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prostigmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prostigmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myasthenia gravis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get back function in muscles after surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neostigmine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703775",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bowel block or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11397 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-48A44A7773-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28260=[""].join("\n");
var outline_f27_38_28260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200742\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200743\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015719\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015718\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015723\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015724\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015726\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015721\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015722\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015727\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015728\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=related_link\">",
"      Neostigmine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/38/44644?source=related_link\">",
"      Neostigmine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28261="Screening for testicular cancer";
var content_f27_38_28261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for testicular cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28261/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28261/contributors\">",
"     Kenneth W Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28261/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28261/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28261/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28261/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/38/28261/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2303345\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer is the most common malignancy in males between the ages of 15 and 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the incidence of testicular cancer has been increasing over the past three decades in the US and worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], it still accounts for only about 1 percent of cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/1\">",
"     1",
"    </a>",
"    ], and its prognosis with treatment is generally excellent.",
"   </p>",
"   <p>",
"    This topic will review issues related to screening for testicular cancer, including the lack of evidence that screening improves currently favorable outcomes for this disease. The epidemiology, clinical manifestations, and treatment for testicular cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18074155\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2013, approximately 7920 men in the United States will receive a diagnosis of testicular cancer, and 370 men will die of it [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/5\">",
"     5",
"    </a>",
"    ]. The age-adjusted incidence and death rates of testicular cancer were 5.5 cases and 0.2 deaths per 100,000 men per year. Worldwide, the incidence and death rates for testicular cancer were similar: 4.6 cases and 0.3 deaths per 100,000 men per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/6\">",
"     6",
"    </a>",
"    ]. In the US, more than 95 percent of men diagnosed with testicular cancer from 2001 to 2007 were alive five years later, with more than 200,000 testicular cancer survivors at the beginning of 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/7\">",
"     7",
"    </a>",
"    ]. These statistics reflect the excellent prognosis of testicular cancer with treatment, even in advanced stages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2303352\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer occurs most commonly in younger men, with almost half the cases occurring between ages 15 and 35 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/1\">",
"     1",
"    </a>",
"    ]. Well-established risk factors for testicular cancer include a history of an undescended testis, a familial history of testicular cancer, or a history of contralateral testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies investigating the contribution of prenatal and later environmental exposures to testicular cancer risk have yielded inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/9\">",
"     9",
"    </a>",
"    ]. There is some suggestion that infertility is a risk factor for testicular cancer. A cohort study of more than 50,000 couples evaluated for infertility in California between 1967 and 1998 found that men with male factor infertility were more likely to develop testicular cancer than men without infertility (HR 2.8, 95 % CI 1.3-6.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/10\">",
"     10",
"    </a>",
"    ]. However, given the low incidence of testicular cancer, a testicular mass found during an infertility evaluation is far more likely to be benign than malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testicular microlithiasis is a common finding during infertility evaluations, but its association with testicular cancer is controversial. Microlithiasis has been detected with scrotal ultrasonography in up to 5 percent of healthy adolescents and young men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\", section on 'Testicular microlithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112467561\">",
"    <span class=\"h1\">",
"     SYMPTOMS, STAGING, AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common presentations of localized testicular cancer include a mass in the testicle or scrotum (with or without tenderness), testicular firmness, and scrotal heaviness. Metastatic disease may cause gynecomastia, gastrointestinal symptoms, or respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are multiple types of testicular tumors (",
"    <a class=\"graphic graphic_table graphicRef81626 \" href=\"UTD.htm?43/42/44715\">",
"     table 1",
"    </a>",
"    ). About 95 percent of testicular cancers are germ cell tumors, divided equally into seminomas and non-seminomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/15\">",
"     15",
"    </a>",
"    ]. Non-seminoma subtypes include embryonal carcinomas, teratomas, yolk sac tumors, and choriocarcinomas. Prognosis is based upon clinical stage, type of tumor, and levels of serum tumor markers (alpha fetoprotein [AFP], human chorionic gonadotropin [hCG], and lactate dehydrogenase [LDH]). Stage I testicular cancers are confined to the testis, stage II cancers involve the retroperitoneal or para-aortic lymph nodes, and stage III cancers have spread beyond the retroperitoneal nodes (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testicular germ cell tumors are one of the most curable solid neoplasms, with an overall cure rate greater than 90 percent. Even tumors with the poorest prognosis (stage III nonseminomas) have a five year survival rate exceeding 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment is determined by the histologic type of tumor and disease stage. High cure rates for Stage I seminoma and nonseminomatous germ cell tumors are achieved by radical orchiectomy, which may be followed by surveillance, radiation therapy, or single agent chemotherapy. Treatment for more advanced disease or histology may involve radiation, chemotherapy, or retroperitoneal lymph node dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2303359\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of cancer screening is to detect asymptomatic tumors at early stages, to increase the potential for cure, or to minimize treatment-related morbidity. Whether screening can achieve these aims with reasonable cost-effectiveness and minimal harm will depend upon numerous factors: the sensitivity and specificity of available screening tests, the disease incidence, comparative treatment outcomes when initiated at early and later disease stages, harms associated with false positive tests, and the potential for overdiagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20186674\">",
"    <span class=\"h2\">",
"     Testicular palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, periodic palpation of the testes by men themselves (self-examination) or by clinicians (clinical examination) may lead to detection of testicular cancers before they cause noticeable symptoms. In the past, clinicians were encouraged to teach adolescent and adult males testicular self-examination techniques, which consist of using the thumb, index, and middle fingers to palpate for lumps, hardness, or swelling of the testicles at periodic (eg, monthly) intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are no studies of the sensitivity or specificity of either the clinical or self-examination for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20186681\">",
"    <span class=\"h2\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no biomarkers for testicular cancer have been used as screening tests. Although serum levels of alpha fetoprotein (AFP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the beta subunit of human chorionic gonadotropin (beta-hCG) are elevated in 80 to 85 percent of men with nonseminomatous testicular cancer, neither serum beta-hCG nor AFP alone or in combination have sufficient sensitivity or specificity to be used for screening or diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Serum tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One small study suggests the potential of the",
"    <em>",
"     XIST",
"    </em>",
"    gene, responsible for X chromosome deactivation and abnormally unmethylated in some men with germ cell tumors, for use as a marker for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/18\">",
"     18",
"    </a>",
"    ]. However, there have been no studies of the identification of unmethylated",
"    <em>",
"     XIST",
"    </em>",
"    genes for screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2303366\">",
"    <span class=\"h1\">",
"     RISKS AND BENEFITS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 systematic review found no randomized trials comparing screening versus no screening for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/19\">",
"     19",
"    </a>",
"    ]. The low incidence and high cure rate of testicular cancer make it unlikely that screening for testicular cancer would appreciably decrease the cancer mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, most tumors currently diagnosed are Stage I so there is limited potential that screening would spare treatment-related morbidity associated with more advanced disease. On average, a primary care physician who performed routine screening examinations could expect to diagnose one patient with testicular cancer every 20 to 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential harms of screening for testicular cancer include false-positive results, anxiety, and adverse effects of diagnostic tests or procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/22\">",
"     22",
"    </a>",
"    ]. Opportunity costs (time and effort required by patients and the health system) of screening are also a consideration. A 2010 review for the US Preventive Services Task Force (USPSTF) found no new evidence to quantify either the frequency or magnitude of these potential harms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of uncertain benefits and some likelihood of harms, we suggest NOT screening asymptomatic adolescents or adult males for testicular cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2303373\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the low incidence of testicular cancer, the highly favorable treatment outcomes even in advanced disease, and potential harms associated with screening, the USPSTF has reaffirmed its previous recommendation statement discouraging screening for testicular cancer with clinical or patient self-examination in adolescent and adult males [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Family Physicians and the American Academy of Pediatrics do not recommend screening for testicular cancer in asymptomatic males [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The American Cancer Society considers the testicular examination to be part of a periodic cancer-related checkup, but does not recommend teaching patients self-examination techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/25\">",
"     25",
"    </a>",
"    ]. The European Association of Urology recommends self-testicular examination for individuals with clinical risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28261/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=see_link\">",
"       \"Patient information: Varicocele (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2303380\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of testicular cancer, although increasing over the past three decades, is low and accounts for only about 1 percent of cancers in men. Testicular germ cell tumors are one of the most curable solid neoplasms, with an overall cure rate greater than 90 percent. Even tumors with the poorest prognosis (stage III nonseminomas) have a five-year survival rate exceeding 70 percent. (See",
"      <a class=\"local\" href=\"#H2303345\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H112467561\">",
"       'Symptoms, staging, and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While periodic palpation of the testes may detect testicular cancers before they cause noticeable symptoms, there are no studies of the sensitivity or specificity of either the clinical or self-examination for testicular cancer, and no evidence has shown that routine screening for testicular cancer through periodic clinical examinations or self-examinations would improve health outcomes. The low incidence and high cure rate of testicular cancer make it unlikely that screening for testicular cancer would appreciably decrease the cancer mortality rate. (See",
"      <a class=\"local\" href=\"#H2303359\">",
"       'Screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT screening asymptomatic adolescents or adult males for testicular cancer by either self-examination or periodic clinical examination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, clinicians and patients should be aware of common presenting symptoms of testicular cancer. (See",
"      <a class=\"local\" href=\"#H2303366\">",
"       'Risks and benefits of screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/2\">",
"      McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/3\">",
"      Townsend JS, Richardson LC, German RR. Incidence of testicular cancer in the United States, 1999-2004. Am J Mens Health 2010; 4:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/4\">",
"      Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/5\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/6\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD 2011. Available at: file://seer.cancer.gov/statfacts/html/testis.html (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/8\">",
"      Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol 2004; 22:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/9\">",
"      Richiardi L, Pettersson A, Akre O. Genetic and environmental risk factors for testicular cancer. Int J Androl 2007; 30:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/10\">",
"      Walsh TJ, Croughan MS, Schembri M, et al. Increased risk of testicular germ cell cancer among infertile men. Arch Intern Med 2009; 169:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/11\">",
"      Eifler JB Jr, King P, Schlegel PN. Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively. J Urol 2008; 180:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/12\">",
"      Toren PJ, Roberts M, Lecker I, et al. Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care? J Urol 2010; 183:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/13\">",
"      Peterson AC, Bauman JM, Light DE, et al. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. J Urol 2001; 166:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/14\">",
"      Shaw J. Diagnosis and treatment of testicular cancer. Am Fam Physician 2008; 77:469.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute. Testicular cancer treatment (PDQ) summary: health professional version. National Cancer Institute, Bethesda, MD 2011. Available at: file://www.cancer.gov/cancertopics/pdq/treatment/testicular/HealthProfessional (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/16\">",
"      van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006; 42:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/17\">",
"      Lin K, Sharangpani R. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/18\">",
"      Kawakami T, Okamoto K, Ogawa O, Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004; 363:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/19\">",
"      Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev 2011; :CD007853.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute. Testicular cancer screening (PDQ) summary: health professional version. National Cancer Institute, Bethesda, MD 2011. Available at: file://www.cancer.gov/cancertopics/pdq/treatment/testicular/HealthProfessional (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. U.S. Preventive Services Task Force. In: Guide to Clinical Preventive Services, 2nd ed, US Department of Health and Human Services, Washington, DC 1996. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/22\">",
"      U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2011; 154:483.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Summary of Recommendations for Clinical Preventive Services. Leawood, KS 2011. Available at: file://www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/CPS/rcps08-2005.Par.0001.File.tmp/May2011CPS060611.pdf (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28261/abstract/24\">",
"      American Academy of Pediatrics Committee on Practice and Ambulatory Medicine and Bright Futures Steering Committee. Recommendations for preventive pediatric health care. Pediatrics 2007; 120:1376.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. American Cancer Society guidelines for the early detection of cancer. Atlanta 2011. Available at: file://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     Guidelines on Testicular Cancer. European Association of Urology. file://uroweb.org/gls/pdf/Testicular%20Cancer%202010.pdf (Accessed on September 23, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16286 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28261=[""].join("\n");
var outline_f27_38_28261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2303380\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303345\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18074155\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303352\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112467561\">",
"      SYMPTOMS, STAGING, AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303359\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20186674\">",
"      Testicular palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20186681\">",
"      Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303366\">",
"      RISKS AND BENEFITS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303373\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2303380\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/42/44715\" title=\"table 1\">",
"      Testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 2\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 3\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=related_link\">",
"      Patient information: Varicocele (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28262="Tetracycline: Pediatric drug information";
var content_f27_38_28262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetracycline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"    see \"Tetracycline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/16/7429?source=see_link\">",
"    see \"Tetracycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tetra&reg;;",
"     </li>",
"     <li>",
"      Nu-Tetra",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Tetracycline Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"      see \"Tetracycline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;8 years: 25-50 mg/kg/day in divided doses every 6 hours; not to exceed 3 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: 250-500 mg/dose every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer 1 hour before or 2 hours after meals with adequate amounts of fluid; avoid taking antacids, calcium, iron, dairy products, or milk formulas within 3 hours of tetracyclines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Small amount of ointment should be applied to cleansed affected area.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Use of outdated tetracyclines has caused a Fanconi-like syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children, Adolescents and Adults: Treatment of Rocky Mountain spotted fever caused by susceptible",
"     <i>",
"      Rickettsia",
"     </i>",
"     or brucellosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: Presumptive treatment of chlamydial infection in patients with gonorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;8 years, Adolescents and Adults: Treatment of moderate to severe inflammatory acne vulgaris, Lyme disease, mycoplasmal disease or",
"     <i>",
"      Legionella",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tetracycline may be confused with tetradecyl sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Achromycin may be confused with actinomycin, Adriamycin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F226344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels in infants, increased intracranial pressure, paresthesia, pseudotumor cerebri",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, photosensitivity, pigmentation of nails, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, antibiotic-associated pseudomembranous colitis, diarrhea, discoloration of teeth and enamel hypoplasia (young children), esophagitis, nausea, pancreatitis, staphylococcal enterocolitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, azotemia, renal damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, candidal superinfection, hypersensitivity reactions, superinfection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetracycline or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal and liver impairment; dosage modification required in patients with renal impairment; outdated drug may cause nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Use of tetracyclines during tooth development may cause permanent discoloration of the teeth (yellow-gray to brown) and enamel hypoplasia; adult-onset tooth discoloration following long-term administration of tetracyclines has also been reported. Do not administer to children &lt;8 years of age due to permanent discoloration of teeth and retardation of skeletal development and bone growth (risk being greatest for children &lt;4 years and in those receiving high doses). Tetracyclines have been associated with increases in BUN secondary to antianabolic effects. Pseudotumor cerebri has been reported rarely in infants and adolescents; use with isotretinoin has been associated with cases of pseudotumor cerebri; avoid concomitant treatment with isotretinoin. Photosensitivity reaction may occur; avoid prolonged exposure to sunlight or tanning equipment; discontinue if skin erythema occurs. Prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembraneous colitis. Tetratcycline can cause fetal harm if used during pregnancy; avoid use during pregnancy. Hepatotoxicity has been reported rarely; risk may be increased in patients with pre-existing hepatic or renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F226334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Tetracycline may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines decrease absorption of magnesium, zinc, calcium, dairy products, iron, and amino acids; calcium, dairy products, iron supplements decrease tetracycline absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F226294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. The pharmacokinetics of tetracycline are not altered in pregnant patients with normal renal function. Hepatic toxicity during pregnancy, potentially associated with tetracycline use, has been widely reported in the literature. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas, 2011; Whalley, 1966; Whalley, 1970).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal, hepatic, and hematologic function tests; observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding to the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria preventing additions of amino acids to the growing peptide chain; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed to most body fluids and tissues including ascitic, synovial and pleural fluids; bronchial secretions; appears in breast milk; poor penetration into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Poor, with less than 60% of dose absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 6-12 hours with normal renal function and is prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primary route is the kidney, with 60% of a dose excreted as unchanged drug in urine, small amounts appear in bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/16/7429?source=see_link\">",
"      see \"Tetracycline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor nails. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 25 mg/mL oral suspension may be made using capsules. Empty the contents of six 500 mg capsules into mortar. Add a small amount (~20 mL) of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in geometric proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable 28 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics. Committee on Drugs. &ldquo;Requiem for Tetracyclines,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1975, 55(1):142-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/38/28262/abstract-text/122864 /pubmed\" id=\"122864 \" target=\"_blank\">",
"        122864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12830 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-190.81.197.98-7F1581CBCC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28262=[""].join("\n");
var outline_f27_38_28262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226309\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050206\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050198\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226268\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050209\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050202\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050208\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226344\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050212\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050197\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050196\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226334\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226277\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050214\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226280\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226294\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050205\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050195\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050211\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050204\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806665\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=related_link\">",
"      Tetracycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/16/7429?source=related_link\">",
"      Tetracycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28263="Sonogram abn ut bleeding3";
var content_f27_38_28263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75181%7EOBGYN%2F60457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75181%7EOBGYN%2F60457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal pelvic sonogram of a patient with abnormal uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The central uterine echo measures 9 mm and appears relatively homogeneous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline infusion sonography of a patient with uterine bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 276px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEUAXQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhr35v2T7D/Z11v/QK8Or3N8v+ydEeu3Xj+HyCvDK0nsjKl1Ot+F+o2WneLIxqdwLWzuoJbOS4IJEIkUrvIHJAz0r0i68VaJ4f0vxFoOn62dQjGlQ2lndQKyLM4m8w4H8OASPwrwoHFOBI5zzVwrOMeUzq4aNSfP1PsPT/AIo+G9LvW1x/GR1B20vybbTmtWAtpQg43d8sMHNcNZeJfD+t3c2u3WsTjWbXz3iszAX8/wA5cP8ANxjbuP5V87b2xgk4pY5XjcNG7Kw6EHBrSNdR6GM8FzK1/wCtj6H8QeKvCd5H4f8ADt/eS+JLKynN5c398pt5vKVG/wBFGecdMYPWsmX4i+F9U8P6FPexXVpqPh52hsbNAZEkiZwdzPxgqvGO+K8Pnnknk3yuXb1PJqPNT7ZJ3SKWETVpPc+g0+JnhvwrZnSfCt/qlxp13IJLqaSIRyBXZvNUDPPynj3rW+H3xc8G+D5Fe0/ti4Y5sm82NB/oys7RsMH7+WGfxr5myaMniiWIclZoI4KEHzJu59OXn7SJj03RotMtpbe5huQ98xjRhNFuOQM9GIIyfWuG+MPi34feMY7zVdMsddh8Sz7APMaP7OoHB4HPSvHCx45pDUSq36GscOotO+wd6ns7aS7nWKFcsT17D3NSWNp9pLl38uNBuZiM/hXT2fkQRH7FMqq4HATJHvmro0OfWWxOIxPs1aO53fwi8OW2n6ql8JBLeQLv34yqduK+x/Dt41zp0LySxksg+63O7uTXxd4L8QT6XI4+dEcYkKHAYe9fQngnxppUthBAbYZkbbt5yw67vavSqUYzpKMEfPQxE6ddzqO/9eR7Df2cGo2b290gkRl5B6fWvJtVSfw7P9jaIrYGTHygvgY+9kgZNepQ3sE0Ky280ZhQ7WUHPQdPrTrk297HsVkLN14BYDvwfauGhVlQdmtPyPUxVGGJXMnZr8ThdQs7qTQHS8mN/C8X76GbBjAJ+UD0PfNeQ+OfhTpeuaUt14Xj850OySBjiUMP7hPDD2r3nVvCrHS7gaTcSo8h3tExysg67fauY2qqpZz2n2CQOBtwSrns2exBFdtOUKqaR51WnUoSTa/E+OfEHw+1PSLtreeJoZgceVcDy3PuM9fwrm7nR7y2fbNbygc844Nfel+s95YxJqFna6sF3I8dzGsq8c5VuoPtWVceB/DM9tBPJ4ajkEhwskLtCApOOh6GsJYaPb8TshjprS9/Vf5Hw7b6Vd3GPJtZm7ZCnFaul+EdT1GcRQ2zZY4Gf5V9r6N8O/Btp5qp4eLBn+UyTu+8jqK0obLT9GtLuXSNOtrQQy7PMgg3yDtjLdDWcKEb2aNJ42drpr8f+AfOXgD4L3jzx3Wo2kiBMM0l0uIwPYfxGvfNH0nTtKS4i0pG+2LGJDcE4Zl/ujt07U7U7tNQunC37PPF8rIWPDngBc/54qreLcRQpZtLcQLtUu4Xedx7Z7V306aStsePWqyqS5pO5evLaVYoGuLxrRZjxvG5lHof8azJoLfVrz7JBHKZA2EkXAWMf3iOc9DU6afqV5cQLYozqyjdePzlc8cegrstA0GHTISiNhN25nkAy7dyPb0oqVo0lq9SaWHlVei0NbTbKHS9PjihI3BAMhev4V5/4lhiPn3t0Wa3jcs29wUdh0wDW/q3iCOW8eCOd4YkQ4YJ8u73P+FeWeLzFfaQyNPN5ynOwkgY9cE1nhaM03OW7N8dWpytTp7I+ffihpljJfveadbvEzEmTaMIeewrz2a2lhCGWN0DjKlhjNfTEvhNn0a2tUWNgz+YXPOSe+K6K2+E8eoRQ29xbRXULN87qOcew7Uq+EU25N2NcJmcqUVTtzfmfH5GCRQMZ5Br6K+KX7O97pMX27wlKb62ClpreQhZIsDPH97+dfPVzby20jRzIyOpwQwwQa8qUGtT6ClXjU0W/Yh4pKWiszYKKO1FABRSUUALSUUUALXSeBBv1S9j/v2FyP8AyGT/AErm+wro/ARH/CQhOMvbzJyPWNq2w/8AFicuN/gT9Gc+srqpVXYL6A0PI8h/eOzfU5rufB/wp8U+LfD0utaNa272KM6b5LhUJKjJAB5NY3gnwfqnjHWZNN0j7MLiONpXNxMIkVVODlj9ai0tjbnhqc8JHAwHYD60V3J+FHi+S4uY7TS2vUt5mgaa1Pmxll64YcGiq9nPsR7al3R29v8AN+ydP/sa9/7IteGnI4Ne46Ojz/sqauqKzGPW0Y7QTgbV5rw40T2QUevqJS0lFZG4tFFJTAKWiigAqQQyNEZRG/lA7S4U7QfTNNAyOBk1vWFjrEtmHto5YrVmOWXhScYP6VpCnzOxlVqqmrtpepz4BPArU0/TvMZWmVnRh/yz5IPvWq3hoxwBy+WPXjpU+jW6W8pMh2RlhgA5/GuqlhuV++cdXGxlBumyOK0jVG84MYjwcdR71NDaKs8YtSzR9iprqZdAeWyleJ2ZGXONpxz71XtbCSAxpIigHA3fdx7+9d3smjyXjFJNp/I0tE0aW/lW2ClJGBIBcAMBXU+H5ryyeWBlSaeNgoBYBgBxnNb/AIS8JQDTUuppZEVXG9lTcQPp1q3rfhyzlvT/AGWS0zMQwkO0YAzuPv7V0KNtjzXJy1Z0OgmcMLiC+kS44lng2fJnHUD1966vTvFFvJDLceV58qHy/Njk/e8f3vWsHwXDPZwGGeG3LuoEExJwAP73TP0qzbaCrW5vkKxXImy6oCFB7Ed8GomoydpGtOUoq8Wdxp3iS2VokllmMroPlZflJ9sdK35lt7212zLkN1A6j8RXki3NxbFbiWxeVQSZZUbYVBPr+Faltqt5YbX09pEe7b91HO+9WXrw3rXJVwabvDRnoUMwlFctTVHeQ6NBChFpIVDDB3fPkfjVWSxv7e93wSo0GNpRicADGOPXrWfp+u6hEIoryOH7VIThGUx8+mela2majPfSTRSW09u8RGWyGXPpnvXPKNWF3KzR1Rlh6llBNPyKUk2qGOdU08mGIBot7YZ2zyCB2rJ1XS9f1C1KxwQwRzSBng83aVPc8da7KS5kVkBRRuHXcMjFZ9xrMVtPmR4hn7w3k4Hr0ohUn9iKCpSpLSc3+Rhaf4SuY7xZbl4nhj3FAUG8MTwfTiti28NWEDN5zmRPvFHcn5/7x561YbW4d235idu4KnDH6A9a5m61+5s7uRJ4zja0igKTkdADx1z6Va+sVd3YxlLC0LNLm9Trbi4sLCBYiY4kzhVBwK5HU9bkub+eBp1is4sEyBSS/suPWufnF/r0Mdy9rI8MshVdw2kkdQfatHTdM8i2lN75Qk5AixnYAf4jXRTw8KesndnJXxc62iVkZuv67f3ViIEtIv7LkQkNja+QfzFc/a2MdxDCWt/tfmjGJX5I+vXFdVfwz3EBePyWRMASRHj/AHQP89a0fD2l3cKxyyW4VJBh1mYZjX2xXVzQpxORqVWWpU8OaFazzwyzf6qPgjGBn0FdHqN8I7qBbJkhi7CPq/qD7VU1LVoNKheD7PE6g5CkY3e9cw3iFDq1vFZmIM7Zm4CCNfWsOSVWXPJadDbnVKPJF69e52uTqJayuMMpTdvXnB9Sa8c/aC+H+h6nBbXC7YNUigI88EJ5mMYLjHOK7Sbxva6fqbRiEOg5eRWAJH1715/8SPED+KtWDWVsUgiUDJ6kepNSqEua0l7v6lfWEo80X73fyPlfVNLuNNmaOdTgdHCnBHrms8jBr6VstHs9VRxMIpzja8Ld+PWuI8Z/CuRfMu/D6OQf+XNhz9EPeuevl8ormp6o9PC5xCfu1tH36f8AAPIaDU95aXFnO8F1C8MqEqyOMEEVBivNatoz2k01dCUUtJSGFFFFAC10Xw/I/wCErsgcYbepz7oRXOV6B8GPFd54a8UrFZQWUq6hi3kNzCJCo9VPY1tQ/iR9Tnxf8CfoyPwjqo0fw1fXz6pm9iLQWOnOpdSzrh5euFKjpkcmux8KaUPBfjbQR4d8Q6FfT6xpe+SS/Cm3gduTHIcnB+Xr19uazvAUnhe38N3EWt+Go9U1G91BrSO5e5aL7MCpwQB97B5xXdL8D9KsbCxu9UfXVjgQyXzxpGRKNhZRAOSTxzkGujlnZOxwSqQ5pa776f1/TNnRvH+ieHrjV7DSdVS1s1v5WWNZ/lycbiuONpbdj2xRXnl54Y8BeHNTvbDX7nXJpDIs9s1qIziCRFZA+ejjJDAcZorojiHFW5UcE8IpSbU5F/wbqV3p/wCy94pNjKYmfUo4pCMHcjhQynPrXgpr2zwmd/7Mfi9TnCanbnj6ivEz1NefPZHv0d2JUkojGzymY/KN24Yw3oPam8bQMc+tNrI2FooFKKEMB1q1p1hc6jdxW1nC808jBVRBkk10ngvwHrHim5T7HAy2mcPcSAhE/Gvqn4Z+A9B8D3Vvc2ZM12QFe4uEyCf9n+7XVSwsprm6Hn4nH06T5VqziPhP8EbGyc33jOWE3sTBobENuRhjq/8AhXqmueENBf7FFbWyw20g2PBGNi+xA7V1+p2dtqRE7OsZT+NcfrXnXibUJodZitnlZ9o/cux+Un616GGgvs6eR4mKqSlrPXzN63+FPhn+znjlWUlhuG8/dB9K8W8TfDiPSpZzG2+2ViUkC5IHv7V61qU2rS6NZsrkSBioaMllI9DWZI0F3em2v7ryXCAboThQfcGt6dJq7m7nNUqRdlBW/U5Hwt5ekabDbXiuySsF808gg9sntWzrXh/T3mhWGBJvN5aHI+76j0NVtQhmjaSCRIHiDfLn7vHcVFY2l2l7HMzpCjnCrvDbl9Paui3Q57nVXel3Ph6S0uLJnNkQCIpARn1B9fao5dT/AH63MFq22VWP7xSRuJzxxya2bTxFHDbot1bFYBlVjkcMG9wOoNcp4m8ZRwzGG3TyQWyro+wR+gKH+dZrm+0jR8vQ6DT9U01Y47bUXR7uM7g4JQJnqrZrVuNeXRYBFcMEeUfujEwZWTPQetfP/inxQXvPtEa/LnY43ZUt3OPeseXXrqa8t5JWmEaj5FLH5fTaKiSjezLhKVro+g77xhYvZYmZWg3YDRDamR7dQa59vGVrBBcRaVPEzlsbwpXHp1/UivF3nuLhzHc3LNCW3hmBBDVq2Ud4Y0ldTHApAUgZyc9vWnFJaJClJt3bPRrrVtRaGNJBBLKJP3TtLwmeu3mo4vEWt6JJIY77yw8mcK+dzkenTpWTpGk3N5PPPPHGEVBsjuG8sjjqOxrRv/DsraWjXMflIroHMeGDA9CB1+pqnFNakxk07orX/izWbqEOZ3byTjcQTg9xnPrU7+MNUvopIy8RYgKVOU3Y7Z61kTWmy2YABSkjbdi/f9j2rEzcW7u72lwqEjavQ8/560rWG5XN248bagDIbqWYTRnCozfNj+7xS2/j7UDNLHcNLGjY2nfkAD+Ee3tWHPZWhQfa2Ml0MEk9vQ/WsG6gf7Y7WoeSMZKqrYY/UdqNUTuejQ+PNRt4iROXSTnl9pXH8vwqS48c3MxdLuW2CMNwfJPH9TXjlxHOvzOuxM4PzdKjRisJMt7GBGTtKnOR3qee3Q19ldXue46f4uSWzjm+0fulk3yeX99j2wO31q3qvjqWC3drSWaGTdkyyNnjuPrXz0urtaSk27y+U3O9uBjvUjavb3ke2RnKu3B5Iz6cU/bRe5TwlRarY9I8QeN76UiNmklR8lYxyxNQ6VqE1xGwV91y/BYgZUen1rgIL8xSOwlUnGBuydta9tqcNnYvKIy14W+Xrge+KFO7uyJ0ZRskj0Lw5o0F/dyDUJgYkO92f+XHArJ13WJbXUriC2lW3tiSI1BBIUe9Y+h+IpraEh5tySndIuMAH3qnf41O/WW2/wBJJbCqgxWjkraGPK+a0jr9NvraGBESSNbiXl3br/8AWrttHuGk8uW7RFij5XYCSQO+TXmNjpdyurb3eGFVIMpY7sewHrXXQeILae5ELeZLAML5a/KrY9TVxZmQ+OvDukeM5hbiOO2kBMhvFXc4+p7ivA/GXhC/8O3LebiezB2pOnQ/X0r6ihKqoaCCIhuAoXaoH1PWqPjq9spNCNncR25ZztxCgHH4jk1z4jCwqq+z7ndhMfUw7stY9v62PkKkr0XWPAU10zXGjwmKPklZnxn6GuBu7Wa0naG5ieKVTgqwwa8Oth50n7y0Pp8NjKWIXuPXt1IaSinA4UjA5rE6hK2/BLhPFukscYFynU+9YlanhhtviPTCO1zH/wChCro6VI+qMcQr0pryf5Hr/wAHZ9Wns/EenaR4S0rXDBO11597MIzbsMgFc9T7Vq6X438Sf8IpbeIE0izhbRpGtpdRW5/0qWQqUH7tjggFhnAPSuX+H+iXev3Wt6bp97Z2lxaamt232q58gNGrEMAe59q1Nd8ewx6B4Rt4bfSnNlrEszt5YMmFmyC3sQcn1xXbayumeU/elbl+fyuef+OrPxDZ+Jro+InWfVLjbczSRyrICXGeSvAPqO1Fdt4jvxrXjHxJf2lxo6wS6jIUJkVQwAUBh6gjHPc5opKmu5p9Ya+yh3goF/2afHK91vrY/wDjwrxTBwT2Fe3eABv/AGc/iCp7XNqf/Hq8Sc5bmuWa909GnuxlL3oNaGk6Re6tOIrG3eU5AJUcL9TWcYuTsjSU4wXNJ2RRRGdgqglj0A717R8GfhLD4ivFufE1w9paYBjgXAkk/PoKr+A/Cx0a5E9zbiW9BOGZcqv0r0y21qezuUd1iLEjdkYOK9WhgUlzVNzwMXmrk+Sjt37nsNjpVno+kjStOtESKFNsSMRg+nTrXN3uoz+Uq3CxxMuchCcA/lXSaI8GqWcV3KyFcfMO+PrWf40jsraxaW2xk8BnPAz6100moy5GedUTlHnWxiR+I7r7DLG08QReB6n8a5q41+3ut0VwkBYHPyMT09RWNq2sQrAUMZRV6lTuBrm7/VY5wiW0CxuvUhMbx7GunSOxzcze56DZeJI5rMWcixxw7spKGIx7VXurryllkaQOwzh2w4I7VwNg8zBtw8yFuqYyR7064HlEIg2IRgkk7T74ppkt9zqW1WWex2yP+7x93cOR246isay1SYZV0l2s+FdmACY/lXP3flQuN7GUHh0R85qpq+tBUWRGKyFtoHQkVLnbccYuTSijqNR1tJBKzzFboZVJM9vbBxWHf6jJcW6NcSpIVGfMPyn6H1rmrvVnRRcbTGBjqAQR7+lVWujKXdJGCHkBWyAfpWUqqOmOFk1dlydImA32+4OxYtEc5J+vSrVlHciItb7WUfKolxkDv1rN0nzbjKrMHBbLSDv9PpWysn2aRWVBcMrfKuMA+5qY66lVbxfIdj4WsTHKwS6eaR1wFYDYcjoRXaaVo+nzy7Lq3W3hVNoMGSXfHvwo98VyPh+4KgRXoUOzY+4VIPY7q3tS1a6iuJjblgsSbXYjKEY6cfzrosrHKm7na2PkPZxW6GONbd/MaQkNIB6ehzU1xLpWrrLC1yILN48MH+8Sp4zgfLivModeW3ikSZ5JmnG1Ajfd9scZFXNI1+502AXGnyRxRKCRuGWVj1BX/Gpavsy0+50GqRWxvILa3DSpKO6bVYHoQe9Y+qaLaR20rXtz++G4IrbsYHQACsu01rVr+/kn8xZICjSh2TcM9MY/hNZd9dajNavG3mON3mAkeY446Gne6JehDf3txHOIo22RsBhmUbmHbIrl57ookoiUfOCoBJGD6invqTENCZztHLOY/mB/HkVm3F1GXyY5oyoJBJyP0rOUi4U23sFzOLSxBkiEtw3yru5598VzepzTXFwsmyOIFcbQSo/CrkWofbQ4uJgF3ZEUZ6/j2qjqgF/EpsfOZojteIjK49c1zzd1oerhqXs5e8te/Qyrq4Zlw0hwRgjJxx7VXjvriONooZisZbO0DHNaGpaik1rHA9sUKDAfvn0NYqtjkYz2rkrT5ZKzPYox5o+9E1ob8QW672ZpM5xu4/GoLjWLq4njd32lDxtrOJJPJzRnJrCWJk9FoWsPBO7Wp3nh26a40+Z3KxRg5z1Zq2NHuvs++TdtTPCo20/nWJ4RtZJdEeWPYWDFVyOR9KLyZre4Nu6EyrycdK9SEmoqTPnq1KNSrOEe56ZoX2S8haSCMtdSZHzfT9arxaebG/Ry0jybskbyPyrn/D2sXFod1scbcbyev0zXeWV9PewrLL5e6TgKOTj1rrjaSPLqRdOTTLKa/fELEm0xgYyynitLTNO+3yNdai8hto/mw0eAxqzovh+a6BuJYXNrFh8qcEmsXxn4qe1/0e2XY2CAh61W25O+wmo+TNqL/Zo4zDGNoXdn8elcb430e21VgHtiZlXYHC4K/jmmR6jdyRSMZPLLHkg5OKUatshC7nPqzDvUStNWkVFzpy5obo8r1zw3faU7F4nkgH/LRV6fX0rGkKFv3akLjuc17bBMLs7Ml1bqTyOexFcp4j8Fo6y3Onvtk6mILhc+3pXl18BpzUj3sJnCb5MRo+/+Z51V/QW263p7dMTof/HhVW4glt5THOhR16qas6QpN9DIHRfLdGwTgn5gOPU85+grz4Jqaue1UalTduqPcfhN4d8OarqfjW68RWemXJtrwiIahqL2cagu2fmUHJ+tYC+B/Dur+VHZ3l3bavcSfafsaKHt4rUuR8sp5ZsdM9az7fQPEfi3XvFWmeH9PF7vnDztuVNgVvlPOBXaJZ+LfDngG1Nx4MsluLaZLf8AtU3AM7qJOI9oP3SflyO1dtoc1mv6uzyb1fZqUXZ2/RHm+uaB4dl1B/8AhFr/AFKewUBS95EqP5n8WAO3Siuk+KL6lZeI4kuPDGj6K72yuLexuBIjAs3zkg/eOMfgKKleztqjSTr392WnyND4a5b9n74kJjO17Vv/AB414oy5Y4HH51738ENOk1b4OfEixhkhid4oHDTOEUbdx5J+lYfw88CWLSWupa3i4jdd62/Qc9M/4UqdCVb3YmtXFww15T/rc8/8LeGp9WvYvPV4rTcN7lTyPavqLw7pGkaT4YmstIs0iRvmd8Asxx1J61maz4bgNustgqgIAVTcPlH0rO0q9utPuPKaQYIwQTXq0MNGivPueBisbPEvXRdipfQtZXhNvcLL6qRjFQ3M8UpU5AfudnStDXQ8m2aJEww5KjNcfPczwySKQrKT3rZ6M47npnhfxM1pZraE7wflz0zWx4g1KP8As/yLMktJjMTfNXmOhXccmwTkthgAqD5hXcyskVi43RowXKs3anFJicmcTr8kVrHtZNpPX5q56QxlMW/moWYcH5hW3rP2ee2dr0+ZKvIkXORXMoDDdRSbJDCRye2KiRUdTo9HNtGUEwmSZScMh6j61Q1bVpluNsTq+OjbcnHoRVR72BJSEOY2HI3cj6ZrFmldZWaLt975Tx+NKUrKyKp0nJ6k966QxtcfKspGRwQBXH3Gpo948qtIGzkMDn9DT9b1uSRHgSTIz1BzxXPOzyfM7hsVwVq6TtE+gwOCcY81TqX77UWuYRGFRecnHUmpLG6k5VnVEA+9kAD8O9U1gAtmmjdCVPKE84+lRPOZNihEVV6AD/OaxdRxfvHf7KLjyxR33h29gNpKu9VJfhgo5/A/zrpdNsH1F1+0oTCThXHygH3Ncl4Ss54rNbp0jEZzkMozXbaVeGG1ESXjxIW3bAAQ9elR1iuY+Xxto1Zcnc6fSZDpdxFFPPFNbxLtjJbOM98f41vS3FlFAf7GuiLmUFflYNkn1HpXETC0W3N3czzG4RtyrEAVb04qno93qdxKtzpVnGrRbizMANw9CDW3NbQ5Um9T1G58L3Eiab5U9gLwuqiYo25ARz8h/pVXx14S1ax08lNc0X7MSC7rHsmx3G3HP1rP8M391eP9p1BTbXCpnykyj4/2TnH6VS8cM91A10904iK/NErtk49SRUSi3qmaRko3TWpwVx4h1PRx9h/4+4xKdrg4Dr7gVdvfGckM20RXNsjJyrRnGccnd2rzXV9fvU1GVYLhjEj/AC5HPHYnHNZmq63e6nIWuZiRjG0cCuOeMjC6uetTyuVRJySSe/8Awx1+p6zFc3XmtdxmJxhvlBf6ZrBv9ZCokVuW2qSCC3DA9PyrnM9Ke0m5FXaox3HU1ySxjkn0PTpZfTp26mpEUnh3i4gilTJ+bIY/0qaGKeK1LH5Y5BzMDksD2waw1OD0B+tWJrl5igZEyoCDaOwohiFa8jaVF7J6FzUoCsEW1jgD7r9ayj1q9bTO4MccPmSnoTyQPYUy7tZIXxIFDAZIXnH1pVoqquaBVN8nuSKyDnnHTvWrpenLOd9x8kfGB3b6VSiUhCQoO3kse1allebCuVWQnABYfKpJ5opU0viIrylyvkOm0mY20SQxxJ5KDAYcBvr6mkuZGuZS1rbMz9HK/wBKalrceUJiFO4Abf6kVPD5+VEjosSnnBxk16Kvax8/Ll5nNblJruf93alPLP8AEq9T9TXoPgjT76+1C3it4ZHZuODkKK5C3t01S9VLN1VVO15EGcfU17jaazpXgfwjHa2EMbX7pl7lxuYk+laU1Ja7mGIlF2jszrrq8t9O8PtZ+dGrouHYfer5z8UXa3d3K7yyYyQD0NamseIoZZBK8rvI5yeTWC6rfv5m4Ig/vdqqdmrIxppp80tila3S8Qpl0X1FLeXSTKqDKEdkFWr+3giQG2kUHuw5zXOXskgcBTj1brWUm4qzOyjCNWXMjodLmWFR8zM+M4z0+taKTTsjJv2q3fPNcfaG5jQss5b22Vu6U5kdBdyBRn5sGnCd9DPEYflble5LqPhz7Vak3UK7eu/nd+BrnNF8D6pqniiz03R0SeaZ90fmSLHwo3HJPHQGvRdT1C2SxRYhGqZ+9uya4LxNchoo5oJGDJKvKnpWeKo02ubqjXL8TW5uToztdL1+TwF4l8fpfaZYX9yjIrW90xKE7x0weetWn8U+HpvDuiLYWk6+L7uMRwy/a9tpblpvushOAMetHw/8O6P4n+I3iYeILWG8iit0nEdzfG0QthOS4BOMGq9n8K7fxBq2t6hptzo+l6bFJOlpYPfmV3KD70bY+dM9643zc1l/Wp3R9m6actrL/wBJWgz4rw6AviC0PiEW0OtNZo14mjuHtt+9wNpB67QmffNFbdz8DtHvLeyu9J1bU3t7iHcTcW4VtwdlPHp8vFFYNNvY6Yygl8TMv4OgN8HfidGOcWcLc/Vq1/DDhNG01lcP+6UEKefxrI+CXz/Cv4mp/wBQ1W/ItV7wlFE+hWLB9shjGSRnNd+B+Jnn5rsvVnd/aZo0USsWhcYYAciuV1uzW0uftEMuUPOGGMGrdw832dis3IGQV4qncXcd7avb3DAuRwG5J47V6UtTxV5CWV4J42RZEU/7QzXK6i5hu5mmMbjPXFJqJOmNnzGXPO4msa/uluAWkJlJ5yh5rGUuhrTpuevQ0NN1KG0v1lBRCSCGFds1/HOi3DSoGxxz/SvJVm8qUGPO3jhuSK2bW9lmKDaCm7kEVNOr0ZrXw7WqOqubYauXmkl+z44LbcZrmdZlW3i8qK6VhFztJ610F1fpHpjx27RiTb90nmuDuJ0lEj3EaEpycdaqrK3qThabm7vZFHW50mjhkQZkz/qwdufwrNbVJo45I5RJG3QAHHHvVa8vw10WVQ6D7u8ciqM0jSuWYkk+przKtdR2ep9PRwyUVGS0GyEMxI70ijLAE49zSUVwc13dnbYkZtxCk8A8Gr9tp7Pc7C4JAyCDnJqlbwSzNiJC3v2/Ouq8PaRPc7dzIrIcruGStdtCLqO7RyYqsqMb3sbml6Ney6MTBMJI1fgyfeX2rrvDvh21udH3kb7qF8sofB/75z0rltUu7nTdL2xiFih+Z0XaxPp70vge+imuJXu5b1HbBAh+ZT7V6cXCMlHqfNVI1alOVW+l+ho65CY5dqyr557AsAozjrXf+Dp18P6K7LbG7Z0IKx8nn+YrEtdCh169adrp7Z43+4V3+bj1zXYXukW2kw2E3lyyFyrGONsBPoR0/GtYrVs5W/dSN17S8vvD9jfXDvFJG2Yo5IRkZ/vHHb61zHjwX11pFxLfXMJbZhAisN5HpjivTP7Z06PTII5I5YUZdqJcYmLk/wAvrXlXxPmnTSESzt3KhidscmPl6kd6It2d0NpJpJnzVrUbw6jMs2/eWJ+YY61Q71p67cT3F4XnVl/uh+SB9azK+er/ABux9rQv7NX3HoE2ybyQQvy4HU5H9M1HRS1iaiU4HBBGQR0IptFAEsEvlyBmXcO65xmrf2lp8xptijJ+7ngVQpSct2/Ct6dZwVuhEoJu5ZmcRS7Y5A6jqRnBpjTNtG1uB0qAnniik6zbYKCL6ateLAYRO/lnqM9a2NJlkljWSeXy4lOAPWsGwljt7qOWaITKDnYTwfrXTQXzapdotpBFAAPmPBAHoM12YdyavJ/I4cVFRVox06vQ6jQ5JLmVLazh3Z4CRrz171qeJNNvNNhYXj4fHA3Z2+1XtG8vRdKW6iiKTMP9c527j7e1ZGsa5/auDOHklI9MD8+9ena0bN6nzN+epzQWhx7O00wBeQ+vqa1bO5WCUReUyIQCWJzWUkckd2X89EjGSVHJrpNHltZAFQLJIw4ycnpXPTV2ehiWox2ui/DCtyhlaQLHjADCuc10wo+23XcTzk1r6nL/AGcRlkLuOeMgVlSst8u44wO3QmtKmqt1OXDJp+0+yZdtOYoFlkYbi3K7OFH17mrFtcJdEeZHszwuMjNF1GY4PuDC849KyZL12JCnDYH3lIwawvy6HqRgqt2kaU908MxEjEKhwUasvWNUW7g8tVA+dSSKoy3AkYmSJZMAjJPf1qCRkMJ4CsMdKyqTvFo7KWFjFqTWqPYfBsc938S9atLXwsvieO5sohJZtMYQF8uM7t31pdR8a2Ph++1fR7j4f2trqMRlt7VWundrAOuCq/3uSW+pqp4d03VdY8ba1ZaA5Go3ejJ5WycRFm8qPoxIrvNC03TX1GOXxIl7JqehobWWK3jZ1jlMe7zZZgCm0dME5zzUuF5P3ra/qcMaijTjeF1Zf+kr/hjK8UfGbUNOubS2tbbULoLbLvl1S0EMpYls4VcDb0wfrRXo3hTVPC/ii0vbzxpf6Ne6jFez28cl5MgYQq5KAc/d5OPrRUOMv6Qe0h/L+J5N8DFU+A/ibECWX+yCwOMZHNGgNGvh/TmaUL8gP3qT9n87vCXxGQdf7Dk/rWBplzE2g26uoBCYzmtsG7SZOaRdl6nZ6pfr9hbygo2jnB/riuTj1uR5/mbO3jOKptPcPCyrK5UdsVlXdvIUZ8shPoK651H0POo0Iu6kzX1WV54QzkMnp1rJRQmGi3Yxg45x+FRLdNbIFnY7TwD0xVqEsUEkRLbu5NZt8zOmMHSjboZt3NISHjztUYOV61cs5oGt1eXdvzjl8VWu1EQZzuGeXXOawHeS6LpGzOigsUB7D61m5crO6FFVY9kjvINSspofLdf3g4+bkfnVDxDBFNZk7A4xkbetcba3iQRkbM59+9XBqXmI6JKyqR91uBTVeM1Z2JWXypT5oMxXG1iMH8abUrBd7BtwxnGOairx6itJo9xMKWkpVwWGelSlqM6LwnFIbzYS6xyDB/un6ivRoI/7OtALYKWkPABGQa5XwZp9nHdpLNeRiAgYZjgKfwr0PWrG5vQkWmLbTuV+9CVcH8eor6DDU+SB8lmdX2ley2JPCukw61qQh1O38wj70QlCbxVrxV4V0rQdSVtDjvLZXxuguhkA+qsOorCt9J8YeHrP7ZdaakmmlsmVCH2n37itB9VvtcMEkwu0s4/lPlJvC/WtU4yd7anJJSppxT0fY6S1sNUu7a3lJiNumMNGygj8+a9I8D6UlwPtUkVz9ptiRw24E+6sOfwrzpNWj0rSlC3qhcfK3k811/hDx5pU8Edo6XUgkOwmPCbT67u1OrflaW4UviXNsak3hTU7sSfbLGC/WZiVkLGMw++3OBXnHxU0htD8POi2VvGwYASiXzCfxBGK9Pn1y3sUu4oWclCSpM67iPRsnmvEfiH4glubOa1njQQSMW+YYXj0YVK5rNyL91ySijwTUZmlnZmx6fL0/CqlWb5kM7FNu3PRelVicmvBr/Gz7KmrRQUUUViWFFFFACUUUUgFxQMd6SimA7qeK6Tw8q2bJIzN5jnAGMg1zVaOm3Bt50yC56D2z6CurCu0rnPiYOdNxR6Peah51rH58jkAbVVj/IViyCW4csp2R9hioBqDwIHn8sN23jJH0FVNS1ZJogBMQe4HevTlO+rPBo4aUXaKHXt1HbxsoSRn9RgL9Kg0jVRZK/JDt0A61Reea4HkxqNp4yeT+FMvLGSzjUsxUdM+tZczTuj0o0Icvs57s6R7qKT57iQSSY6dMVlvfypc7INscQ68Ek1mWaM8mXl8tM8setJcTfZbo/Z5Scd+tJz0uxQwsYtxWv5HVxgzxAs4PHIxVWTSnnLCADdnr1xWdYa1LGFRERgTyzZzXXaesPkFiQWPJA9a2ilM4a3tMK7nB3lk1oCHZM9zuzWcx465rtdWsQ+5iDtzyAetcrfIq7tkLJjqSK5K9NpaHq4XEe1Wu5694E8P2Hib4nQWmp28txAdISYRpc/Z9zLEMZfsK6S70W20yDxctv4kuvCXhWGVLS4soLj7c1xO0QPUfeDDg+leZyPqM3ibTLbR7N7y+1DSI7VIVPzMWUjj8qwddg1fw1a3PhjWtPktLoXCXLpJw4+XAGPQg5rOq4qT+Zy0ITlCKXZdvmYSwl8leQCQD60VojQNciggk/sy9EU6CWJhCxDqSRkcdMg/lRXNqeg59pI9a/Z1+bQ/iCnY6HL0+tcPpzZ0+EFe2M5616D+y8LRm8ZR37yraNosvnGIDeEyMlc98V5gLqNGaG1bfArkJ5gw23PGccZxXXQlZs4cVBz0Xc2FYQHeFf8AA5qSW+EsREcf4mskEuRtYKp/hzmpVgZjlGdQBzgV2KT6HnOlG95GbqT3Zcq3lkHjBNWtLu0t4fLl2xt6k8Cqt9Z7n8wuSfVj/SsnUAeCzhgOmOPyrJycdT0YU41oKBp6xKFdmSdQSCR8uc1zx3LngipreZY2y+5l9PWm3DeY+5V2g9hXNVkqkbrc7aNP2XukHakpaSuFnSFFFFIAq1bWU9whaJNw6VWq9pXmrdR7XMYY4yfu/jW1CKlKzRnUbjFtGxpemvbx/wCkPs3chlOdp969j+GFqDcCdsSLFhiyHn8q86uIo7ax+WAyK+MtHgr9a3/BMuoadOlzpt/HE+4fKfmU/wCya9uilTaSR8vjKjrR52+p75rJS/0ieSxkEcq8tGyBUmHuM9a831+4ubJImgsdhGcmDGAfcjrV/VdT1PWrYrHCBdj70afKJPpVG31e4GLVorvTLqMAMdhZG+vrXTtoed5lGy1C6N1byW1/9mlZgSUjbBPrtwQa7bStM1G31D7dJcJLBKd8jGEKzevy8V5tfaleprJYXoCIwYrGhUg+tdx4f/tTxFc7oniaLOMGYKTx1+bHNJNXux2Z0Os3WjLFOkkauH4Zo7Ulh9ev6V4v4vtNJZpxa3DSRoSfK5x17A9K9I8dGHRLPYYHsrgcb2kDBz7Fe9eD+NdahuovJMbecTncynJ9yc81nWnGMLs6cJSnVqpROX1VYEm2wRvGMZw/Ws+nMSTk5plfP1Z88r2sfYQjyxsLQCR0pKWsywop8u0NtQ7lHfGM0CM+WWI4quVt2QrkdFLRUjA47c0lLmihgWtNsZtQuVht1BY9Seij1NbJsrTTbhIo5Be3h/unCp/jWdp2pGyt5VjUb3GN3eqG9vM3gkNnOa7ISp0oprV/kcs4VKkmm7R/M2daufLUQjb5pwWI7e1Y5VictnHrTHYsxLHJPekJJxmoqVlOV3sa0qXs42RrwXr2sIKSxBuw2ZP51qQapLeRqnlGeQ4wAOM1j6ZpjXDRvJxGT+deg6RZm3KC2tohxgtjNd1BTnq9EeVjqtGl0vI5DV9OnjtxLNGInweBzmsKFWlkWPHU+ldx4gE0z+WI93XOa5i9CWqqI0ZZD/FjiipBJ37G2DrucEnuzSh06G3t1bed79Qp5qaxlZWxiQJkdTzWTbagCEEzD5Scgc5/wq7e6tBJdqsdskKbAm1OhPryetUpR6Gc6VRtqWp0Rud21I4g5b1ORS6la232ULqcjR25K+a0SZdUyMkepxVfSHjtHWSbqQMAkVc1dzd6beO5UBonI/I1s9YO55fwVYpbX3Nm6t9NHxJ8P23gy4vLmK50oRWclxiOVpGDheegORXTw+AvEmry6HplxYi417SZ45tUFxcIzpGy/KWYk7gQD615paWdvqeveDIrx50tTYAymBtshVHkJ2nscDrXo138NrTWPEUSaRd65ocd3pyXcHm51GS7LMQMmE/ux0HzGuLnlHZf1ozu9nTqWu7P/gyR0Xh/xT8R9d0Kxk0HUrQxWitZz+ZLDGfNSRuzdfkKcjiivH7f4ca0lhaSm0kJmRnJW+RckSOpyuMqRtwQfSis279F+Jp7q05mdN+zId154vjGSW0OcA/lXmNoW8uIxja/TJ6V6Z+y8S2veI0P8Wi3I/QV5raM0kKKBnHGadLVnRW3ZPdyhUO5FLgZ68moLXUNzKhkKFuoI60t3DKGGSW9ieMVBCZi+IV8o9Du56dK6L6mMYRcCXULpcmJY2WQg4JIwax2eRHO8AH/AGhmrFxNc+aonKAjpkAVUuWDsTkknsDnFTOWlzso01FWIGBZicflTST0yfpTgrk/KCaa2c/N1rgl3V0daG0U8DI7CmVi1YYUUUUgHxqHcKWC5PU1uWmjzPJGcM4BHyqetYSEBgSMjPSustr3T/JCFWt5R9wbyF9iRXfhFFp3OPFzqRS5DotLtLhriOG3VME/MGYYH4V3txo9lp1jEJ4FguGx+9Q8H8q8P1HVZZbvzI1FvKv8UDnBrqdE8ayQWqw3N40wGMCYFulelSrwTszwcVgK7iprXy/q56vo6vpyeZMttdITlR5pU/kRzVC+8S6dPqrR36PZwgcSwjdj6gVnaJ4nt9TtZEu7EvGRhXiAwPpU8+grqVkXttPllGeSG2sBXQ5cy9xnmqPJLlqIp3cFvcXU09jqazoOQVLKfqQa6XTo3j0qBYtcf7ZjK27JvVvTkVzOmWD6VBMZLa4nGfuMxBX296228S6ounhdOt4fszDAWS33bD/vCktNWDS2Wxzni3Vry0Ew1O4li25zHuypPoK8d1K7a8upJGZiCTtz2Fdt47ubue+aO9lsY5GGSI4z/OuYh0IPjdqFtHkZO/IxXn4tzqPlitD38tjToU/aTerMXnA9KSr01ksb7Rd27gHqpP8AhVWRNrkAg47ivNlSktWe1GalsR96UDJAHWp7W0nuZNkMbM3tXpnhL4UajetBcanBPb2rEMZCowR7dzV0sNOq9EYYjF0sOrzZyOn+E7m6hSSSSKJW5JZs8fQd6seINHis9PXa0spT3IUfga9kl0i30q3nsNJuzbKpw0s0Klj/AMC6gV5X4yaKG3eJ7truUH+B9qj3I716kqEKdN6HiUcdVxFdK+l9v6/zOBo70HrSV4Z9KFL16CkpwznjrQgLtrp09wB5Me/IyfRfrUFzA0EnllgxHXac4q6NWu47YRR7Y4wMcDBrOeV3zuPWuur7KMbLcwp+0cm5WsMxUtqEa4RZQShIBxUNXdOlMMysEUuxwrMOBWFFJzVzSbai7HsnhLwvYXlnFNcNDBGo+85G4/QV0MtisETIr28NivG8Al2+grz3w3fvNcJHK6SbTjKjivRH16xt40jQo8i8kjtX0dJxcdD4jERmqjU9TidaurREkISZV5AzGQTXCX93HcI8UUbRZ9eCa7nxlqaXavKsZijB9Mk15zNJbRXay5Mo6heuK5a8tT18rpLl5rO5Xe2eAbipA9Wogm8qQuVDt6mrerXkd0iLEu05PBHNZ6OYWDdW9+xrldoPTY9qHNON5rU7DSLS5kiFxcBTn7q+gqvrmqCGGS3QqSwKkKenFYlxrd3NCIRIY48YIXvWYzE9SaKmJgo2iclPBSlPnq/cjtxqiaO/gzUpommhht2EkatgugkYMAe2QTXo2ifGXwjoF/Emh+GdVs9LjhAEUWoFJGkDlvmYHleema8j8Qnd4a8NsO0Uy/lJ/wDXrnK5qtWUJWXZfkjTD4eFSHNJa3f4SZ7vo/xo8MWVgIbvwOLucySytM96QWLyM/PH+1RXhFFZe2kdH1Wl/KvuR7d+yyf+Ku1pCfv6RcD/AMdryyCZYEBIb5+Mgj+Ven/sqt/xXl+gz82mXA4/3a8rdlEJPJYMR14FdFF3ZlON5NEwu3klHzErj+I4NSySrFGG2umDzyCPxqhHIdhcqWwfm75qN5Imk/dKwB4Kt2+ldFxeyTeiLbJHdIGaTYV7bs8VHHFbhWA3SNjPBximRW8o+aBwBnndxWoLe6WA5EU3oFO0016EykoaJmTtlWfbEQ2RkcdRUs0bh/Luogr9Qen/AOutG2gtnbbLBLFIOQQabfDzpNlxFK4TAWRB0HvTS0F7a8rWOfcYyAMVHXS32kRPZNPbEcDPJPNc4wOcE81xYik4u51Ua0aqvEZRS0lchuFTPLJIiq/3RwCRUNTJO6xlAQV9CK1pytdN2RLQ3GxsnmgOQ2QcfSnRorg5facdxT7TyVm/0jcyDsh5NaJSbSWiYm7JnTeHfFmo6LbhbKTyx3Ur8rD8a9D8M+KdV1G0IluI49x+6V4P0INcPoH9iysPNRsZwPOAx+OK9W8E+GbDUvNXzLaGIjIlRiAPyr2KCl/NofL5hOnzNKFpdzqNMv4IdPWO/s7uCV1yJYJhhx6lWrMufClg1lcTf8JBdQPKS3kxJzn35xVrUPDcttH5E139thBxG5P3B16mug0zTf7PtreCXyZ4WYEESROB9e9dDs9zzk30PnDWPC7z3zK+ooJGb5WuMrkfjVBvA2reZhfKlXP343DqPxBr7RvfDGlXNtGLy2heEjB8phjP4ZNOsvDWkW91AdMaBGiOT58RKY9ORXDKFKWp61LF4iCUU1+H/APiCbwrqccwiEW9zxhCSfyroPDnw6vryUPqO61UnCrNGVLfnX2brPhnQNSZJbiGIXQ4SS3+Tn8OtVH8Padp1mv2m2mlmLY81QHYD8TxU040r3dzSri8S04pr1R5Z4T+H1tZwRbo7Ni3MbTLsVvoe9dFq1hZWskh1W8ubeSNMCO2QSLj2IPFaHikaXNJBHbJPHJECfOOU7fka4zxFqdjd2zw2nkXsijazLIyuD9cYNd6vbsePLfXU4vxLPZRxyrpVxJOSxOJkCsa8q1/Tbkymefyo4zzneOPwr0rVdLZnVL24uogVyFmHC/iOtcZ4h06GyiczySsoOABHgH8etY1k2tTtwFVU6mm78jgZAA5CnI9aaaklxvOBgVFXgVFaTPrFsLTkkZCNpx9KaB15pKUZOLug3HyOXbJzjsPSmUUUm23dj2Fq1YJvlBdlRFOcscVUp244xnirpTUJXZMldWNddQlspz9jmzF16dTWvpmstLMHnWFEzyxfJH4VyBJNODEDiuqOLs9TmqYOFRWe/c6/wAQavDMpWLz1/uuwxn6VyDEk5JzQzFjliSfc0jDGOQaitXdXUvD4eNCPLENxHQ0bj3pKSubnl3OiwUUoOCDjPtRUgb+sMz+FNAyBhWuFBx/tLWBW9qA3eDtJbIO24nXHp901gVtX+Jei/JHNhfga85f+lMKKUAnsaKxOk9m/ZVP/FypVP8AFp9yP/HDXlNxK0c0qqFA3t1Feq/solP+FsRCTOxrK4BA6keWc15t4pew/t3UV0iKdNP89hCs7hnC5/iI711Um0rnO0nP+vIzZJmK84B9RxSLDldyuoI5xUZBx8o7c0zJPGa0nNX95Gij2LykKoZ/MyOm0jFSyaiZQqBShHRlrLwcZz+tLGzKfl60fWHdK1iXRT1Z2fh6WZZCs7KvHG7knNaaWKNcyTq4wx+ZGORXJabqMqyGOfDL0BJxiuisyWGUmVFJzwdwP41305KSPExVGUJuV7XLC2EcYkeyiKpySM5Wua1i5t3ZlaFY5Qf7vFdFqF7LbwukcbsSMbhjFc/HdxzSEX0CovTcOo/OipbZFYRT1qS1+epgEqWywwPamHGeDkVu3NhakN9nnMqA53LjiseWMRk8gjsRXm1qDWp7NOrGewxI3cEojMB1IGcU828wzmGQcZPynpW34ZR2gmwSFMig56E7WxzW79ob7PBFPcSs+CpVjnOOgHsf6VnGkmr3MamKcJOKWxwXSlXqMda7No1e1JKTLL54VSwAUjHI+uTT7wxSXDMLeJSkSozKoILc5Jz7VSo2e4vrnl+JhaJNcW5LrHHJGeokIxXd6Drc4Ki2/wBFPcnlP1rDhVPPhjjhjClhglQS2P07Vq+G5bmW78vkxEkgCMOBn2xXoYeWvKeVjmqkXOx3en6lqE88YmQ3UYHAhk2An1raiso9SD3DW62t0nV2k54+lYGgm6stQJYWuDn7zNHgfyrt4NTlldR9sto8kAg227H4jrXoLzPEKOlXGosRtmEqocAh8j8sjFauo6brWmItxFLdOLnhojJhemeoya37DwzaSHzxd29+snVUUIc+nNaWi6h4ajufsFzZ3Kyx5AQSl+azlPS6VzaENbN2OUsNWubNBHdXE8RXo0krMi/pVa/8SeddLDJbxSI3HnxKVP5k16Pea94fS0mitrJmYcHzOcfrmuQsbnTGunuGgjuIY+qyRvsX+tEJOSvy2CpFRdlK/wDXoc7c6ddX+GshNdDp5ascr+J61BBoKWy/v7byJPvHgYz7mus1DVYzPi3/AHNq3QYMaL7g9a5jWtRjhmWKTUzPGRkkplVJ7A4rVPqzF7GTrgjmglikjRNi/KxJw2PSvMPFVkqRLNc3ayBeTEowM13OteXMN1hdzyyEcpJFn8sdK8/8Q20kSSma0c+u9gOfasqzujowmlRWf9fM8+uypncxgqmeAe1QVNcMGkO1Ag6YBzSLEWheTeg2EDaWwxz6DvXz9XWbPs46JEfb3pKWkrIoKKsXGx445V2hmGGUY4I7496r02rCTuhaSilFIYlLTmx/CSabTasAUUHHakpAFFFFABS0lLQB6B4zvfDl54A8Pjw9pVxYTwzOl2803mec+xcsPQE9q8+rek58Ew8/dvm4+qf/AFqwa2rbp+SObC6Rkuzf5jgxHQkUU2isrs6T2D9lg4+LdoAeWtbkY/7ZGvL9ZAGq3a+kz9f9416X+y6wHxh0wY+9DOv/AJDavNvEChdc1Bem25kB/wC+jW0fhMF/Ef8AXYqbwFwpaojilJ9OnvTTSnUvobJBR0pKWskMerlWGSeK2Bq5hCeT5RXA3AqeaxWBU4PWm1vDEShoZTpRqfEaE+oSNMZInaLknap4FWbe/up54w5QknG5l5H41jVIjEDAOK0hiG5e8KVCLVkjoZJbrTJ1uAm5ehO0YNVNS1G3vlYvZJE/Z4z396pJqV0qhTKWTptbkVBPN5xzsRf90YrSeJi46Mxp4e0lKS17o2/D2VhLb2EZc9eQSAO3rgmtaScukMiLtER5IGOufxzzWbopeGwiIGSzNIuOxHGT+Rq4XV40UYU7mY8YYgY49PpUReiOStrUbJLVWmMqtuEaFpCQMgDH16VakK283lyRyIGgVpN4yd2B27Dnp9KbHbG5MixsFj2DAU7cnnAx+dU5bV7a+WKUJMWhWQFXyo3KCMe/P4YpmaSZPIsbzooY7kQlxjo3TAr0LwEbW3gEyTXCuowxRSVB9684hkEZkwDhOVX8/wCtdz4b+3RWKS29wCW/gyFP09/xrswb95nn5h8C9TrNR1trqdEmu7fA5VwpJI9CDXofgn+zBp4vLuRCyn7kVrgn33E15pHp+pXrRmZViXOd0iAg+2QK6bSriaDNoLEXEaD5lQFR+Yr0GnI8yLUeh3Gp3Nn4gVrq0hSIqCuZ2KD6naa42aG1eFobm5P2tDlBCodCfr1/Wqdxdx2MrtBprW6ux+SSM4P4k1IlrKtmt59jgtQSCZY3xtH0qYpJWRUpN6m/p2nhLYG60yKYsvy5+Xn1OTWZdwSaeWU3ltaOettFlt498ZFWm1PV9R0tzp2p2skEY3SbkUEj2zVLTL1b6QQmeKPHZISu4/7wFCBozNV1UXEaIZTlD8yKSox7jFULzUrSWx2zSxxIP4YyX3H69q6TUbFQzhdNN3Nj73nBuPccVhXGkX0aySQaU8Kn/ZUJ/Ondk9DlF1mS3hf+znjRD/EDlv1rjtd0e7vrg3F7cRojHI3jJ/WuzvtAeeM+e/lgjO2BSP1og8MT3BVNI0+5uGxkyTj+WaynFyVmb0a3sXzQ3PJtZ09IUBt97kDG4R7Vx9frWCwKsQ3WvVfFvhdrNt2pyhW6CNZs4/AV5nqEKw3DCP7nbJya8vF0ba2PpcvxSrRtfUqUUUteeekJRS0lABRRRQAtHQ8UlFACkkkk8k0lPTbzvyOOMetMoAKKKWgApKKKAN1AG8FSn+JL5f1Q1hVuWrA+D75e4uom/wDHWFYda1fs+hzYfea8/wBEFFFFZHSeq/sytj4y6GOmfNH5oa4DxSmzxLqgP/P1L/6Ga7j9m5tvxl8O+hlZc/8AATXF+NF2eLtaUDAF5MOn+2a1v7hiv4hjUlFFZGwUUUUAFFFFABRRS0AJRRRQBchv7qGJYo5mVFztHpnripjrF8UVGm3KvABUVnE5606MbmA9fWtU22kmZulB6tI2bG41i+mT7GrSuvACIK1fO1WxvPO1OwkjZUCbjCFUY4B6YzxU/hyGex2Sx4AzuBVgea9y8O+NZrnTorS8htb1ehjuUDbh+NenSwvMtXqeDi8cqU+VRXL+J4haSW1zcDy4ZgzAY2p8oPTPNbthAInitpVmhAPDYGD+detQeHtIvLj7RBp8loS25lgwQPotdZHonw+kthFqZLsR38yNh+GK6PZqkr2u/JHC63t3ZaLzZ5gdb1XTrCK10qLfGT/y1cbDViyjv7m2Et9cS2bu2Sbc7gfyr0yL4Z+ArsI2lXNzCxPG64wCfxras/hxDawbLGGykXHyPI5598qKPrEft6epP1Wb+DXzR5m2mW97bRFZ57yaNSBvDIQfWnJdIskdneXKxgABt0hcj8K7+2+HOt/a2+2XKtaH/llazkDHodwqlqfw401LxptTWe2gU5G0eYxH1FUsRTfwsl4SrFe/FpHDPpOlrcs8epNeKCW8nZgfyrWn1WzW1Vbef7M8Y4SM+WCff1rvtM8BeH5EFzZX2phQvTzFAP1yK5yfTdO0/UHfzvLVCcbo95bn8qqnVjO6XQirQlCzezOUi1nUL0lPlC9N6pv3fUik1DS7m7jjdWS3x1Ikb5v+A16bdmzkshNZmRnQ/diGB+IArKvdR+2WqxQ2JLgdFiiB/NjmqUr9CeTzPPYXt4CIr37ZtUY/cy7if8K5zV9cmtZTHYpexJ0AebLH8BXot3o91c7FFpEXYdJpNp/JBV/TfhpdThZLiCwzgn55WwPTjGf1pTnGK1dghTlJ2SueAa5b3l3GGuIZGLc/MhH864HVNIuI2Lqi7euF7V9LeJ/C1zpu7zr+wCjjECEsPzrzrVbS0cmOIXl/MR/y0GyMfgKxq0lUR2YXGTwztbQ8WJZQVPAPWm10XixEiuguyOM9diLjH49658BdrbiQ3bA4rx61Lklypn09Gr7WCnbcZRS0lYGwUUUUAFFLSUAFFFOU4YEjOD0oATHWkr0vWPFml+I/Bup2sHg7QtKuLWOGRLuzjYS58xVPJPQgnNea1c48tvMzp1Oe6tZr/JP9RKKKWoNDc0858JasPSaE/qRWFXQadbzr4W1lmhlEf7lgxQgH5vWufrartH0/VnNQ+Kp6/wDtqCiiisTpPR/2eG2/GPwz73OP0Ncv4+Xb4215QQcX8/8A6MNdH8AG2fGHwsfW8UVL8dfEQ1zxvfwLpWm6eLC5ng3WkWxpvnPzOe7cVovgMX/EPOKKKKzNgooooAKKKKACiiigAooooA3tP0Fr6NPJMnmMMgbM5AGT0pJdAnM7Jb7XCnqGqbQdX1XRpxcWbMHaNotyNzsZSpUY9QSK9I8CfYLtVa5s4kbPALEGvWo0YVNLWPGxeKrYb3r3Rx+keG9TSIeQJM9SK7PSfBniq7CS2djJdbef3bjP5V6tBZ+HtOjEn2qGIsM7Hau08N6dpeoRpNp1+8TE/eibGT9DXY6cacdzxnialeXvJHiDR+K7VQl1ps9uqnBZgcqfWtXTL3XN+63vFmQfeWQFsfga9j8U3rabYvHfGPUk6YMZV/zFeS39ndyzpdaRZ36Q7iSqrux+XNXTldXZhUjyysjS019Wu7xT5UXy84ROT9Aa6WG61xo2Sxt7/wAyE4I8sqp+hrm7HU5ZblIrm4ubG66L9oh+U/j1r0rw1a3rWxe81eGWA9BbzFCPwNFSaSuVSi5OxzEHjzxhaThJNKJhTj5wQTXWWnxHW9tF2otvcN8pWXqD9KuLL4ciZlkuDLOOol3ORVb+3dHtnWOa1tzCDku0fP61yOEJa8l/wO6NSpT09pb53KmoahrUy/6JPFMX+95CYbn2xUH/AAh15exeZM8gYjLLMQP0Fdrpmt6SSiW8iJuHAAH9K0LnVraFC7XUCKB1dgKyliKkHywhY1hhqU1zTqX/AK9TgNF8HvZ3Mjtp5uxjAxOyJ+R6101n4ZikAeazhsV7LG+5vxJqnqXjaCAD7GJZ2zhpFjYqBn3xmsq+8fhYvmaRT1/eRbP0qmsRU1Wn3iTwtNWd393/AA52kGmWEHETRbh1Z8E1meJbrTra1lVtSFo4XgxRhj+FeZ33jXVrlnktQGt8EAyRMOfbGOMVx2r65rxk83zwCecbAv6E5qoYWV+acrkVMZTtywgl95s3Mtlc3+b+DVb2PJIbbtz7+lcp41vrGC1H2TT1tU5GXlAZqr6x4vv57do73UpiQuCoG2vNryZ71pGRpnYd5m4FdbnY4YUvaPyMTxjewTeWkVuobqXLFjXKVs67HJHIPOkjLdgmax68XFtuep9Zg4KFJKIlFFKoLEAck8CuU6hKKfNG8MrxSqUkRirKeoI6imUAFFFFAC0la/hfSzrGsw2mx3TDSSBCAdiqWbH4CvSItI+F3iW1gmtNVvfDN86+QthKpuEaToJGlP3VJxn0rRU21cxnXjGXL/XX/I870IBtK15T/wA+qn8pUrFr2PRPg54mW51W2h+x3Wny2mP7Wt5t9mPnUk+Zjnbg5AB6Gmx+AvBXhXFx428WQ6gruBbxeHpUuDkcnzQw4B4AxWk4Nxj6fqY06qjOb7tfkl+h47SjrXdeMtT0HxHp893oXh220R7J0UiCRissZyASCT82RXCVlOHLbzOinU9pfSzR6U/xF8Q674A1Pw/qt5HLp1vBCIYxAilQrgDkDNebVueHhu07XB/065/JxWIuNw3dO+KuprGL8v1ZlQSjOcV0a/JDaKWisTpO++Bs7n4t+EFYkql9Gqj0BP8A9esv4rLs+JPiZfTUJv8A0M1a+Cz7Pix4Ub01CH/0IUz4xrs+KXigf9P8v/oVafYMVpUt5HG0tJRWZsFFFFABRRRQAUtJS0AJRRRQBatJnRxslMb5ABBxivVPAV80HlfbLaG+XIHMm1sfhXk0W0OC+dvfFeheEbjS5kEQhmZwP4CeK9XBTvu9Txs3hele34H0vpHhTQ/FVlHcJb3enyKOiusq/UZ5rF1jwtrmgzP/AGfewSwKcgn5G/KuB0bUNZ0ebdpl3NHASMLNyPpXsmja34tu9PR5dNsr+JhgkRZyPzrufNF36HhRcZxt19DgDrmoQFvtAikkBIIlYsDVFdcvY5vOjuotPbP/AC6sxz9R0r0vT7d73UvL1XRbe0jYnKSDYK3tR+HGnNH9p0pI4px8wjyrofwNE60ItKT3HToTmm4rY8/0HxS2oyJBq9xJdAnALxqpH0Nb/wBqh0+8VrS9e2jc4w+Dj8jVbUtNitnW11/S4kVjhWQKgx65FYWteD9EDrc2szumcGKGVmx+FX6Geq33O5nvZUCXNvrVjcsOcSgIR+lWLW9uPEEb215d6aqH5D5Mwz/KvPo9HjS3RdKeYNg5S5QYH4mn6VoeoWpM0kcIKsCSq9e1ZumaKr9x63p3gnQ4IwyyGWYjO8y8/pV0+HbFBhAGf3lryttZ1NbpIha3s6qMbYmVQf61ppq2rNG8T6XdwL2JXn8TXP7Gpf4zq+sUmv4Z3sqNbEK0C28WfvvOGz+FR39xbW0BmaOxmK85eRQa86mgv43+1iITBclY5ixBNZreI7qWRo9Q8O2sMK/8tCcZ/rV+w1V3/X3mbxC1srf16Gz4j1V9RjYW+6IA4AjwRXnl5CizH7bOY377Ii35npXZ2ni2OKA/YrOM44KxqCf1rlNU1S+1W/ZSskO4+zfoBiujZWOWTvqcXq8MLzHmJoicB35P5Vy+rNaW8Z2mR27CNOK9B1DTpI3LTk3R/wBmMCuD10XAYrEhtkB5d+34VNTYvD/Gkef6pJM8rM0TRqem5efzrPAywBIGe5ra1i3JIIuJLqT0CHgVikEHDDH1rx8SnzXPr8PJOCsNpaSiuQ3F60lFFAC0lFFAHTfDu+j0/wAV2skwYpIkkHy+royj8MkVjW1hc3GoCzgjZ5y+zaozzmq0MjRSpJGdroQyn0Ir6U+Gnh+w8S+Hm8R6O6XmsNzqkDbRLFJz8yqOqkcjFdeHhGraEnazPPxdSeHbqwje6t91/wDMp+CNMvPD+g3Fkt7c5vIHhuIxIfLKv95QOn4jmvKvHPg2XRj9qsy01ofvDHMf/wBavePKywKsdmNu3HfPX/61PsNBfXbh7ULGIlUvcSyEBIo+7MT0GM169bC0pU7NWt1PnMPja8KvMne/Q+a9OUR+FNWmMiZklhhEZPzH7zZHtx+tYVdx8WJvD8etx6b4QmFxpFqufP8AL2eZK33jj0HAH0rhq8Kq1dRXQ+rw6bTnJWcnf9P0Nvw5/wAe2sDjmyY/qKxK2fDh/wCQmucZsZf6VjUT+CPz/MKf8Wfy/IKKKKyOg6z4USeV8SvDLntqEPT/AHxV744p5fxb8VL3+3SVj/Dt/L8eeH39L6H/ANDFdD+0Cmz4yeKgBjN2T+YBrT7Bl/y9+R55RRRWZqFFFFABRRRQAUUUUAFFFFACg4PTNdr4DuJEm/dukOO5Q8/j0rihXReHb4RsE2YxyTng13YN2lc4swpupRcUfTfhuO6udNUkQXKkdUAJ/KvUvA+o6fp9l5NxFHBIDyVBz+VfKOna+IUHkOwYYB2MQa6nRvFIkkXz7i4jYEDcHYV61RRrR5Wz5WlKeHnzpbH1B4iu9Lv9IuB5okYp8vY57da8GlfW7C/YWOtQx5b5UcscV3/gjUb24jiSGQ3SMerfNXct4TtruUy3ccDEjOBAFIP1rmThhVyyeh2tVcdLngtTwxrzXMg6nqQug3QIoP8AOo7q7UYMz3bqSf8AVbVYfka9e8ReA457YiwiJkHRc4rznU/h7rS+b5kUkMe3/WIu8r+RNbwr05r3Wc1TC1qb96JV0y30WXEs2ravHL/zydMgfjXRWmpuubaLxLbwRYwsc8AJP41xHk3+iyNAJAUHeSPbirL3kbuoMMMhA58o81fLdamSk07nqGlaXdGRLqXV9NYHncIQcVvXF+qQFf7ahJH9yHmvLoeYA8VrdjA+60gH8zWVqOp6nHmO204QD/npNchx/wB8jmsp0eZ3k/wRtDEciaivxf8Amdl4i1W/yqwarAkZ4LSHk/h61ki10y6hzqty9y5/hExT8OK5a2try9uN97JEFGc7Yyw/nU96UtZEY3EsajkkREDFbKKS0OdzbZujTLZovK8PWbQ5PzSP84/U1esfh1dTw+ZezmR2OSYz5dZGl+ILGGP9xd2okHd1+c1maz4l1afcnBh7GGYISPxqZKVvdKi4rWR0d94FXT4vnubS2jXvNclj+Ved+IF06CV1mntLtgeETPNH22OWFmktCx28m4nL/jXFapJZxXe+G7WSVufLgjJ2n0zQm4rUGlJ+6n+Y/wARarELRlisba2THSGI7m/E15JqLiS6d1Rkzzg113ie4ujanalwgzyzcVxT/e55rzsbO6sfQ5VQ5IOfVjKWikrzD1woopaAEopaSgBa1/C/iHU/DWrW+o6NdS21zE4YMjYz2wR34JFZFGaadtRNJqzPpKD46+FNRto5/Enhe4OqgESmxn8qJiCcEL64xmuM+JHxovPEGmz6H4etE0nQHVV2A5ndQOQ7jqCe1eQUlayrzkrN6HPDCUovmS1FPWkpaSsTpNnwyC1xeqO9nMP/AB2sau3+G/hXUtcj1nULFYDa6fZytOZJlQgFDjCk5PTtXE1rP4I/M56bvWn8v1DFFJRWR0G34Jfy/GGiPnGLyI/+Piu1/aUtZrf4yeIWlieNJpVdCykBhsXketcH4YbZ4k0pvS6i/wDQxXpP7U13dXHxi1aK5nkkit1jSFWORGpQHA9skmrXwsyf8Rf13PIqKKKg1CiiigAooooAWkoooAcCR0pKSigArQ06a1jyt0jHJyGXqKoVbgu0jj2PAj5PU9a3oNJ3vYzqrmjY6LSb2GSRljEhQdCTjFddpUkUyBElSPkfeOe/NecWs9m0pLiWP/dbA/Sut05A1sHijEieobBr06M7rTU8LH4dLXVHqej+I9Q0CaJNJvN5U5wGHNeqab8X7pbeNL3TyZMDMpwF/HFfPfhu609H3OhimOVJYZwDXa6fa2kwUxTZjxwCjKK6HShV1krnlQr1MO2oto+i/DfjCw1+Pa9xHA+AdocAmtm/u7S1tSVZ3H/TNyWr5hbU1sMx21vLId23IGAPxq7b+I9Tg+e2eRGHJXzNw/I1zywUea8XZdjsjmc+W0km+57z/ZEWq5nS58zP8EsanH5isLUfB+muzyXscoKjpAsYH5AV5nbfErxJgQqVK8/diAP51r22v3l1DuuzOsjDoVLVcKVS++hlOvSsmo6mlJommgusVt5WOA8rMrD39KgXwpHbxmbUJbSWEcgCX5qLS+1F0/eJBFD6zE5P4VeXUbp5FRX05wT7NXQ1LocylF6shGn2csbCCK5mi25KoAoA+tc7qmjtCd1jFcpnrHI2Qf1rr9QtLieISNMiHqVVti/iBWBJq8Olsf7QuIwOQvk/Mfzpoh9jmJ9CYP8Aar4JB7MpINZd7q+k6e20J9ocdxFjH510l9qNrqEoMt+fKA6Nxmud1KGBPmtoLe4A/idv6U35E7GDc+IfDxctcJIGH8BBx9DisjV9ZhkgkOm26wJ2KLg0nieS4jYu8UC7VHyRAAVxt7rmY3RoWHsTisZTa0OyhhvbWcVf5mTruqS3ZCNIXI6msM9anuHaVix6E5Haq9eRiZNy1Pq6FNU48sRKKKK5TYKWkooAWkopccZoASiiigAooooAKKKKANvwi2NZABxmKUf+OGsWtjwiT/wkFsB3Dj/xxqx61l/Dj6v9Dnj/AB5ei/OQlFFFZHQXtDONb08jqLiP/wBCFemftSf8lm1f/rnD/wCgCiirXwsyfxo8loooqDUKWiigBKKKKACiiigAooooAKduOMUUVUG09BMns41mnCtkDB6V2FmVRFURoQB3HtRRXpYT4Ty8xeiN7w9fMjLthg477M12zX9y8BQSlFwBhOKKK9KHwny9f42bHh6HerNJJI5I53NmptVmWyhaSC3gDgdSmaKKvoQt0Y+g6lLfXZE8cOBgfKuP61tX0jicRq7BPTJ4ooqVsU9znbq4licbXYjBOGYkVt2niHU2AhS5MaBcjYoFFFLqX0Kgurq91GOO4up2ViCfn9a6S+sbOytWeO1ieQcB5Msf50UU4akS3OG1a+n885YEAnjHFZd/qVybYAOFGM/KMUUVLYLc43UL6d4nZ2DEN3Ga583ctzI4lCYx2UDtRRXJJu59DhYx5XoY11w5UdBUFFFeXXfvs9uGwUUUViUFFFFABRRRQAUUUUAFFFFAC0lFFAGv4U/5D9p9W/8AQTWSetFFaP8Ahr1f6GEf40vRfnIAMiiiiszc/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Saline infusion sonography of a patient with uterine bleeding reveals fluffy endometrial tissue occupying the right lateral half of the endometrial cavity while the left side is thin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28263=[""].join("\n");
var outline_f27_38_28263=null;
var title_f27_38_28264="Valproic acid poisoning";
var content_f27_38_28264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Valproic acid poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Michael J Burns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28264/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/38/28264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valproic acid (2-propylpentanoic acid; VPA) is a branched-chain carboxylic acid introduced as an anti-epileptic drug in 1978 in the United States. It is widely used to treat partial and generalized seizures, acute mania, and as prophylaxis for bipolar disorder and migraine headaches. Although acute VPA intoxication frequently results in mild, self-limited central nervous system depression, serious toxicity and death have been reported.",
"   </p>",
"   <p>",
"    The clinical features and treatment of VPA intoxication are reviewed here. A summary table to facilitate the emergent management of VPA overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef74180 \" href=\"UTD.htm?24/23/24956\">",
"     table 1",
"    </a>",
"    ). The use of VPA as an antiepileptic agent is detailed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not fully elucidated, the anti-epileptic effects of VPA appear to be mediated by several mechanisms. The pharmacology of VPA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FORMULATIONS, PHARMACOKINETICS, AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valproic acid (VPA) is available in immediate-release and enteric-coated, delayed-release oral preparations, as well as an intravenous formulation. Therapeutic daily doses range from 500 mg to two grams in adults or 15 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonenteric-coated preparations of VPA are rapidly and nearly completely absorbed from the gastrointestinal tract; peak plasma concentrations are observed from one to four hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1\">",
"     1",
"    </a>",
"    ]. Peak plasma concentrations occur four to five hours after therapeutic doses of enteric-coated tablets but may be markedly delayed following overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, the peak plasma VPA concentration occurred 17 hours following an overdose of Depakote in one reported case [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic serum concentrations range from 50 to 100",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (350 to 700",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. At therapeutic concentrations, VPA is 80 to 90 percent bound to plasma proteins and has a small volume of distribution (0.13 to 0.23",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VPA is metabolized extensively by the liver via glucuronic acid conjugation and beta and omega oxidation to produce multiple metabolites, some of which are biologically active. Less than 3 percent of VPA is excreted unchanged in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. VPA is eliminated by first-order kinetics with a half-life ranging from 5 to 20 hours (mean 11 hours); the half-life may be prolonged to as great as 30 hours after overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CYP (p450) mediated omega oxidation, which is normally responsible for a small component of VPA metabolism, may generate toxic metabolites that have been implicated in the dose-related and idiosyncratic hepatic, metabolic, and neurologic adverse effects of VPA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. During long-term or high-dose VPA therapy, a greater degree of omega oxidation may occur, increasing the risk of toxicity. 2-propyl-2-pentenoic acid (2-EN-VPA) may mediate cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6,7,9,10\">",
"     6,7,9,10",
"    </a>",
"    ], 2-propyl-4-pentenoic acid (4-EN-VPA) may mediate hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and propionic acid metabolites may precipitate hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. Other metabolites may produce a false-positive urine ketone determination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7532864\">",
"    <span class=\"h2\">",
"     General findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with acute valproic acid (VPA) intoxication experience mild to moderate lethargy and recover uneventfully [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Central nervous system (CNS) dysfunction is the most common manifestation of toxicity, ranging in severity from mild drowsiness to coma or fatal cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. The onset and progression of CNS depression is usually rapid, but may be delayed with ingestion of delayed release preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Patients who ingest greater than 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of VPA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have plasma concentrations greater than 180",
"    <span class=\"nowrap\">",
"     &micro;g/mL",
"    </span>",
"    (1260",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    usually develop some degree of CNS depression, although plasma free and total VPA concentrations correlate imprecisely with the severity of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical findings following overdose can include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs &ndash; Respiratory depression, hypotension, tachycardia, hyperthermia",
"     </li>",
"     <li>",
"      Metabolic &ndash; Hyperammonemia, anion gap metabolic acidosis, hyperosmolality, hypernatremia, hypocalcemia",
"     </li>",
"     <li>",
"      Gastrointestinal &ndash; Nausea, vomiting, diarrhea, mild toxic hepatitis",
"     </li>",
"     <li>",
"      Additional neurologic &ndash; Miosis, agitation, tremors, myoclonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recognized but rare complications of overdose include fever, hallucinations, heart block, pancreatitis, acute renal failure, alopecia, leukopenia, thrombocytopenia, anemia, cerebral edema, seizures, optic nerve atrophy, and acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. In contrast to poisoning with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , nystagmus, dysarthria, and ataxia are rarely noted following VPA overdose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41863?source=see_link\">",
"     \"Phenytoin poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=see_link\">",
"     \"Carbamazepine poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic VPA therapy may be associated with non-dose-related (idiosyncratic) toxicity, including hepatic failure, hyperammonemia without hepatic failure, pancreatitis, alopecia, leukopenia, thrombocytopenia, and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6,7,12\">",
"     6,7,12",
"    </a>",
"    ]. Myelodysplastic changes may also be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H45#H45\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema is associated with acute and chronic VPA toxicity and is not clearly correlated with the dose of VPA ingested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/9\">",
"     9",
"    </a>",
"    ]. When associated with acute intoxication, cerebral edema becomes clinically apparent 12 hours to four days after overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/7,9,10,17\">",
"     7,9,10,17",
"    </a>",
"    ]. Cerebral edema likely reflects abnormal VPA metabolism that allows accumulation of the 2-EN-VPA metabolite in the brain and plasma. 2-EN-VPA has a prolonged elimination half-life (mean half-life 43 hours) and may be responsible for the prolonged coma exhibited by some patients despite normalization of plasma VPA concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperammonemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperammonemia may occur after acute overdose or chronic use of VPA, and is not always accompanied by abnormal liver function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/5-8,13,14,18\">",
"     5-8,13,14,18",
"    </a>",
"    ]. Increases in plasma ammonia occur in nearly 50 percent of patients treated with VPA, and nearly half of such cases are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperammonemia is believed due to propionic acid, a metabolite of VPA, which inhibits mitochondrial carbamoyl phosphate synthetase, an enzyme necessary for ammonia elimination via the urea cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/8\">",
"     8",
"    </a>",
"    ]. If the action of this enzyme is sufficiently impaired, ammonia levels will accumulate, frequently producing encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, VPA may raise serum ammonia levels through interaction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , a cofactor necessary for mitochondrial long-chain fatty acid metabolism; serum ammonia concentrations directly correlate with the dose and serum concentrations of VPA, and inversely with serum concentrations of carnitine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Valproate-related hyperammonemic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hyperammonemia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    therapy is often referred to as VHE, and can sometimes occur without abnormalities of liver function tests. VHE has the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/8,20-26\">",
"     8,20-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical features can include confusion, lethargy, vomiting, and increased seizure frequency.",
"     </li>",
"     <li>",
"      Progression to stupor, coma, and death may rarely occur.",
"     </li>",
"     <li>",
"      Onset may be immediate with loading of VPA, or insidious with chronic VPA therapy.",
"     </li>",
"     <li>",
"      The degree of encephalopathy is not clearly related to VPA serum levels, which may be in the normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum ammonia levels should be monitored if VHE is suspected clinically. VPA should be discontinued immediately if serum ammonia is elevated. VHE is more likely when VPA is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Urea cycle defects and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency may increase the risk of developing hepatic failure with VHE. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hepatotoxicity'",
"    </a>",
"    below.) Also, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute VPA ingestion may result in dose-related and reversible hepatotoxicity, which manifests as minor elevations in aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. Chronic dosing of VPA is also associated with mild aminotransferase elevations in up to 44 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12,28,29\">",
"     12,28,29",
"    </a>",
"    ]. Discontinuation of the drug usually results in complete resolution of these liver function abnormalities, although idiosyncratic fulminant hepatic failure and death (with histopathologic changes similar to those of Reye's syndrome) have also occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12,30\">",
"     12,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such idiosyncratic reactions usually occur during the first six months of VPA therapy and are not preceded by minor aminotransferase elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients at greatest risk for fatal hepatotoxicity due to chronic VPA are children less than two years old, particularly those with organic brain disease, developmental delay, congenital metabolic disorders, and severe epilepsy treated with multiple anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"     12",
"    </a>",
"    ]. The incidence of fatal hepatic reactions in this at-risk group may be as high as 1 in 500, whereas the overall incidence is one in 50,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both acute hepatotoxicity and idiosyncratic hepatic failure following chronic VPA use are probably mediated by 4-EN-VPA, an omega oxidation metabolite of VPA, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. VPA (itself a short-chain fatty acid) combines with carnitine and results in carnitine depletion during long-term or high-dose VPA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/11,18,19,31\">",
"     11,18,19,31",
"    </a>",
"    ]. Hypocarnitinemia results both in impaired mitochondrial fatty acid oxidation for energy production and impaired VPA metabolism. Microvesicular steatosis and subsequent hepatic failure can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"     12",
"    </a>",
"    ]. VPA-induced lipid peroxidation and glutathione depletion may also contribute to hepatotoxicity through less well understood mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common metabolic abnormalities after VPA overdose include hypernatremia, hyperosmolality, hypocalcemia, and anion gap metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/6,7,10,14\">",
"     6,7,10,14",
"    </a>",
"    ]. VPA is administered as a sodium salt (13.8 mg sodium per 100 mg VPA) and therefore, can produce hypernatremia in large doses. VPA and its metabolites are low molecular weight, osmotically-active acids and anions that may produce elevated osmolal and anion gaps and metabolic acidosis. Hypocalcemia is produced when calcium binds anionic VPA metabolites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533916\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valproic acid concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic serum concentrations of valproic acid range from 50 to 100",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (350 to 700",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Serum concentrations should be measured in any case of known or suspected overdose or toxicity. &nbsp;Because valproic acid levels often peak several hours after ingestion, we recommend that serial valproic acid concentrations be assessed every two to four hours until a decline in the level is noted, which suggests that a peak serum level has been reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7534804\">",
"    <span class=\"h2\">",
"     General testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system impairment by drugs that prolong the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following tests should be obtained for any patient at risk for significant VPA toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic serum electrolyte concentrations, including sodium, bicarbonate, and calcium",
"     </li>",
"     <li>",
"      Serum transaminase concentrations (AST, ALT)",
"     </li>",
"     <li>",
"      Serum ammonia concentration",
"     </li>",
"     <li>",
"      Platelets",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate the emergent management of valproic acid (VPA) overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef74180 \" href=\"UTD.htm?24/23/24956\">",
"     table 1",
"    </a>",
"    ). The general approach to any poisoned patient must include the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation, including the recognition that poisoning has occurred, identification of the agents involved, assessment of severity, and prediction of toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"       \"General approach to drug poisoning in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=see_link\">",
"       \"Initial management of the critically ill adult with an unknown overdose\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management, consisting of supportive care, prevention of drug absorption, and, when appropriate, the administration of antidotes and enhancement of drug elimination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"       \"Gastrointestinal decontamination of poisoned adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link\">",
"       \"Enhanced elimination of poisons\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is the principal treatment for VPA intoxication and results in good outcomes in the vast majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    may be beneficial. (See",
"    <a class=\"local\" href=\"#H7533050\">",
"     'Naloxone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Carnitine supplementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with altered mentation may require tracheal intubation for airway protection. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benzodiazepines should be administered if seizures occur (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    &nbsp;5 mg IV; dose can be repeated and doubled every 5 to 10 minutes as necessary for refractory seizures). The use of benzodiazepines to control severe seizures is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H19#H19\">",
"     \"Status epilepticus in adults\", section on 'Benzodiazepines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=see_link&amp;anchor=H7708122#H7708122\">",
"     \"Initial management of the critically ill adult with an unknown overdose\", section on '&ldquo;D&rdquo;: Disability and neurological stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533050\">",
"    <span class=\"h2\">",
"     Naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    (0.8 to 2 mg) was reported to reverse CNS depression in several cases of VPA poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/33-36\">",
"     33-36",
"    </a>",
"    ], although this effect is not universal. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. While the efficacy of naloxone is questionable, the risks associated with treatment are low and thus we suggest that naloxone be given to VPA-poisoned patients with signs of central nervous system depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carnitine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because VPA-induced hyperammonemia and hepatotoxicity may be mediated in part by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency, carnitine supplementation may prevent and attenuate these adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. We suggest the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours given IV; maximum dose is 3 grams) for patients with hyperammonemia, lethargy, coma, or hepatic dysfunction. Treatment is continued until the clinical signs of severe poisoning resolve.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    administration reverses carnitine deficiency, decreases elevated ammonia levels, and improves lethargy in patients treated chronically with VPA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/18,19,41\">",
"     18,19,41",
"    </a>",
"    ]. It also may hasten the resolution of coma, prevent hepatic dysfunction, and reverse mitochondrial metabolic abnormalities in patients with acute VPA intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/11,42\">",
"     11,42",
"    </a>",
"    ]. As an example, a retrospective study of patients with severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    -induced hepatotoxicity noted that intravenous carnitine therapy was associated with a marked increase in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    alone is sufficient for the vast majority of patients with a VPA overdose; we suggest this treatment for all patients with suspected VPA poisoning. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed solely for the purpose of giving charcoal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) is suggested in patients who have ingested enteric-coated, delayed-release preparations in order to prevent the on-going absorption that may occur from delayed capsule or tablet dissolution [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3,38\">",
"     3,38",
"    </a>",
"    ] and in patients who have ingested a large amount of VPA.",
"   </p>",
"   <p>",
"    Orogastric lavage is",
"    <strong>",
"     not",
"    </strong>",
"    routinely recommended because morbidity from this procedure outweighs its theoretic advantages over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    alone.",
"   </p>",
"   <p>",
"    We suggest whole bowel irrigation in those patients who have rising VPA plasma concentrations and clinical deterioration despite appropriate treatment with MDAC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Enhanced elimination techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although its use for this purpose is not well established, multiple-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) may hasten the elimination of absorbed VPA by promoting passive diffusion of the drug down a concentration gradient from the intestinal mucosal capillaries into the intraluminal space. This process is referred to as enterocapillary exsorption, reverse absorption, or gastrointestinal dialysis. The intestinal mucosa serves as a semipermeable dialysis membrane, and the intraluminal binding of free drug by activated charcoal drives further drug diffusion into the lumen. In one case of VPA intoxication, MDAC produced an elimination half-life of 4.8 hours, as compared with an expected half-life of 10 to 16 hours without MDAC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/38\">",
"     38",
"    </a>",
"    ]. Indications for MDAC are described above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Gastrointestinal decontamination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because the excretion of valproic acid via the kidney is minor, forced diuresis (with or without manipulation of urinary pH) is ineffective for increasing drug elimination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hemodialysis and hemoperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of controlled trials, it is unclear whether extracorporeal removal of valproic acid (VPA) improves clinical outcomes. We suggest these modalities be used only for patients with clinically severe VPA poisoning who manifest refractory hypotension or seizures that cannot be successfully managed with supportive care and other less invasive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodialysis and hemoperfusion have both been used in this setting, but data guiding their use are limited. Theoretically, the relatively low molecular weight (144 daltons) and low volume of distribution of VPA suggest a potential benefit from extracorporeal therapy, but the high degree of protein binding of the drug hinders the efficiency of these modalities.",
"   </p>",
"   <p>",
"    Hemodialysis has little impact on the overall elimination of VPA at usual plasma concentrations because the amount of free drug available for diffusion across the dialysis membrane is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the efficacy of VPA removal by hemodialysis increases in the overdose setting. At serum concentrations above 90 to 100",
"    <span class=\"nowrap\">",
"     &micro;g/mL,",
"    </span>",
"    protein-binding sites become saturated and there is a progressive elevation in the concentration of free drug, which can be readily cleared across a dialysis membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. A slight increase in clearance can be obtained with the use of a charcoal hemoperfusion cartridge because there is direct contact of blood with an adsorbent that can remove even highly protein-bound substances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/48\">",
"     48",
"    </a>",
"    ]. Hemodialysis has the added benefit of reversing VPA-associated severe metabolic abnormalities, including elevated serum ammonia concentrations.",
"   </p>",
"   <p>",
"    There are a number of reports in the literature describing the use of hemodialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoperfusion in the treatment of VPA overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/3,14,31,49-57\">",
"     3,14,31,49-57",
"    </a>",
"    ]. Alone or in combination, these modalities appear to enhance the plasma clearance and decrease the elimination half-life of VPA substantially. In one series, accelerated clinical recovery (resolution of coma, hypotension, or the need for pressor support) was described in five of eight patients during extracorporeal treatment.",
"   </p>",
"   <p>",
"    Plasma VPA clearances range from approximately 50 to 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with extracorporeal methods, as compared with an intrinsic clearance that ranges from approximately five to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/45\">",
"     45",
"    </a>",
"    ]. Elimination half-lives ranged from 1.7 to 3 hours during extracorporeal methods as compared with 4.8 to 21 hours in these patients before and after extracorporeal removal.",
"   </p>",
"   <p>",
"    Initially, plasma extraction ratios ([arterial - venous]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    arterial) of around 55 percent are achieved with hemodialysis and hemoperfusion alone and up to 90 percent when the two modalities are used in combination. Plasma clearance rates and extraction ratios decline steadily during extracorporeal treatment because plasma VPA concentrations decrease, less free VPA becomes available for removal by hemodialysis, and saturation of the charcoal hemoperfusion cartridge occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7534834\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patients at greatest risk for fatal hepatotoxicity due to chronic valproic acid (VPA) toxicity are children less than two years old, particularly those with organic brain disease, developmental delay, congenital metabolic disorders, and severe epilepsy treated with multiple anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Valproic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7532899\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs or symptoms (eg, somnolence) of severe valproic acid (VPA) poisoning are admitted to an intensive care setting. In addition, adult patients who ingest greater than 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of VPA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have plasma concentrations greater than 180",
"    <span class=\"nowrap\">",
"     &micro;g/mL",
"    </span>",
"    (1260",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    usually develop some degree of CNS depression and warrant admission to a closely monitored setting. &nbsp;",
"   </p>",
"   <p>",
"    Asymptomatic patients who ingest immediate-release preparations should be observed closely for six hours. If the VPA level is low and the patient remains asymptomatic, further clinical deterioration is highly unlikely. Patients who ingest sustained-release preparations should be observed for at least 12 hours.",
"   </p>",
"   <p>",
"    We concur with the recommendations for the management of unintentional ingestions of VPA developed by the American Association of Poison Control Centers, which state that [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28264/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with unintentional ingestions of immediate-release VPA who are asymptomatic, and more than six hours has elapsed since the time of ingestion, can be observed at home by a responsible adult.",
"     </li>",
"     <li>",
"      Patients with unintentional ingestions of delayed-release or extended-release formulations of VPA who are asymptomatic, and more than 12 hours has elapsed since the time of ingestion, can be observed at home by a responsible adult. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533908\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valproic acid (VPA) is widely used to treat seizures and other disorders. The majority of patients with acute VPA intoxication experience mild to moderate lethargy and recover uneventfully.",
"     </li>",
"     <li>",
"      Central nervous system (CNS) dysfunction is the most common manifestation of VPA toxicity, ranging in severity from mild drowsiness to coma or fatal cerebral edema. The onset and progression of CNS depression is usually rapid, but may be delayed with ingestion of delayed release preparations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other clinical findings following overdose can include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vital signs &ndash; Respiratory depression, hypotension, tachycardia, hyperthermia",
"     </li>",
"     <li>",
"      Metabolic &ndash; Hyperammonemia, metabolic acidosis, hyperosmolality, hypernatremia, hypocalcemia (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Electrolyte abnormalities'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Gastrointestinal &ndash; Vomiting, diarrhea, hepatitis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Hepatotoxicity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Additional neurologic &ndash; Miosis, agitation, tremors, myoclonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperammonemia may occur after acute overdose or chronic use of VPA, and is not always accompanied by abnormal liver function tests. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hyperammonemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic serum concentrations of VPA range from 50 to 100",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (350 to 700",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      Serum concentrations should be measured in any case of known or suspected overdose or toxicity. Because VPA levels often peak several hours after ingestion, we recommend that serial VPA concentrations be assessed every two to four hours until a steady, significant decline is noted. (See",
"      <a class=\"local\" href=\"#H7533916\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care is the principal treatment for VPA intoxication and results in good outcomes in the vast majority of patients. A summary table to facilitate the emergent management of VPA overdose is provided (",
"      <a class=\"graphic graphic_table graphicRef74180 \" href=\"UTD.htm?24/23/24956\">",
"       table 1",
"      </a>",
"      ). Patients with significant alterations in mental status are likely to require tracheal intubation. Seizures are treated initially with benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      &nbsp;5 mg IV; dose can be repeated and doubled every 5 to 10 minutes as necessary for refractory seizures). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      for patients with a severe acute VPA overdose of",
"      <strong>",
"       immediate",
"      </strong>",
"      release formulations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); we suggest treatment with multiple dose activated charcoal for patients with a severe acute VPA overdose of",
"      <strong>",
"       delayed",
"      </strong>",
"      release formulations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      may be beneficial in some cases. We suggest the administration of L-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV given every eight hours; maximum dose 3 grams) for patients with VPA toxicity associated with hyperammonemia, lethargy, coma, and hepatic dysfunction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7533050\">",
"       'Naloxone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Carnitine supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend consultation with a nephrologist for possible extracorporeal treatment for all patients with clinically severe VPA poisoning (eg, coma, hyperammonemic encephalopathy). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hemodialysis and hemoperfusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     McNamara JO. Drugs effective in the therapy of the epilepsies. In: Goodman &amp; Gilman's The Pharmacological basis of therapeutics, Hardman JG, Limbird LE, Molinoff PB et al.  (Eds), McGraw-Hill, New York 1996. p.476.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/2\">",
"      Ingels M, Beauchamp J, Clark RF, Williams SR. Delayed valproic acid toxicity: a retrospective case series. Ann Emerg Med 2002; 39:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/3\">",
"      Graudins A, Aaron CK. Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. J Toxicol Clin Toxicol 1996; 34:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/4\">",
"      Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/5\">",
"      Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/6\">",
"      Gram L, Bentsen KD. Valproate: an updated review. Acta Neurol Scand 1985; 72:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/7\">",
"      Dupuis RE, Lichtman SN, Pollack GM. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf 1990; 5:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/8\">",
"      Coulter DL, Allen RJ. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet 1980; 1:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/9\">",
"      Khoo SH, Leyland MJ. Cerebral edema following acute sodium valproate overdose. J Toxicol Clin Toxicol 1992; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/10\">",
"      Anderson, GO, Ritland, S. Life threatening intoxication with sodium valproate. Clin Toxicol 1995; 33:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/11\">",
"      Ishikura H, Matsuo N, Matsubara M, et al. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/12\">",
"      Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/13\">",
"      Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr 1981; 99:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/14\">",
"      Mortensen PB, Hansen HE, Pedersen B, et al. Acute valproate intoxication: biochemical investigations and hemodialysis treatment. Int J Clin Pharmacol Ther Toxicol 1983; 21:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/15\">",
"      Jones AL, Proudfoot AT. Features and management of poisoning with modern drugs used to treat epilepsy. QJM 1998; 91:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/16\">",
"      T&oslash;nnesen E. Delirium tremens and hypokalemia. Lancet 1982; 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/17\">",
"      Berthelot-Moritz F, Chadda K, Chanavaz I, et al. Fatal sodium valproate poisoning. Intensive Care Med 1997; 23:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/18\">",
"      Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982; 101:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/19\">",
"      Gidal BE, Inglese CM, Meyer JF, et al. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol 1997; 16:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/20\">",
"      Marescaux C, Warter JM, Micheletti G, et al. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982; 23:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/21\">",
"      Zaret BS, Beckner RR, Marini AM, et al. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982; 32:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/22\">",
"      Batshaw ML, Brusilow SW. Valproate-induced hyperammonemia. Ann Neurol 1982; 11:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/23\">",
"      Duarte J, Macias S, Coria F, et al. Valproate-induced coma: case report and literature review. Ann Pharmacother 1993; 27:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/24\">",
"      Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002; 17:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/25\">",
"      Auinger K, M&uuml;ller V, Rudiger A, Maggiorini M. Valproic acid intoxication imitating brain death. Am J Emerg Med 2009; 27:1177.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/26\">",
"      Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/27\">",
"      Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979; 20:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/28\">",
"      Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984; 25:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/29\">",
"      Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. Am J Emerg Med 1997; 15:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/30\">",
"      Koenig SA, Buesing D, Longin E, et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/31\">",
"      Matsumoto J, Ogawa H, Maeyama R, et al. Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 1997; 38:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/32\">",
"      Raza M, Al-Bekairi AM, Ageel AM, Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res 1997; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/33\">",
"      Alberto G, Erickson T, Popiel R, et al. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann Emerg Med 1989; 18:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/34\">",
"      Steiman GS, Woerpel RW, Sherard ES Jr. Treatment of accidental sodium valproate overdose with an opiate antagonist. Ann Neurol 1979; 6:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/35\">",
"      Montero FJ. Naloxone in the reversal of coma induced by sodium valproate. Ann Emerg Med 1999; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/36\">",
"      Dingledine R, Iversen LL, Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur J Pharmacol 1978; 47:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/37\">",
"      Connacher AA, Macnab MS, Moody JP, Jung RT. Fatality due to massive overdose of sodium valproate. Scott Med J 1987; 32:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/38\">",
"      Farrar HC, Herold DA, Reed MD. Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal. Crit Care Med 1993; 21:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/39\">",
"      Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010; 44:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/40\">",
"      Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/41\">",
"      Raby WN. Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 1997; 154:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/42\">",
"      Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996; 37:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/43\">",
"      Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/44\">",
"      Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 2009; 47:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/45\">",
"      Marbury, TC, Lee, CS, Bruni, J. Hemodialysis of valproic acid in uremic patients. Dial Transplant 1980; 9:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/46\">",
"      Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/47\">",
"      Bowdle AT, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980; 28:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/48\">",
"      Kandrotas RJ, Love JM, Gal P, Oles KS. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 1990; 40:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/49\">",
"      van der Merwe AC, Albrecht CF, Brink MS, Coetzee AR. Sodium valproate poisoning. A case report. S Afr Med J 1985; 67:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/50\">",
"      Roodhooft AM, Van Dam K, Haentjens D, et al. Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis. Eur J Pediatr 1990; 149:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/51\">",
"      Tank JE, Palmer BF. Simultaneous \"in series\" hemodialysis and hemoperfusion in the management of valproic acid overdose. Am J Kidney Dis 1993; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/52\">",
"      Williams, SR, Clark, RF. Hemodialysis of a valproic acid poisoning (abstract). J Toxicol Clin Toxicol 1995; 33:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/53\">",
"      Fernandez MC, Walter FG, Kloster JC, et al. Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning. Vet Hum Toxicol 1996; 38:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/54\">",
"      Kay TD, Playford HR, Johnson DW. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol 2003; 59:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/55\">",
"      Al Aly Z, Yalamanchili P, Gonzalez E. Extracorporeal management of valproic acid toxicity: a case report and review of the literature. Semin Dial 2005; 18:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/56\">",
"      Licari E, Calzavacca P, Warrillow SJ, Bellomo R. Life-threatening sodium valproate overdose: a comparison of two approaches to treatment. Crit Care Med 2009; 37:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/57\">",
"      van den Broek MP, Sikma MA, Ververs TF, Meulenbelt J. Severe valproic acid intoxication: case study on the unbound fraction and the applicability of extracorporeal elimination. Eur J Emerg Med 2009; 16:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28264/abstract/58\">",
"      Manoguerra AS, Erdman AR, Woolf AD, et al. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2008; 46:661.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 338 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28264=[""].join("\n");
var outline_f27_38_28264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7533908\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FORMULATIONS, PHARMACOKINETICS, AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7532864\">",
"      General findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperammonemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Valproate-related hyperammonemic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533916\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valproic acid concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7534804\">",
"      General testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533050\">",
"      Naloxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carnitine supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Enhanced elimination techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hemodialysis and hemoperfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7534834\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7532899\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533908\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/23/24956\" title=\"table 1\">",
"      Valproate toxicity rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=related_link\">",
"      Carbamazepine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=related_link\">",
"      Initial management of the critically ill adult with an unknown overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41863?source=related_link\">",
"      Phenytoin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28265="Colonic adenoma Light";
var content_f27_38_28265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a colonic tubular adenoma shows mildly dysplastic crypts without invasion of the lamina propria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACsAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3ECnDJ6Uwe3SnD1r22cKHjpnOQPWpAe3eowOeaeuB3496hjHcnpRn5R/jR+XWgVIwGcYxQPrzQcZ4/nQfccY/KgLi5Jzjg0g4FGBnimgdz0FAxwz2pePSmjpx+FPPPBNACDnHOemcUh69aUYznNIPQ0DEXBYA08rwCTnimEHPNBc42/qKBiseMgH/AAFNyOp59qQnPTjPakPNNIBQSOlJmim0xi5BOBR2pOAc88Uh6cUwDqPxpAfxFI3TnmkyeeaYCg54puRz1pG780h5NUkAuc45/Wkz1xmkJA6mkJ/CnYBe1BPP8qTP5mk3DNBIpODnpQD7VGcZ70oP51VhD9aP/FLJz/y+D/0A1yvbGTiup1nnwshxnN4P/RZrlONx46dq6ML8D9WYVviF4zuPU0pPB64pvHPal75/DrXUZWFz27U0knvx6UHBGOg9qO9AIdnH0xSZP40lApDHHsADxTc89eaXPU4z9ab70DHZ60dqbQDkfjigQ7cQDg/nQODzxUaFizblwM8c/rTwfwoGOB5OT2pc9ecjNN3dhQM8c85pAOzntxQffp/Omk578noaXpjAyTQOw7PocfpS5H4g8Ui4OeevrTjknkUAL+HvmlBGBTQDjk5pQc57UhD88CjI4/pTc4pSaAD1NND9u/8AOlz6VR1FJpECW+WLkK/z7QF7n1ppXY0rjZtYtI7sWwkDS43YXuO+KuqwZQVPGOKzotKhghCRFmOchpDuINXSrqiKm3jGeO3tVadCpKP2SRj1G79KQ89OnrQcn29Pek4GetCIaDI7mmk8/wA+aD09qa2cYFMVhaKb19qKBnZg04HI6muF8ZeNP7Isx/Ylt/aV4JNssag4jXB/NjjgVwkXxG8Y39nHNDYJBJJu/dLGv7tV7sSD74FckMDUmr7ep6VLB1aiulb7/wDI92BHbmn8E+pr550b4jeLNQ1VrW4kmgKDzC6wqECk9OQNx9x/9euqTxh4htmjkad7iHcBh1TdJ7ADkZ9a0/syq9mvx/yNPqE/5l/Xqj17rxj3pSeeveuFn8cDT4ka90+5aVxkIny8evNRXvxO0qykP2i3nSE4xIzKuenY/Wud4Gv0iYrC1mubl0PQCf1oyMVwN58VfC9paRXE89ysT/dPk9fpzz+FdEvibS1uzaXF0Le4VVZlnG0KSM7S3QMPSspYWrHeLIdCot4m5jnk9qaenv3xVaG+tJ4WnhuoHhBILrKCoPpmpnmRIxK8iLGcYdmAB/GseVrSxDTW5IBg8jn1oyARzyelUrjUrK1K/aLy2izyBJKFz+Bqude0lsY1Sy4P/PZeDVKlN6pMpQk9UjV74B5pAeMdKpxalZSxh4r21dMfeWZSP50x9V09CQ9/arxnmZR/Wj2cuw1F9i/3x29KQjpVI6nYhN/221C9j5y/41Edb0sAn+0LTGcf60GmqU+iYKMn0NHPakJH0rjdc+IGk2EvlW+68mxn5GCxgDuWNcjrvxcig0p5YVjs7mNir+crOCfROma6YYGtJXtZeZvHDVJa2t6nrxYZwaXIzjmvBbX4yX1w4jhi86YANs+yHdIMdua6GP4o3EE6G/sYjFIUCqu9WG4cc4IOOQfStHl9XpZ/Mp4Spa6t956wTkkUhPBGcVymn+N9Iu3Eczy2knOROMKD6bhxSTeO/D8cu06gZBzykLkZ/KsHhqqduVmfsKt7cr+46rI/SmnqOPeucHjTw+VU/wBpxqG6BkYH8sVHqHiG0vNOnTQ9b02O/dR5TyuCBzz8p9qaw9TrFr5MXsp3tJW9TpiaaT14NVbabbboJZ0klVQruSFywHJx257dqgm1WyicpLfWiFRlg0yg/qalU23ZGduxfJOe/vTdwyOK5XWPHvh3S4y1xqKSbeW8gGTaPUkcVw2s/FrzmddL8q1hG799IPMkOBnO3ov05rop4SpPpb1NqeGqTdkreuh7C0mxCTkgDPBpqSLIu4dDXjlt4t1HWUgibUGJJBUbFjUkcgvjnA64OM0/+29eFpqM0OpW80GSNxYfMQOSucbR/OuhZfK2rNJYRxdnJf18j115HEqrHFuGMlywAH+JqUEc+teS6F421KytCs9pHcA4dd8hRsH8/WugtviRpghdr+Ge2aMhZNuJAp98dv8AGs54OotlcmeCrR6XO91rnwouAT/po/8AQDXKk84PWsD4teIob74QR3ekXcqRf2ysMhXKMf3DNtPfuprxHSPEer2h8621OdQhztdtyn8DTwtK0Wno7slZfOquZOz7H0bS/SuT8P8Aipb7RUu7qIo6ukchAyMnAz9K1L3xHpNlKYZ71PNUBiiAucHp0BrdU5X0RwTozhLla1Ng8ikJ4qhZavZ3tuJYZMKTgbhjmrgYhcuVBz+ApOLTszNpx3H0MegP6U0HK5x9KI2Yrll2n0pCHdTQKWkP/wCukAooA9elGfekBPpQMX3oPAorJ1/XrXQv7N+1xzP9vvYrCLygDiR84LZI+Xg9Mn2qW1FXYJXNc9f/AK1H16UA9zSgDcBzg0wAd+M0oGMUe/Bpe4GOaQxAQcnmnGk6k8c0p+p56UWC4D6ClHU8UnUDjn0pPp0oAUnrigsaQnnA7UgwegBxwKBj84z7UduaaBxx9aUYwO9ABkkY7UHODyfrS9etN9hkZpiAZGOc0h6kfNx39aX6UAcHr6UwGt/u/rTOnJ5/pT+2elNz35oATp2ooHGaKYjzjxTdXmhqkkX2pFhjEcFyxBjZnfBaUIOgAHzc4zg9aHtMz2q3ckgsbBVkmS1tWgT7QzlUXjlxkFjnAA5PUCr+j67f6hd7b2TT7KGZd8Atb4yJdeX/AAxqw+7z8xA5Ix2zWZ4p1e+07wlpcF9q0ey+knnlcRM27L/IVJy2BznPPTAGK7U3KyPoIyk2rvcz7ZNS1bXb6RHaSIMyKTEsMYY84X+JjwcHgVc0hU0rV47q6Uh7dxKQPmwccZ7D6GsrwRc6ZBDI13HazRMSsVzHGTGTjBDDrn39624NXj0pr6O13TWrjcpxhW4xnk5wPxroXvJo6FKo04KOjX5+Zra3fS6lP9oEezAHkSRnlV6//Xrk9PuJ/EN5dNqaWh06KUW48wYk88HBBBP3uPTBDGrMN3qOrWlt4atYpBHes7R3cGMwOvQEjt+X6V0cunWVtNvdo5EtZ4pmuJbUiOWcoQvlsCDK5PAzhfr1rNyUPdQub2SUGtv6/rzK62kVvff2Lp8Fk/iMFZbaKVTMkS5y0jBchRgcZI5xWbrzaZq1zazT3uoQahNO0Xy2ksbFycOShGB/vZ4rTt7dLXQtf0eK1ltkunRA91MsDXKk7mUOMkoCecZ6Yz3rQ0fT7hvGl2mmy6hPpFkq29xZXBKNDOoGPKLE/Iw5z3H1rB1OVtt/1/XQzdZuT5v6/E5HWdLGk2Xm3WtG007iJA0WdzH+J25JOM4GPxNVm0zW7zTkaz1mC6gQl42cfum6fLjsAMnjqeOK6PUdN8Q2+o2bWsH9o/bkmto42gCW8Z2HDMqcMOuWduOw9H+CtOsLPThbW82lwmRni+wszhp5VAExVZOq9QAOMHOav2ytuV7dX/4JgnRtVe7eVtYsYlb5IYxhw4DAkg+uMjjpxzVa90awsbSP7brU84Cm2mEcRZ3O8MMBeSy8dunWupv9JstMsr4f2roNrZwyCKG1llRI7OUHMg+RXffjkr+FbGgX17b6NcW/he0gudQsrg2+69k8yNZCcs+9OTkEHb2BAJ4pOu+XmX/AJ+srVR1froctD4Os5hNf28l1pyzpHavKYWjOBz8gxuy3c9q1NZ8O2t5biC4unY248z92DF1BALEnLcHpXQ+LDqUC2eqF7wTmN1uL6InNtH1Ihgwd5PTJ5ArAsk0bVLoO+gT6hdG8Ek2IfKa3YqNskoLDGeuF6dxmojVbXMONbRtrQzdNsrCNLe2s7tZIkxD5zYckg85Oef51VTSJ766mkm1i2Nhc7hbQWrANIu3HUfMMHJrupZPDd9vtW0mZJoZ2d2giCIrkfPJuYYI+brznnFYUPhmaDXYprO00fTdFNq8EdxG6s0jlTtVc8sMYOAR0/Oo1rb6FvEqaSatY5Wz0bSdcF1bI94Dax+W5uMq21MDeV6kE45PXFa9zo9u0FvE1tBLHFGF3uo4OeMDnjocjntVzUtXsraO7ga50yC7d1huHhi3klBnbI/ABwDjnjHSm6jqT6JbeRLZmCKZFeCfzQ8jjrgIfmVQOcnrWibdvM1pzUtu5z+k6K9kslzeQLZCEgAG4DKyc8scdB2zW/HYm9hhkS8ieB5FkR1KusqqeVBPAyPfIrgZ/Fs1yAbWKKWKYMsgu1ZoSoPcHAJPpXa2kumajFZrr7TwR3flrbWVupNqk65YMjbQV4GSDwB17UTdloOpUaWmq7mP4mtJNC+03to6mQkxtDPJtjDM3zHPdjwM5wO1c7YeKLmC8El3Y7bZpWid2RiyqFyT9c/p+ddtDaZvbm3srF5NLUM8rvIJ/tT43AW+WKj0IPT9KyLC4nuYdQC3FlBfzSki1vreRFES8BcgbmbryARngUczsR7VX0djHuNEubp/t9vayQ3MmQjSOQIs8BwPTqT9eKntfDGsx2NzcT3E09w+S0cSK3zHAUrn0H9TWhpWsXbXNlb22tPqN2qHbby2TCO43Lldz7RsAA6jtVw38ltezyS20ssJEUC2s0ixxPI33gsjEZHUD+Ic0nLqg9pDV9f67FVtG1RDIimNcPG3muNzMgA8zIHcnI/OszUdNv821vNcAXzt57ssWFZAclQO3BHU5J4rRW+uE89NIltobGwSGWO1tVkumliYnIDY67gRnr64q9aaXfXN5dtJdMt4WDtaCYq1urKrIkisMI+M5HP0p87b1ZUa0Vuyn4V0Ca6aa31NZYLUsG+0yj5jknIwM8dBxUep+EtMtp0vIv3kUDZQc4Zs9SD24rVifWtNmtx5crZgeOS1jMYQPn5pmy2/YFPYdB2q3q4i07wTfajLc3ZN35XlNJFtCIF58pTyASc8/pUSk7iVaLlZ6/ccVoFvfyalcWaoJ5jukbDKodicnjsBwAOp610Mz6ZGYJYreKG7ikw9sVOWx1Dtzn2Nc14L0VJLqS2+3fZ3kdm82R8GQj06c9en612Uej2pszZQQxf2iGxK7buP+mm4881uttTKpNXSm3bsv1OX8QX1495HbWMRVLhZSsSMCOnClvxP51uaP4WtI4xA0q/abqJFkjkk/1hC88kjJH9OawQn9neK0iluAJywRkWTg7TncD+fPua6bTrfTbq1sVudbtL2Sa8lNvchmjmRjwpiyMKqpnJOeeR0FZyk1ojSc401zR/rYu+N9JdvglJaWc0TzL4kG9l7FbYrg++APwxXjegkXL3WnagDDeRcAAfeHb9cc+9e5+LRZ6J8EYG014prU64jyTq5cS7rYkuG/iJyOa+f5tSmugxTYLgkbZ1GHbbkgE9PyrhpLWUk+r+ZzOr73MjpPDXi86cklvMXg2uIZUb51x6kevWuuvrvT4Ar6ZdwpGSPNbG4A+/69a8WkW4mupZCxMkq+YxJ+8e/9a1oVmg0u5sghImCzEd29efx/Stqc3K6aJU5c3Md54z1y+tVsbvTrpgkTNHMqHhtw+Vj+RrWHxDmu9NaK9soFuHjKbkl+U8EA47c44z/9fjvDWiXF4f3yyyW1xZ8pnsGxx7jiodSiS38SPFOZVtXRW2kAr045+o7VvG19UY1KCm+Znofg/wAQRNeQ3MLXUVohaKeB3L5bb94Dt83pXWaV4rWa6aPUo47Tdkxnfkf7jH+9+leEy2c+mXWj3wcmJizM6ZOcHv8AhXT6ZLLc+I7u01G4RPMUqFZcgseQPfsaUoKd7kzw9OestGez6Vq0WoySLbxsVQ/eHb0rQZsKTjI56c187aNqT22q3tnfr9laM/JLHIUxg9CcjqO9bk97BaNIUnuYQqfNJ57dDx2P0rN0U9UYfUG9VJHte7KqegP609SK8LsbiWKQS6ZqF7AxTcrCYtke6kkY+orqNM8X63bII9RtoL9CPlaHMcp/Dof0qHQfQieBqRV46ryPTa+fPiT8UEvdXtLBNGnh/sbVo7pjNcKHdoshoyFDBfmJG4M3TPevbfDmpf2nYCcq6ksRscDcvscV4H8cfCrxeP7N9Ltv+Q3tCKCiq9zuCsAOMZyhJbqXJz1x5WYupCn7nfUypRSm1I9t8A+IX8U+G4NWFm1kJXZRG8gl4ViuVIwcZB6gHIPBGCelIyBz9M+tZui6Pa6No9np+mrshtYxGhwAXx1ZsAAknJJwMkk1owsTEpZVDY5AORXXC6iuZ6mMt9CQdFB5NDcZ5FBwRnmg4H0+tUIcOuMdKRWBYgfjTGdd4XIDt0FKSOATgnp9aAsSjnrScdO3WoJrqG3XdNLHEuersBTPtsBTzBNEYwMl/MBUD65p8rHYmY/MB0z3x0pVGB/UVSGsaaYhINRs/KxnJnXGPXrWZceL9HilEUN2lzOxwsUJ3k/j0A96pQk9kVGLk7JHQqwIyDSFuKw7nxHbW4ImgmJHXZgj6AkisZvFl7NIkdjZRszsRk7jtHYHpzimqUmaRw1WSuonak5xigMCeSCcdM84+lcQviq6kVLqa3WIoCPIil3CTnnkgdPxriL7ULv+111rU5SJJiELxOY/Lj6AKQeMfzq1R7s3pZfVne+h7cDwPSms5DAY6968jl8Y3OLiBNYWWC3ADN8u8knABOM1pSa1fyXzQw38kkEQ3MVXBXAyc8c1SoeYLL6vdHpe4nP8z3piklQDjd3xXmkXxAMcqW18ZI5jzwnBHbJz6Vu23i6K4jngVVkuwuUjQ/eU8Bvpmk8PNK6MJYecZcr3OtDEj5cMPY0Vg2OtadZWqRTTCMp8rknOX70VLpyT0JdCpfSLZzWl6uurapp9zrrWVtcyRfZDbNG0MySF2wqjONjYOFwDxzXO/EHRdQku5Vm1C21LALxBSP3UfVRtXIx/nNehacLWeEC2tRLPBMuZ0VCqgqRuLA5Q4PPfB75rjL7wxLf/ANoK3h2SKOIbLHyb9VjmVj867zyADltuOK6aclBvtt0Pai+R26Hn+n319Y5iktflg+WRQeFOM59QMe1bWmDUdckc28TyJ5ij90ynKEZO9jwigc7jXUp4csrl01OBtWubO3mSFbGOIxzx8YLbpPvw8cHG4E12lroGoa4b3TbnSodI8OkgpFbIQ90mfuyMeQcgcCnLEKC3+82+stQ3fzM3QLKwjbUdA8Nm5FxOhlub4RMIgduSqv8Awr0579q57w9AdFtru5067sZ9ZlmWzV47iSeJGzl2di2wOwX5VXkdCeufSdSttUsVGlaK2nWGirbGJJS482G56KpVmG/g565rBvfsml3mn2Mel6bqytJGELW8ZlS5AxJNJyOmPvHJ9DXNGo5p29f+H/yORz9pIreGpXufsWrto1/LrT209qdRA2rE4OHCjJQnJ4fGPlJzzVe4sdU1PQ7i119rq6ggWSS2iedknuQuOW4GFJO3HQ549a6Gw0N77XLjUGgu1mEa6d8oKRqi4ciMNwV55bnnIFUbnTovsr29lpn2qxVGZmtrozb33kmNOeT+OO3FVCUeZu+v9eZceVXT/wAzG0+GOCAJPqd8k+lzrcPYQ3UeISQDteNML5ajPHfn3ro4dSsruye/3Qrdyho7Ge4jXEIcdWAJEm4/MFXrkcVzF7b6odWsbIaml1r12dkulWGAn2RlGBMGyqED7zHJxgD1rd07Tby9vTptlC+m2Fkr+bqKoLcjA2kQN821euXOCR0ok48t2yXJNMt6Dc293F9p0+1VLyZAJ7s6eIJWx/FtxncfU9KbH9gurq98NWNtf2tokYeW9s5FVYnJzsJwfnJ5Pr71xurfEjTvDGzSPDT3GoQ28jfaby9Yzvct/eR8jKj6fQVzM3xT164lfCwW0T5kWJQF3KRjoe+Oc96UYN+X9f1YtR512R7dd2Fpocx1XTNLutW1ggwjy5sKGI6nLbYx3JUVpLpi2OnwWSxW1lZsMTBned2HU+WTnuTyfyry3wL4v1XXvEy6WdXVLSSzKs1vGN8T44MRx98dwcjmu9ublL21vW8M6kt3LbP9lkNxuKrIuBI24DJOOcDgk44FYTpyjK0n89fl5fgZTi4SszkLq/1WMS6eZdC1FJ2MEmni98pY0xgsgYAgkHcc7jkHHtb1iFL3RrWwFhb31xatEj2yyuiQIeBLvONwAGfXkZ61p6HoMY8ttYudHM894wsJ44gJS2wkjj5S3UnHy+tOTUmv7oQq8k+mWcAT7XLlzcuASzbQPnwAOVGCxAHSt+dX93oaRs3ZMxRDYa4+pahrFn9ns9IZojh94faNwkVQNpfkcYx0zmvPPEt4dV1ZQ95KzB/LlZ2jWZj0JJ4xkcHaK9L17UtKtzJbX1haSMlss+n206v9ocvgvJOn3V+YKQOTwK87fQp9f1W5vbC2uvIMpG+6Cjc/HMXGf6V0UdVzNaHRSdrt6J9/69CGLw3HMGhuprONbeIrFGsZCZ6gnJByO/50eHbvXfKurOyliuNQjVQHmueApJJyo44z26gc11Nhp0F5avaJay/2jGSkzTHhPVsfptFctp1hHp/jKWK7vjYRxAyvcRT+XtUEEqePunGOfWtZpdDWUlrbddP1/wAjuLqyvtHnvJ9CeyutTntzJ/Zsc6H96CB5oj4PPJbnAxiuUjtphqra5rMV5cSrMXiaBmKIr5yUDEMgUDPp6CptdV9O8W6hqkWrDTpYZhPJLPF521ZGwItyjKqDwVB/Crd5pja3Po93psaXAlQyCO7LxxwhjzIoJDEE8bSeeB71hHTWRzOPK9eg62vtP1e60m7i1i7v75hLFHE2baG4RDgCRcYCjcMuepPPSrlvd6jY+HdRbS9OgvTHLtgtlsPKNu55LbnzvCnJDgEn2FRalf6rNc2lkNOtkbVF8o2NwjLOoUnJOGOwEDIX1OSa3vC+lWeoi1uf7RlmtrZlmgjWfMqSZ+dJZFJDrjClegxxUS+G7Mm1Yo6FDfzWU+naVqN1qRd2tr7UUuVgNpJtBIhwoGA3XB/iyKp2ejW9wtxZXzjWbeNObtpU2/alG3ZJt+dmAIbLk4GPpXYrpGn2OtR3C/ZoFkb7OsIlI8+QZdvl4UufvZx2qqmm6NfXkWpwS2LQ28jCQWoUiTJ+ZGJPLdMnAbjGcVCkriuuhjS6bqbaY0t9DNLKIFBaKVYo5XLKT+/bDHAU5IwNvGDWT8X9WRX0X7FcN+9hMplUeYHQkABOox8vHqK7mDR5tW1X+0fEken3Eao8NlawxMAsT9AdxwTjIJA9s4FeParJJceLyNQtV+zWgMMEdoR5EMa/KoGec4x3z1xVUm5yV90aUE3O/Yv6DqttBdiO80+5mWaMEyEAmPGeOe/PQVavJ0ttVbzYrmzs5QN0SyfMRjv/AIVbsZ4NQeCwt4nleWQBA44UZ6/lWnJBDbaldiztpLuKNzE0pcFyQB0z2rtvrudM5Ri25RabXf0OL1ptOm8RaeNLhERKk5ZTtA44JPIzg13Ph6HTrXw3o9/qy29wk1w/2ZIYGVYxKNoXGM4AyCx555rm55tLHjzRWjt7wFpRG4CbfmLAdPUZyfYV6rLbPcaNImh3dvDPGDHFLMWdevKsRz6HiuWvJKxzVZ+6ottevmupy/xyihsfgpbW1q8cUMOvRxKkG3agFq/yYHQfWvnK8mS2gCRxssvyyB1PB46j/Cvon4m6U3h/4C6Zaz/Zbt01pXuGYHZKxt5MnJ56454NeFwadDfywAxGGFULrIhLggn7vPXuK4aKupKL6szhFyVolvSNNEqGWXY0cqAgAEMoOM49q6G106KCCF41DvFwHkALEdTz6cmrlrDG8cCphE4Q8cADAz9K27HTvNRxDFJOqNkPGAAR7Z/nXcmo7nc1GCKFnO8Cr5B2Hrk/w56j8apaw6NAFuIRJk+SHx90H3rf/s6Tn7RAy/wxSk4AbPQjnNTPolx5aIIN24ZKlhnjHIz7+lHtI3JlOmUbCNDpdjF5W2eGYruxkFOoqKC3jub/AO0TriUP5iOOMcnnPcAZrp7G1W2Mq3lpIjlcJIGxsP4VjSxfvViD4l3FQpypI9TnpmkppmalGba6HM+KdNm1HT0+zBQzygDI5K/WifRIodJERbMqxIjEdMjqf8+ldeLD7OIEkaM+cDsAk3EY7+3esS7jS6kcO3yIxCtnHyj275qoyV7jtGeqOW8GQTvrUuImkhUFd2MbeeOfwrodevhpEiXNzbb4GYBZVfleOmP85rP8RS3lrY26WBZGeXezxjBwOg4rHvpZGs7sXjMY775Y1fJG4c7l9AKpNrUxnGycDvtJ1rUbUxSaSmHuyMRTYZZcD73B+UY75rqb5f7RvtLn1vTbV73TpvPiELrINxQjgsM4zhscfMintXm+jawunWOn23LXMEGzcThCrdt3YjjrVv8A4SPT1u0iu4rr7X/HHvUknsBzUypxqayRxVqOuiPVf+EgtV1CKzZZVeXGxmUhc/3SexrY3Edq8gu/EK2sguruJorUJ5SiY7nOTnkD6cY/OlbW7x7P7VZ312tuV8zbFM3T6HNZSop7CWBlJaaep6zdXltaRh7yeK3Q/wAUrhB+tU28RaKr+WdX0/fjOPtC/wCNeVz27XC+ZLJJOWXcXlkLkg9+a528hu1vIktbOFrLjjaM9e1L2CNf7OSV5S/A9n17xfpWlRP/AKRFdXmzMdtC29nPYEjOAfU15fL4k8RXd3LJdah5fmPuFuI1CKOyg9QPfNJaRxzPItp5QkGN0a4Uj0JFcp4t1VrSWMWxIkBIbAwQffNWoxpas6IYSjQjzS946bUN9/As2oytsQkBS+1F/H0+tVLi0t4ljkAj2scKE5B+gBwa56G8D6QyqVmuLlgZIGyQw6hgOxqxHpb3uiwiGZobhJMhC33D/TOP0rXm6nRCcbWhFDpL6xj1K4tJ4CsiZKtsHzkDOAPetHQtctA0V5bxyQuHETxKg5Yjg7vSrGm2Mo8qS+CT3UYB88rznp+PFbFtBbxqI4YIkAOfkjAyfXApJvqaclR6t2+Rm6xqWvSwI9vCrEPyQQx28cY96vy3N5/acMS48u4AdmJ4XIxg+vNXvJj+ZsA87lwcCptOsjdX6mJ40YttUuwVRjpk/wBKLi5FFXucdbaZqupX1hc3sjILG6O/JIypPUAdeRikv9CutRgSAX01xHPeead5yIY1zk9fw9OlemPpRtmZXZJJ9uf3LbgSTzk46+1UIbEwRDCYjjXa7Lgc5zjP1/pUXUkYx9m07HAa/oEWmQR39g8jhZ2laBlByecOx9j2oS+lfQra0kuXhubv97cTs2CIieB9T1rf1YfZyI5oslgW2sPvk9MA9qivNNjlMJuArTAhlAH3f88Y9K1g0vQ1eHvqnucHeSTa14kd4g8dtGFhQHnai8DI7k9ee9bDa1DpkywaWg3rxPPjcWA/hH8ia6WGBYXZreCIH5icICPc/wA+a43xQkFk+2wBimmfLNnp/h68Vmv3a01JlSdNN3NwX0+oWcdzcXDoS7DZHhNtFUdAuptFUxyJFN8gCho84HUnnuTRXTG1t7EpzSty3+aPoa10Qw3Vnqek6bBp85yZPtjsuUbGcxoQvmYAALZwBWpb2OqT20Q1eeyV2ZhJHahgpGfl2k88jqPWq6axd3+qX9kdMktZrMKVubhP3JVj1VjwWA5wPpmqV34tsNFa0stZuY77UZi4LW8W1Dt5JILHYAMd/pXkfvJPRa/ecPvN7a/eXRoOmaO9/qt1qGrXVssBBtPNZ44lA5McagHdgdQeO1c/ZeJoX0K4uLhJ9H0fyn+zJLMZLm+QfxRhm345Hv2rG/4WdqH2u6tk06zN/btvNuk5IePjDoxGM+xrX1GabxT9g1JB5N9tAst1qJZInYjJweOMEc5A61rCjNO9T+vl+poqU170jN8HeG7S50F7PxBZXeoW90PtZZ95ghBBCIoJ3BgCOCM5PWuj8M6GttBPqb6GYdWUfZo5JVHmyRp8qkkk7eOMeg5qW51eO61q+s7u5MQ0PYZpPtAgiZ5FwoYA4b1AOOTVh42sNP0XS7vXVubrmadpELNKnJYjYcDBICg8YHcipnKUnr19X5kuTdkYt5qviVNdlsrTULoTS+XNG7abmzjhXO6ISk8ueu7GBUWm6Te6JaXSnUbrVoQpW3skjRJGdmyz5BGWOSCxIAA710P9kXdzqtpJb3E0dmqES2sknyMOoYhRkt0GCcYHTNU/FvjDSvAFsqzwS3OpSrvESYXg5+Z2Jwo9B19u9Lmt7sFd+X6hdLRLUp22haP4T8M6nEgl0qxuV2zzeeZpEJGDHC2AQeeMfWvNfG/xEj1mOLRtAlk0zR48IGd/mmwMAMPSpft+p/EK4m1TU59ukQzBJLWMFJI0IzuUDqOgJ6nqPStxPCug2kF1ClnE0siF7eUsXZTwNo7HnHPvXZSpctnLV/1/X5G8HGLV9zhdE8JxT3KpqF08Edxhopim1AwHTJ4yeead4i063hiWG4YXSRJ5MNxyFaMcADHXv19K7u/knuvDTQzx2sL2xEZiHzOSjY4AHH696yvHuyXQ4JJ7iG9R9ypFbxqrZwPmPOSox04rpWu6OqMrOzXdd/ne3Uxvg1FJ/wALDtZ4Ink+zpIZUwcwjHDc9OMCvZ7y9ijtHW0toIbuVmhs4AcRy3ABblgvQdS2MDvXE/DTwpqNj4envTcLZ3WsW5itIwvz4Awrtk/KoPzADrx9K7ttA/tWSx0vUInu7W2gSW5vN+1JZRwECg5JJyxzlRgDkmvOrzhzczf9L+rHHWmrv+v6/wAyhFYalrIitpESxv4LfyWvbUD9wWA80Rk8Lkgc9eM1yOsePG055tB8KSS3N2C6zam4DmNhk7VAGAo9fXmnfF/xXNFfQ6DoF2sWnxfubtYD8zMeuWGeFHbuc+grH0XTbXQtQgudMlfUonBWbcmGI9uOR36VvRpc6UprTov8/wDI1p0+bVr5f5+pl6DDc3eoG+1WKfVVhy0kifMy7hySe9dTpmpWkN5dW2nXXlW7hJY4WX/loTtPXke/Pb2q3bT2y6pcvp8kcPnoreWI8hpBnqG6H9M1XV7VNbjkil2tcqRK86YHmememDzzXW9ehq/eupJrQr39jfLqRltriS4vJEZyYSFGBjkY/Adq5zwLbPqOqavfTrpv2mzicudTjcwpgjmZe4GCR7jntW/4h1ObwxcLMFVjdx7UWPKkEHr9PocGqOjuljoWoTatOEh1cpczNdwsYo4dwBR/Qu3CKM8LnvWdV+5buZyqylDW1rf19x0k1rpMuoLdWbOLa4uGe72FJIbiR03EybiSo7r3A7Gs/RYbmXxgptNSlexubNJVjnjCvcR5KrFGrfMqJ1zjknPpSeJv7HsoodTstOWe4ndLeKSF/JlV2HEqkjkBRjgd+tdhfaXHqGjB72zf7Q9sCTDdeXOzZ4XzF4UNzz2rmlLlRnL3dDE0670WXxRfTQafJNqFlE1k8iw5Mrnl4lJ5aTA/ADGeeblrocr2VxBN4ihttLOUia2gjieGXeCpJzj5fu7cc5Oa29Gt5LrTrLzbafTvLUia1aYO+/G075B99sYO7vWbpHiG2uJlsItEgtNOkcxwubdwJZFOXJQqNqjjDE5LdKxcm9FuYuTbLniBpINMstDtb23kv7tSk91K7JN5QT95MpQHa+OnI4rF0fSrqx0GwRrfTtTluxIbnVLZtsaKBhGCEZeQ4AzgH1Oa6rQre+toLsaveRyyT3ckiRbQFhhP3UPHJA7HNS3kMCWH+kXCrasGEkkb7Dt/2CP4u/ArJS5dv+HIi+VnE+MNRfSdPOtCy1G31ra1tDBLIoUDbjeUU5IXsCepyRXBeFW0Kewlk1yZjf3DE7kQgADpjnr61D4n1WDXtRg06wiltdMtF227Tu29VPO9myTuY8nd60mmWAs5xbXhkusfdeMh930969GjTfLqejSpe7q3fy/rodh4Yso7WS6vrGdZreJPJjJ4HmN23fT+dU3ttXtJPtFjMWeQ5cqysrH0wR9RVvV4ns9HtNLiVQyASyI3DknkAgcVy2p+KNU06xKCN9gO0eZHu2n0Ddq0TunL+rCipyTmmnfv2/rU0/Bwk1vxDqN/qJRrK2jGVT92EYcYJ/P9c126Pc6npyi1nXR7+5dHVEZZ2jB5zgEAllHXrz7Vy/wqsrhrMsFW5jvpXWYSsCUUDJBGMNksOvauvtrnwv4eEsyX9nAZpZDJO025pJABvwe+3gfLwBxXLVlrbqc9aWtjkviTMH+B0LR3F1d2tx4rKwm4TaUQwSYC46jIOM+pryrRpoIIIImKtK0hVABkEnnP4V7v8aNTsrn4MWd5ZSpNGdbQwylMgt9nc559s814HoV7DaSIpiZvtD7N2OFz1+n4Vz4Zu8m+7KovW53lpZCa0W5uZXijGJEdMfvNvO3HYHvWJoGh6/Z67aaveXpj+0EupEmEcEHA9OtdDe69bafJZpc6YbnTpFWMzw8snbIwM9a63wr4bg03SrpZtQN/BcSGVDLjaikcDHY45PStZvqyK2JUJe8iaxQtawyzRk3CqCNx+VyP5HNVNctdUudR+3w6fiaG2ZUcPkDIzxzz+VW7eaOCWeG3ljnijUHeANyMP4c9+Mc1Q1vxDc2WlzvFau12o3LHu4PfpUJtO6Oe0nK6VzI0zU7+00G6/tZme8hVpIi68kduKd4Y1O28TaMb14THLCwiuApx15B/GmLevqlhZau1lJbzMGE0DcgfgegNV9LtYNBN3Po8/leeRI9pKNyrjJGPpk1pJ36G8YNpOBN4rvINIsBfyaddw2M0ixh0X/Vpzk49T2zSyQW89taXdvcLLDIqiKNU2SsD7Dqfeur0DxXpOuW0tvNcW8lzGuJ4SNwI6Zx3FVmttFXUDrWlahFD9nQo6RSDyjxjoOhGO1ZqTvZoiGJnB2ktv63OZuYo5AyxKuSceVuyRjHGDVHV7GDU1MV3HgLgopO0g4/hI6HtSav4rU+NTpV/AYYePKnyTuYjIPupyK2ptKmt4kNzEqiZNzfMCATwMY6VrzaHZTqxktTltV8P+bFFNZP8wVcxMMIQOMZ+lUr/AES4/tibWVXzC6hwsSltrYAyPYV3EUMy2ixT20rKTkSdCje3qOlMs44LaCaC4Fx57sCs8WQgX6Yzinz38xOMXqcJe2F7dRfZ5Ij5EaLKj5/eSseox2x/SnTvqMF3YWdufLhhVNwXADdzkdx2ruX0+GREn+yv5xyVlUscjPXH9ajksGI3MjjHR2j7Gn7VdRxjF9TjZdX1vR9Y/wBIZpYZH+SIAEbOgI4pmoT6l/bdhb20Ey27hXKgZA55BPbFdwLVJX3GNgBk7+Ov9Kt/2ZNK6DySFC4wE5x13D1oVS3UTjFXTZ5rqGk3+kXd7qWnyzySSMRtaPJwT+tVrvTbrXLO3u7u136hG3lu+cZQdCR616VPppjlV5/MQAkDIwKkfSmPyrC3pkgjPak3Fqz2Hy0++jOBvdGfdbXkMUT6gu0yMG2gkYx7HAFa1jYJaCV4YX8yXlyCSOvOM+9djH4duI4mP7sp0xvySfWtTTPDwkiee9heQkElVcrv9OKXtEloN16NP3kc9omg3l/IRGQEB/1pGAB711Nn4KihXdLcGU4+6qYB9s5qtrt02lacrW8YtLWE+ZIi5BKjrjPWuE8JaZq3jPXH16PW5I7CGbAtS5LDuF25wBjv+lTdy1vZHJWxFWa5lKyOk1jXPDXh7UTbalCFnYfIsgLEehI/rWX4q8Qafoptbh7ETCc4SGJDtIx2xjvXR3Om6TP4ji1DVLa3klt1AEiEOc9BkHkkfStWTX9D+0R28kUiIQSWkiI2Y7Y6ik27aLUSnNbJvQwdHtjc2UNze26WD3Ee5IbiQq4HPJTrmp9K1DQblZLWO6hnuEPSGT51XPVgOBVxrnSNbkntLe3kDTI0YkkXbkEdAeoyK8q8aXkPhKAaT4d05raKRQ89wSS+4/wk+39aHJL4h3nP4tD0y30K3niN6ZI0bcQr3B3Mec5z347VXsNFjluXmtcXTwSfvA6YQsOcfjV/4c6mmseDbQxgPexIA4lXo3rVjUk8QT6tFb26Qw6aq5uZz8pb/ZXHsBk1V2pWuR9ZqJuLdjl/FWoXF1JsuAltbwAkRpt2n3yO1eU6rch9aSaKCS8I+55g2xRr247+uTXsPi/SoYNGS6gvvtQSQBsAYKk5HTrjpXll/tt9Ta4aW3vrwKPJsWyFTI79if8AZqotW00sdsXGVFcv9feaGn3Ul2Gad1C/wmNDj88YoqzoGvzfYgNQVYHH/LMIePoB0FFdtubVMmNSSXwMl1Dxb44S3V71UFlKxRBvyCRjK5z3z6VyN19puIbrUL2T95KFwkkRWKXB2kkg8NznnHQ/SvUJtKe6RRmUzAkx2xiwqqG5Kk8AfjXmniApPrMVvZNMnSJpIY2L7gecc/NjuK56kFCLaY5JKOjJtA0HVNRuDJp8fnTW4zvtZcYJUlTu6fNz1/HFfTXw/wBHuLTSIpb6WR7iVB+6PWI45Ga5D4W/DttIikvtTnbzbgDgZzIAfldgTwa9K1H7TZ6cWtopLqdsKqLiNfqx/hQdyOcVwVq3MvZxZzV6qS5IvXr/AF+ZzWnaPpup6Xqcp0Z/KurySa6hmZZjK8YwrYz0yOB+NXNHjW71N4dNeJ7KEg3N2pUl5evkqAMBR7VBZeHxq9jHC15YwaKxaa4tdIDIlxKTksZyQzDrnAGeM9K5n4g+P9J8H6fHoHhuJI5gCgW3G1Y/YN6n15oTc24w/wCG9fMzg224r/hvUteO/HK+Eftmm6bcpd6rw5RbYlbVOAXfBy7Y9wB6V5auk33jXUVvHnE19F82ZkKi8G7lsZIAPA9Ks+DoL60u5tZima9iJZbqC4wZGDdWB5wenPQ4NdaZrOJj/Zm20+7PbggqQH++uDwQcZ616NKj7PZa9zqhS5dErvv/AJlWPxE9zJFLp1lNBrEJMF1atH8u1R8ysRwQOqkc4NJYXE1xZm5ja+bUIiWiQANDGhPAw3Y8/lTpmIuxeeWI+vy8SAnGDn+8KVr/AFnTrN7m1iS8s0gMJ8k5bywSRx3x0rXl00N/ZqnFWtfz/If4d1tnmuYrq+gspXcvvkTazsevzdvoa5+30eLXPGN3aWQvNT03z1a4W0HMj4yWDE4Uc4zUOv6rpPiTTNLtdP06+ub2V9jNCCPl9M9zk9K9x8F+HLTwho8VrZbZLiVgHcj7xIycHvXPia6orTdmFScY3mla/T+ug2Hwxb6jZ26a5aIJbe4WaNbaRh5W37iBs5IC4B7E5xXP+P8AxLNc6k/hrwzeJb6juK3EzEIiDafkU9SfoOuB611fjjxHB4V8M3V9dXHl3LKUg+UMfMPAIXPO3Oa+efCs9i+pT3HiBJdUhucPHe4zIGzk7lzlfqK5MJF1X7Sey2OejGVR89rgvhLVtN1C4SeSQzOcIzDCS55+8fU+9dv4J0261G3YSZWwib5pmJV0YdVX1IGc+lS6PBPrF8thp+sT3OmSjc0dxHuESA8lW6k9BXU+INQiSNNHhuDaQlDG8gTCKMf6vd0XIPJ/qa7p1JJqEd/nojtnWlGKp21/LzOR1Ga1N87vv0mMHMFz5ZcM3pJ6ZrnNe1rUBYzWF1p8ctyvzQzRvlWGe34/zrrtXivNIs5P3huo4gA6zbZE24/vDkH65rznRo7nxF4xhax0e4ns45VJgh+bHPJUk4QcdTgY9eK15klzX0KhKLXN2/r1/Q1Phx4XvfFEw1XVrtlson8pIkHMjqRwOwX1Nd5d3Nrqms6zpYkvbucqsrgKVWIoANkGRtxnrnk0nie+t9JgiNqY0trmXZPb6ZB5hZc42hwcKeME1ujw7aXt8NQivNTM8siTzqr+Wsuxdqow9ADzjGSO9cc6j0nJ/wBf1/XbnlJ6SZzGg2djf+JLvS7nSHe4hYXu/VQ0jShjjdEo+VRxjGRnvW5DDa6f4sKado99JeNPF9tuB+7hji5wQW4cJx8i/XrXV3jS29u00t1DZWcYJ3tjAGOhJ7DrWL4bhtpraa7h1aXV0uJTIrvOJY4ug2oV4VeM7RXN7RyTfQwcuZGJpuo32lPqV74lNtp+mtO32WxRkV2Y9DJJnBLk5wT9a6Xw/qv9tQT3Y+zkwzfZnit5BKIWXqGbHLcjPb0qW/bT7XR7ufWRD/ZijzJFljWVWA6EDGSc9OOtS217FqPh2DUtKhksrd2EvlTW/lM4zjJXtngg9+Kick+nlciTu7Fqfc0sYeNTjOAwx9OfWvNvi3qNhp72rSEy6miPFAw4ECsAGCDpux3612Gt67HodsbzUDPPbyb5vmCgQHA2RjHXJzjPOMk9K+cb/VpvEmvm81RryK1kyqywqQVGewJxmtsPTbak9jbDQ97msdH4LeW0tpvsjwSJP80sdwCCTjpn/wDX0rr9D0+wkv5NWitW0/TrLDS72DEyY/hA4A7/AI1xVto9pYzxytqA1ODdmMlmimAPZl6dveut1XVbCDTLDRROYtPx5k8yDLO5ORkdwD/SvQldpW0O2VPS8E9d/Tr8yiqWWr3Us0t9NDdPIWwCFzzwOevGODWXq+ranPqS+GLeTT3+0Msa3EMX7wHsMdFPuBU+pTaZDpxjttZ027RssFcbZkI5wO9U/h94am12Z52/dQ3jiEOW2OsfWRlwM5xhfT5qUmkvIym4yXOnov0+49L8JabrukPDYLbwXEEqM02obgiJg8BUHzMW7k49ai0nRtMhunNxBp17cHfC0EapIIFLHKrxgAkktxnOa3tThsY9bgW3hhW+ESQ71J3iPPC59OKt2WgWmn3c1xZ29vayS5LNHGB1OefXqT+Nee6nV9Ti59Ly6mF8arNLr4R2sUqoA2sqVVV2jIt5AB+lfPWmxTGWzge0BS1cMu4ZDY6gnpXvfxwtZLf4QWyW91tb+3lfzJJDkgwScZ/p7V88S35sLqO2sYB9oYL5kmCy5OOVX05qMO0oyfmzopOKjd7fmd7Hpeo6g8Js76O0ihm8yeEBsrk/Ljjt6V2RjnsyDKYZbeZt0rru8z8B69Pyqp4Rlkvp3a8bbPJAsYZV+UcdfaujtryCLS5obqFI3th5bR7hhvQg9s1rOTvYxr1GptWOMvdWtU1DVm07VbeR4bdmEaRnz45On0x/Wl+GZmuNGfWdZcSRNIY4yzDLY65z71J4Z0bwnba5c3IEIvMOpPnMUOeuc9+taPiXRdG1Tw4un2yTrZscwtA2AjZ+8Qe31FS5O1miJN/BrcwvEMWsajrVs9gzWltu2oirgOM9iKveBtai8RRX2ny6dm5tHaO4kGPnwSAc468dPatHwzoUHhq1sLaO7e72lt3mkcBuoGOgB5ra8P6Zoug/aXsWEZuJN0ju5bJ+vpSlK60FVq2ilFHEL4at/C2sy31rab2eNkwMhNjcMp9CaxPCWiHw/wCM5reGU/2ddowMc7BQUKkgEf3gcc16ZKTd61E8qzC2t2J2GLcGJ/l9ap+LPAen+I9YsdX+1TW9xBtBWPBSVQc4x2PuKXMk1dFSrRSXOtTiLw6raWr/AGqxGorbSqLYmIM0S5ydrYJwPbI5FZ+o674j0ayvJNQjikty6C3hkBPlr15/Dg57mu38U+Er628PyPol5Kt1EMjM2DjPXd+P0qhpml6ywSHVY4bmBohJJISJFlbAzz/Me1a8yaumbKcJ6p/8Oa+i6nPeeHdL1F1eNSnzQg9Segweuax9U1eB9YisrbUTbahK+PsrAck/dBP5UvhzU7m88c/2Y8TfY7Fd80vSNTtz9AOcfga6jUtG0LULya/tbKzuNVUAxzbsjcO5Ge3rUt2dzJzVOXKtSkPDMusiDfqkkMcJ2tHGASxHXk+tZfi3wffy3Vpa6RqF5bGZyjMy5jUAEhnIOQCRjgHmrUnh+8v9Mjh1l1tFkOWSJjjIyQVYc9KisPDmoRXsdra6jq7RsQzGWTCKOSMA89vWk239orXVqehseH/Dd5oWnKmqXkeoPnBfbgY9Ofatu41WK3iKPZzpJ0GQMfUEHpWXY208l0lq+oTvLGxSQE7hnHVc9a17PQkFxK94pmbd+6kZiXA9/epb/mZhNxX8R3ObuPEVpqc5ijtYZ47bmYt1Vhxnj0rQa9lhkWW7lhgtcExxFgu7jvk5NacXh/SYJdiW6LKcPyfvHPU+tcf478Cadqtyb++ubqN1G3EbArgd8Hp+FVzx2RSnTl7sUbkVwjzYWYKsjfK6cgn0PvT5L+7SCZDIY5Y8uGB+V1Hpnp9K4uWUWWjrplk0sMKx4VmAPHsPX3p/h/ULO3h8i6d5ABjccnIz3FXynX9W05mijF4v1hbqddf03ybNs4uXcFRz/DuxnI7CvQdMtdMsbG3msoQsEq5AaArnuSAO/vXJ/EXw5B4ru7DUVvlWKBAojX1Jz0/Ku20O0cW1m2pXMcl3bKVG0Dayn2PQ0r3jd6HNUdop7L+vI4jTtd0zW/Ec1loekXUNyAytI6EAY4JB/h/Guht/DkUe+ecS3B3Ayuke4vt4wc9frWnrevzabrOnWlppzzQ3x2tdoQUjI7MoGTWlp82o3MZa7t4oYz0YMVY++OcUudpIh16ijdaL8TCOpWdjqkj3E6WsJVY0kuhtA46YP4c1oxaZJIz3sl5GzPg7lVSrL2PPWvK/F3gLVLrXbxo5xqQuWBVWlyIlz0J7Yz1rY8S6CW8Mabph1h7G9tHV0l+YhsDGFwenOadk1puaTg9HTe6Nnw/HqHhyG6tX1KHUxM7TR3DgiSJOcjGPn561tQ6gdT0O1hkkld72IhhGAZQD3x2FWIbuys/D9vNq8sSRBFD3LlUEhxjceeMmnWWt6JZ6cbyKSK1s9wQTEYV/TBHUU+j0vY5pTW/LqcB41ae8jtJ9JvreLRrItaT2aMN5k7ggcDHH+TXmF7bm1vWe1KRqTuluHAYgntz0r1TxHpnh7TvD9xd6BcSOuoXZuMBt6uwyG2gjgc/nXl0dpc3bFFtUWzZ90vmP83Xr65q46rVanq4f3qKsuv8AX/BOos9Hje3E1tdKY3I5CnBOKKhs7C6itES2t7jyF+7tBx/LNFdfPFHRHnS1miHxB4pc26wWct1HcKMRfMxADHkL6HpkGvRfgp4KltWl1nxDcAknzIYGAA9S7gjIx6H+VS+GvhA+nWyXUsscOpb8yiIiRtoJBCM3ALDBJIOK9AtrZLi0mt2jvdNmDlUt7qRWEqjoVIOMH65rhrV1UVlL7v6/E86daMlaMvu6GxBq9nqM8kOl6hZzyxqGkMUqybAenAPesvVZzq6zWFnqawwKxju7uzlVpYmHVB1CHsSe1cpqFhFqVtfaMka6PGSPt729qCXxggE8bgQCCRjBxgmqnxSvH0TwxpujaGgS91PEUZQKpSJcf99E8A5OcZrGNBRkkv68zGNJJpMo/Evx55kZ0LwxNCqiMq8juQ0qAYKxnpn3PftXD+EtEEMz38xa6uLYCZJZxu3ISeD6+me1bFpoNvo+nxWF5Es0xYSNao4kAcggvFJjKnPVW6VoRS6fotnEdUzekrtW3BKxRHI64+9njPbNenSpRpxSSO+lCMY3iv6/rqbFppCX1xFdWExttMkUSm5Hy7ecMg6dcZOeAapa1AEYHw8kb+U4PlXGWadCOq8dD64qjL4r36vZwahbp9kjYoLTYNnlsuA69mI560abqmjWVnpkN/qUYERktke4cqyfMSrZz02kDPtiqSlG7kxN1Kestv6+8pXGq6lpNtNdyL9p0qCRJ4gseDDnORnvnBFUv+E/utT1UWHgfT5p3vgQ0c6DAk/vgDgcdT0rT0m71nXb+70nR7Vks7vfHJc3MY8p0PV1I+7kDnqPTBr1Twn4Lh0FLJNIKWsandeSLCC90NpATJ5VcnJxycVz4msqXUxrVVrf+vvKnw48IxeEbAtcvHc65dNvuJUTCqcYIUDj6txnNbvim/1LTtNur/T4bRhaKpRZ2OGH/LQk9uOB1PU+1XG1O1TxHDpUaiSZ4jJMyyrmEDpuTO4g9AQMV458XPG0l0LjSLa6trOzhnDXHk3O6Zlzxnpg55IHQY5PNefShKtUUpLzd+xzxTqyuzndV1a58f62k3iW9ksNOh3JAEtW8lT7nORn1JGcVvJp0lpMBaWlrayMAqxlCYbtR/cPZx1B6888Ve0A2sOnRQ2l9Dd3s4VVi34lbI+8rHhl571Uisore3eDy7XfBI5MkdwdxPsgOMjI5HWvYhGMdInoQSXurYvadqLaZ5l3A62rkFTxsRCOCX7emT9Ki0ya+mv7jzb+OOa4If7PcxCRLj3DZwfoKo63DcXeiS+fdCTTRI0bNFlTvPVT/dz7jGa4HVtUghg/snTWuJYQQsC4O+Jv5g02lq2ayUeVtW/r5HYeIrfxQmqR6Jp+BbXrqqpb8naTgEq3zIOfpXYaFp6+G54tA8Oxm4vBF52r6koLkAN/qlGMZJ/rTfCOiz+E9Ca+1aSW48TX0Z8hp5C5gXGBnPI69K1lu8WSRPO4tUJRbaMBQ7Y5cnqeTmuOpNzem35mMKbmr/0/uOdvtFuNN8NagukXTS3UjG4uJJXG2BS3O1xwPlzwB1ru9H8rRdH0+0tX1DUnvJv3csgLldwzlnAwkY9T61yypPqUttpQ0ua6srsGCa6HEMMR+8e24/h1Nd4jxaTprqn+j2NsgUy54jjUdz9B1rnrzbXKyMU9eVGPremyXkyzWdnZXOuW9uYRJOzmCHceQFHBODz3OBTvDuiahbCB73UYpoI4vKNvb2awqsh5ZhjpxwP1q3oeq3OoWt80VsLa2bLWV+JFmW4DDIl2joOnBPNWNBj1SOO6bW7q0LtNuge2QqfKwMbweN2c9B3rGU5Ri4nG5tKyIBYafbanPqi2ZF7PGIWuHLEiMHIUA8DnB4HNZ+rm81HW9G8xzZ2trM80ySgk3KhcAAg4AOSeas6Hq76lqF1BqcAs7yNmlW2aZZCkAOFkYjgbuePxrMHiuK71PXJfJQeGdOtEdb/DYupG/hRjwVz8vHU04pp7agmk/M5P46eIIrXSrDTrbYJpgZsY4Vegbpz3xXHaPZxjR1Sx1aK+hYb5LSeArJux93A5Psao62bjxh4tl1HUJY7fSWfykvFLNHFtHCZUcdhzVvS55LTVLu1uYN04QeReQuV57Nkc59iK9TDQ5I2O+nGy5Vuv6ZoWsZtYkEZQrINxib51VT0J7ggjJBHamXKW5kmi1GFdQiY7lmSHep7HnGePar9v5cl2JTafumRswwThcsB13E89MkH1rEu9YutLu5W0tzYRj5vs8rbwT64554/St/kdEry922v9djkvFLWDajDDpcSKdoXZsIOB9ecfWvoH4a6TNo3hO2k1ENHeXK+YUcf8e6fwoPTjk+pNeU/DG1bxt40e81fy3e1VZNyxgfdPC8etewSX73PjGKAyxSQBJFWF0+cyKQWKHONoHXI61w1m5XivU8+vKU9Om7NhvKW9iN3IpuArPFCOydNzev1p8cUVvHIY3lGSWJMhPJOf61DdtdPbXlxbLD9qVNsC3BxEzf7ZHOB3/Sq9xNdRi1eWS0CNGDJ5SEndjouf4Sc8muVK+hzpN6HO/Hg26/B22+1ykqddTbJGpzu+zydc9e9eBaefKQQ29zGZohnzGTblcZwD1xXvnxeI1f4RWe6MGOLxAgZJkK5At36Djn5hXh2jSx3V5L5PmsuQoSVcbR6f4UYZNc1+7O7Dxa3Oz+G+r6hd6ZqoghQTwRP9mlxxI+04z+OPzqHRdN1DTPA63WtebLfz3DYR8koG7N78MfxFXNB1vSjdx6Qjr9rkcIAmQCc9CRWjdp/YkWpWXijX1t7HUZiLF0Yh0z1HTgdOenvWr0ldnJOfJUve7/Md4K0/TdQ0oy3ehpayiTCvIADJ/tY7V06wJZvIu5Ui2ZZABwR0x9f5155o+l6r4YvJLC51drwXB/cRnkgE/eOema19UnuYCILO3kuZgBudVLBW9M9OtS1zO5SpSn10Z0tjYi4YyXEiJGwysQAHfjJqHV9LvG1izi0oRLbNk3ayOcYx2HUfUUaW0pjs49SMMTzLmRV4ZD1GPy5rohaQLEo38LwGZsnNRzcruc1SbhLcyi506eBNRYJBKREjMxP4bv8AGprO2m0u8lmln86xmHYZMXpz3FZviCwW/RI9SYTWcTb/AJOASOgNLFJ/aNw1pbXiAxKCsfaQY4yfTpTtdFct43e3U6NbyzuAYzLE4cbdpP3vwqi2k2tpiW3iEIY5MafcJ/vYq9EYXhh+0x28cvRkyDhvY1CNLtxerLbp5WFO4xsfmJPeovY54tRdrtGH4l0fTdSsJLK+lezhYbibQ7Q2OmQOv41xU3gKO2ggvNC1K6s75QXCuxJdexHb8K9QvNEtLiEoTJFJgjzEbDc+vrVa00pkaOO4W2uYlG0y5KuR7r0zVRnbZm8KsOXcxtMS5NtDb6qyvdRfvPMVSu49hgd61rq/a2O7VJmhhAyEQ43H0J61a1O4h0iFBFZh5Gwq4G0Z/wBogcVgza3ZtBdXE8Uc1yn/AC6x4dvqSaavJ3sXG9RXS0HaTZzarctfJdodLA+SONCjhs9z39atNd2NrqAtg28v94JuZt3bvjNZ/hfxhJq1zJDDppt4VIG7+nHeul00IbxiqKhI4VB8h9/r2zTldPUTco35xL4sYyIrMxyKBtdiq4Hv6CuC1ODxdf38tto62ltahh5s8w3bsY4Geg9v5V6lKwRS7YwByawbjxPpEumXVzFeRGGElZJOiqR79/wqYydnZGdOcrWSPOfEm3TLdVuJlec8M69z7DsM54rlbe8ckCUDn+LpxRrmu2+p+ZKj5TkjK8n3x6VyD6qJiSgfz16DnkAVs6ihuz3VUjTiuZ3PQrHWpYLgwbwYnXDKT1H+NdJBr0T2JsLjVUg3nPmzOCU9AP8AGvGo7i6/4+plKNG3A7/j/jXQaXcadfY+0oIpmU7mPT8auM1Pcyny1V7uj8z3231TS10/ziLeRVjKpOjKwkwMHDDv0zXn3hb4qXEvi1dG1Gyit9PdzEpUHdGc8Z9v8av+DtJ0nVNKWwspkQQx/M6kEEE5x6g+9de3g3TJLaFovL+1Qt8t1sVmyD3NZyUYy1PMnGnBcs3qZHjq51bT1zpAnj81WhYRAt82fl+nFYWta14k0mHRLOSFLm98oPcmaASbix4X6jj8a9MMrxBlvLfDqoJdeUY+3pWNezNvmvngAhjjDOCw3g9Ac9hx19KIy0sVRqp2Uo7ficuug6j408IXtp4gSC2vY2kW0jCeWA6/cJI52Z4IAziuF1PUrfw54Qk0TxL4f1Cz1K3TfZxyXDPbTyHZu2uvYbyxUEjA27gTXpGneLIPEUqW+iX8XnW5UMQhOQeDjgcD1rP+MPgHVvFz2NzaanaRpZoy/Z50KqCcl5A6gkk4QbcY4zn15cV7WKdSjozOTcZK73/A4zXfGNjren2V3p8T20CQiA2x/wCWLgfMAeh6ghu4I4ByBH4ZhsLUxzzyiSOeQGSRznnHA+mTya8+n0XVNGuvLVopFfhikmFPPT5sfnjv9RXr3g+1s4dKEUyRhtoQlgrAZGTn3+hxXVl9SpUhapFqS8t/Q73Nwp8sovRWOlt7twM2rckYIbDZHqDRXN3Gn2jKEsIZldT8zxysoP4CivS5W9kcqoQerZ9Hj2zRJEkibZFV1znDDpXnQ+IsqMBPZQIxBKqsjOXx6cc/StP/AIT2KODdJpd5JNkDbAysv13EgAY55+leE8JWXQylgq8Fex0N7oFleTRSy+erxO0iFJivzFdvI6EYPAORXnHxf8I6pc/2PqdjJ9pg0uJo7hXO1jHkndx1x3xXp+lapZ6pZJd2VwkkLDIOcfmDzV4FXXghgfbrUQr1KUtehEKs6Uk30PmbQdQ02a1kgubu3sojCZ0mnGyQk9Bk9vbNWNU8R6JpjW8NmqarHMWhlCn5lDDo2eDz0YdhXtniDwF4Z17zDqWk27yMmzzI8oQOvGOAfwqvonw48L6JcvcWOnHzHAG6WQvjA7A9K9D+0oW6nTLGqerujxZfAviDxlp9nMstuNNVStm9w22SNc8plRmTA/i6cCu58EfCLTtEMsmszvqjsx2o6bEUe/dvp0r0O98NW1zfLeQ3FzbTLD5ISKQiIruyCV9e2Rg4rCax8UO8MCNe20qy7mukvEkgZATxhhuGR/DisXX9trGSX4f18hKqpr3ZWNuyv7H7Nc29m3kw2b+TIY4tqxEAHAGOmO4qaDXbGaxjvbe9gOnshkWeVsIyDOWDHtgc96tQ216Y2Sae32tncvk7vlPY9M8Vkala/wBnaCyXun6d/ZVrGxaKOM7YU5yQvOeOfWuZKnN2/X/gIwspPVnNeI/FU+ieHdW8Sf2dYtcuqQ212hVvtMZ+6ysOdoByFbmvEfDOnXup+dfXSi4+2SmFXkjXLu3BUk9D9a9M1jRrm/8AD8em3c/mJfXZ2T2zZitI8ZjwpAIXAwcZwc561yttb3vhu8lt9V01r/SY8NHPFJuRu3IUcE9a9ehTjDY9GhFQd0bf2X7dpFuniS1ULaK3k722pI6ZGVKAcjHc8808RxlrspdWi3tokcjxzkS+awGWZHH8HQcd65248RSXehy2Vp4W1AXTszQSh2EcSluuD6A496m8MeHr7xWLa51q9s7bTbRMie2nAPynkZHLA91xkVq5qKfQqN1foYF9r2sa/rH2DRJJblr1QskaDcmOQCTjIxnqa9Z+Fngi30Scz61YS3OrRjm4nX92jDHEYb5mx/fwB2HSn+Hl0jT7O5uPDelSIbyBla5ceVOwyfur0jz26dRWhbarDaRafplsbuzeJFVJFga6wvUo0nJPJ6k9q5KzqVE0tETUU5fCrIg1bTtQn8VXcNlqAvbuRvtBt7hGiFvHwAFYjDDnsc1o3fhSSSxnBntL68IDC3lDxws2ejsnzYxnGOven6x400+306eLVxOLdQI5JXygbI6Lj5s/QVd029gi06FNMguDuQJGNxZvYtnnPqWrButyrS1v63/4BPPXUeTb7jR/tfTbS4hsbm8tYbhysQhRgDvxnbjqBjpmp5Zo50kgjCyRFdjoVDB89QwPasL/AIR9ZpGuLnRLQXDSi4kuZI0aVnAwCeOWHbNUpPEGpWU98p0+6hihK4jFs5luMnHyOMrj1yOP1rFUVL4Hd+pgqd9nc62zs1VVEaoqABQqDAUY6AdMfhWPrN9FpqR29/O8VxNJ5UDCAnex+6oA69Oelc/ruv6jqMC2ekwR2VzcF0a2vVlWYxZ2b18s8ZOcHOenrVSA3Vlby6XDpFxPc2cKSwTapumTA+XK4JYKDkZxmrhSlvIqFN35pHR+EkuTHctqmq6fqTo5iZbODakTDqhbJyefQVyPxu1eCy0C0s4HUTM+YLZMYJAxux0+UZwPU+wrrLK7ubi0srX+0I7HUYAs09vp8KvGwB+ZdrDO0/gQe9eNfESdfEHxMvY76CZrC3VYjDt2smR/Cxxznk1pRpynVClGTnzMq+FPM8P26rr13Pbi8PmW82Q6NkDKspzg9Occ962DEQJ3il8xULID5AVNpx0B5U/Xp2qtbeGLfz7O2gRjZTLkLfNHIVYZOVw2fzx+NX9TuRa28CBwloh+W42/ffPdvwPPSvViraHdSsnoW5LS2t951GbzHBy0sKqyoScKcH76k8exrm/FF2bRPLlgKW77kVoUOJGI7A9KrX3iK3tJriOWxtdRnmbMYeM7j7fL/wDWrqvhZ4Wh1eNdd8Q27yqjH7LBI7OvB/h3dAD+frUVKippszlUdO7nqzq/hd4afwp4U86aIHULlfMZQPmHdV59u3rXQ6Np1ppUE8sKSm7vHMkvmtuZGbqo/uqOuBUU15bR3hvLm7LEKEitlkLQqM9cKOWNUJNQ1LUdJml0WKY3E4PkzSwMqKc46HkDAPPWvOcZTu31/qxwcspNt6f1+h0YZcqp/cxRDPzN1rEYQ392JLmO7WOOQ+WsUjKJR/eYDqPbNRarp/iK8a3EEsMNuqDzIniEnmOO5YnhfbGfepn8O3UtrFD9qe3UDBETGPbg/wAO3pmlBRjq5DioqOsjI+McEF58JrRAkix/2+hGCd2RbvySf89K8as5LFYfNvQYwDwyMWyRxzjr3r3Px7Yzp8KbWC8OGj1oEMJN5dfJfBJ4ryrTNLs7aX7G9vhHVnKtyo9OtGHslJruzspStDQ3vDI8PTarZ3draL9plUiG42EbmH3hj+9jnPvVLxtoUGv+M7C51GdTZ2cWWt16yEMfl/E4zW54TtFs7GJDAqorsVOd2PXHoagu7cPqLzPgI2VJPJXvn8aJ2k2ccIr2j5jCt/Duov4m1LxHqUyTLLE32e2V++PlyewGO1ZHhrTtb0/xHcaz4ivpodLiDGeR3ITkcAKev0ArttNvJP30ACvIRtDheT+H9a5bTtJ8UXviLytVuY7rSN/zxTsGQqOmE9fSj1KlFxTVjN8U+NP7T0kp4fU20zSbBJcAK8ieqe+ccVqeAtb1A3txoOtSo9/Eu7Mg4kU9Qc4zgHr1rZ8TfD7T9X1OO7YiCSNFHkgfIVHTpwv0pNasNE0bU9Gubu626xGpSGRusqDIw3qMHGaS956EqaskmdLpzta6bFZypiEEoqs29vz71zeuzXmkC6vbKKOW5QM+xUIOB2rD8QXXiiTXbaHSHiNq67gQoxju2cHp7V0MesWqadDBqmrW0d+hw8igop/2c468U0rM15XG777mHZ3CeMdOW400y6Rq8bDcy/MrN2yO4rf8P6Z4tihll1vULQg/IgTncnrkEbT9M1n6DbanLrbLJFops5Q3zWkg3xnB2lvX3OKsXF49mnlGALCoxIFJG5vY1bveyYRg6lknt/Xc7PTY9Qe2WNbmPzkb5mkPmNj0OPUCpr/Q7C9uTczNcCdFwTBMU49wK42y0OeyuZZotRkMFwobZGWEnI9Rx3//AFVLpGhtp2oxajbajK8SSfMpB3t6o3OPbms+VX3IlSSblGdvRfgdXp19bQuLW2uJGjjyXaVtzLjsT3q61vYWnmvKkCLId53AcnvXGa7rOk6VqIutREtqJiN6CNhux/8AWNczrviLxEdVLaXo1vd6S7AW1yyyNlT3OG4P4UnT6mLotvS53P8AZ2pXOpXrrJZw6I0YWAQJtf1JJH41FrnjzRvDVzBY309xcXLIGWOGPcQOgPYDp061k6tN4nt7DTTpkdhLI7/6S5UrGqcHauTniuqXRtNS6j1G5jgM6DatzKF3KOvBI4/nTl5kyWlpfIj8W6rYL4Onubu4ms4bqHEe4bJckdADyDXm97oQXwRHF5jm3MqzuuMFx2z+dd9rlhpniS0kifyr6a2YSIGY4DVznxI1OLR9BtYJY4kuJFyVRuABwoAqoSsrLqb4aMU1GXc8a1GdZluYY7cQscYYdcen0qxbhLHQySELuxZWByVH+RRc3TXwEJjiRs/IxGN/pzVmHQTcWY+1RyYjclfLBK+4Y4wa1SerSuzv5HOXNF/oZNnp84ijuY4tzyk4iPdT3p4SHzoonuGtJYskqMryOgyf/wBVekeAfsxW++ztEb5GCYPGxAP4R6UnjeK3ubS3SS3El4xO0vhmC4POevJqlRSWhk5Ln9nEz/hvrKweJYUgcKGYJJn7pHpnvzXpd/qUhstT0zTgNP1Z96whDlXIz8yV8+XkdzpaiXzPKCMpxHkENXb22v2d74t8J63rEl4kjlYSEOxVbOPMY++eQOuKyl2e/wDVhV7S96S2X6mp8I/ET6hqUGmapqE9zcxGSVYGGE2jqM55bPOMY4NeneIBZ2MV1M0Mkz3Ns8KnaTFtPUORxj61iN4b07Q/FK63b2UM7vKF8xW27GJILHHfOa63VWgn065tYmDN5ZPlL1/KobbSbOKcv3kWtUzivhV4ftdBvtTS2iG6VEJY8lRk4UGtn4jeIrfQ9HWCT5ru/wAwW6DrnHLH0AH86n8KW72lrPNcMWOAp2+3eub+KUGnXmlR6zLIsz2BwjxNkfN1Hpnim17yXQrljPFeV16HjV1NDf3Gye1uQYsoDG2ePdcV0Si3igiWEvhQMBvvYHrVHwtbW99dfa7y8laIMQwZ9pJ6gZ5zx6V28x06JCtnaxspIGQhYj15/wAa7YQdr9z0411GTbV2/Qg0/VLHyEVLs2bjO4PEGB6dCc0VB9nt53bbFGuP4dn9KKtp3MXhqcnfU1fA0V5rN7dQeI55bOS5XbZyK29GfPfk7fYDrmur0nwvrdrNJDvWd4mKu4/d4HbjuMdxXf2Hh7S7N5TDYwqZJPM5XO0+3p61sgDr39a8ueOab5dvM5nmDjpDVef/AADwuXw7qS6omnW1o1vLvEKzxuwMS4yN5OSy5PQEdeor2GwtLzRfDVtbQML+7tYgpMhK+djrzzg/nWsOmOR7U4HnjpmuavinWtdbGFfFutZNbDICzxq7qEYgNtJzin44zz+NC9+KRyVUlRuIB+XPU1y9TjvcdzzgdPSoDeW4MgaeEGMZfMg+Uep9K841q513UfHunwfYb6zjtLZ590Tt5chPAXeOGP8Asnp71ydjqdvDcSX2o3wuzazH7ZEjmUnec/NhQSRyAVGB36V6FLAc6u5HbTwil8Uj2uHV7KVvkkYjGQ5jYKR9cYq9FKk0QeNg6nPPrXiUmranZC2bTdRnuFuJ2NrsDiMJngSD+Ehc5zxx+Fd/Y+LkgtYzrTKgzg3I4Qjt+Pb3pVsDKKvDUutgmlenr+Y+58HyR6qlzoupNZWctyJr2zeISxzLtwUXP3M+1ZN38MLb+yYLHS9Z1OyMBZkmJWU8nO1geo5rsdO1vT9Qt1mt7tMEZKyHYy/VTyKmu9Ts7S1a5nnQRL1Ktu59OKyVfERdtb+hkp11K2tzjdL+GtjZnzbi4+23QyTNcQhzn2BO0D2xWwvhC2WPYJ9o6gx20S4PqABW7Z3ttexLJazxyqwDfKwJHGeR1H41aJAGW4A5JPAFTLFVr6v8hvEVU9X+ByF/4CsL5ZDNcSiZlIWURxgoT3Axg/jV/R/CtpptjFbyT3V2yrtaSSTZuGc/dTAFbcM8M8rxxTRSSIAXVXBKg9MgdAccVg+J/Eb6MrtFp9xcxQlRNIqsQu44AAAJPUc9BRGtXqvkT/QaqVqj5U/0NOPRNMiAC6dafK4cbog2GHRue/vV85z26YrnLXxFN5d5/aNkIZIAWXy51cScEhevBx36Gsebx7maWCCyjWeMKzxySneqt0JUDjNH1etN23+ZX1atOVt/mv8AM7k8r+NAJA4PFec/8J7fJdIslnbtAfnZhlflzjaCT179K6iz8V6PdzNGl35cgGdsyFOOecnjse9FTCVYboVTCVqe6+7U3D1znkd/SjJHes+TV9OitHvJL+1W1Q4aVpQFB9M+vtVC28W6Hc3zWkWoxC4UA4fKhge6k9Rnj61mqU3smYezm72TNSaytpX8xoU8z++Plb8xzXkHjvwPrOi3cOueEPtOo3KxiC4gkVZXlQHK7g33sDjI54FesPrOnRzNFJewCReo3jA/HpmroIIBBBB545FbQq1KT8hqU6e/4nzTa61d3DPpkul6jBfSuf8AQ1tSMy9tzEdP0xWfdeE/Hk1wYf7ElQSMUGXUhT6nnGPevqRiSQxPPTNNIOcfh1rqeYSfQ6Pr87WWh414K+EC226fxKlo8zENshycHvyOMV6VpXh+2sbJLZ3mu0jyE+0Nu2L/AHQOwraA5z2ox9cDjmsJ4mpPRs5pV5yILe3ht12wRJEvogwKl9cnNOxSYGeaxbvqzK7b1G47jrSYyfSngc8/hRjn1ouBxvxws7u6+FUUWnSrFcDVVdcrndiCTj6mvHfB0OpXOg3MOtxzG8hG6HcAGMeeh7nn9BXuXxWt7ib4fWQtZREU1dGck4yvkvx+orxBPBk1v4wt9XS8cwI4kEZJ3HgDaD6VvhdIN36ndSb5U0dB4Juvswu4ZYZ4ZRkpExB4H8QrVuWi07T5tRvroggcbl6H0x3qLRbmR5zFfQyRGMhVkOBla2dUtNJ1G2EV7AJoY3EhBJAyO5x2reb94mU7VLy67mN4dujrFt9pSERSKcsNmNwPQ5963btGjurRrdfnjBEmOykd6u28IWECJ0iULwqqOBXK3finTLLUzp17dxIx7ytj8z/jUXu9DNv2k24rTsburXtvb6RdT3JdI0jJZl9PavHY7BfiPHJIZpIJbDcsJjTcHQ849j0/Wur8fm61jwpO2imW4ET7ZUQEq4/Lnr2pfg7p99aeHrltSiSHdJiGNFwQuPmzjrzTtZWsaRh7KDbHfDfw7c6FC5u7l5pSxA44VcdOeeak0zwDpST381/JJexTEkBskAk5HHt6+9dmWZWMfl/u1P8AF396zNU1CO3hdoLiIMoyQvGfbOMVSbBOU5e6ed2F14Cjv5LZhLbXkchTLB0GVPtXoxuLa8gtZo/3kK7TFMmHB9gf8a4RfEmja3ra2t5FpiyA7SbmAb2b2bGB+ddXp9pFp9hJb6ayWO99z7Rvjf6Z6CnZ21NXHuzto5oltxIHRUAB3E9B7muZ8Q+JbfTNRW1lt0Fm8DTzXJOAAP5n261nQa6kOpQ6PezQxSzqSrDLB8d8dMVfvrCD+zpzq93ZtYkHzPMwUUduT0FTy23OeFKNOT59SHwx4q0vxFD5cUsd6YvmMcigsB2JBrpnmjuXEU0HzfwKTx+NcBo/hzR7PTb3VfArWd3crG3Ik8wZH8OCeCfQ074c654h8TwSXN/FDBFBJs+4VZuPT2NFkwlCMveR3Go6hLZ284W2jWZYi4VXBBIzj/OKxtCvP+El8LxT+INOwGYlUkBALDoRXM3Os6N4q1q50i+njuJ7bckaR74mdl6lXHHGD164qx8P76ytfGGoeFbGDUvIgg83fdzeauQBkAYwo54PeqtFR8yXDkXN2Oy8LWdvZWoW1U7pmLuSc/QZ9AOK8V+K95Hq/iOdY5kBibZHGx4Kjt7HOT+Neu6lLLotlfJIGX9w728qjKkj+Ejtx+lfMt/NLc6nPNkNK7MW2nOaV9bvU66Ks5VHrfQ6DQ4o7aUGdCyIwMiSDGOuSpr1OHUFaOPbMJYUUBHhbBjH0+lcr4CsbOTRo5dSijvLpWwsLsQoTGfmx/nit6XwzZS7zbQGxuCCy7HbYOOnPUV3QVlsXWlTk1F3VjB1xrZdVS4tGUTsCZWi4IPbkVTiF9czySRJNcXHZjljn1NdhoscMOl232WKKK4ClJ5MBizDg5J7HjgYqTQnFtvhdnjLMWJjwM5Pp7VaT1aNfrKhCyjdrucFreja9MFNwot7VuCZE6kep5qnaXE9vMEsmguTbfMslxGJF3Do2Dnoa9Rub20skWR76GUPwySD5j68emK8g13ZYy3cmnu0VtJIdsZPJXPC4rOSUfeZNOrKonK2n9aH0D4E1GTxP4SjvJ4Da3b7op4yuELg9Rn8D+dbGmPDfQy21xAkV5APLlRD0HYqfQ1498GfFsluPK1KSFUQfO0jYKxg9cetesxae1lrlxrEMizQXqouxP0Pp+Nclk0n0a09Tgq0+RtX31RfeGOJZbaRpBFONocHnLcHn1964H4lWMWgeDrK2tPltopDv8wb9+VOS3rXYXur2kWt6dBdOsX2hmji8zgs4/hA7H3rnvioDd+H5YvKMgtpA8wHTYc4/wD1URumisJzKtFPr/wx49o95B5xgtYbdUYb2EYIYkdODn8xXcaV5nlqf7JkOeM7id3vjtXn3h+7s4rtVgjaCQsAGdt2R6Z7V6rpdtdSxZMWN2ChfGG44wc13w0je56Fadqa2I5JRMSv9nzGQY+VQMD6UU7UXltvLNzGYsjhm4DUUaM51GTV4r8z3Xd1ySPxqRcZGe9Rg8E88VItfOM8lMeMY56jmnZGOlNz7jigdgefqKgY76fjSIoDs4Jy2Op4H0pD7jilBP4UCHEleM4H9a5i98CeHLq9mvH02JLqWYzvMmQxY9SOwzjmum6gAHg06qhUlTd4uxUZuDvF6nCa/wCHDZxo+mxyNCCfMAbOwAEg4PJ54rmLrRpkkaPT9NA0pAstzdmUyF2PPCn0PNexLjAxxVOKxWC/kuYGCJID5sYX77cYOe2Oa7aWPlFWl0O6njpL4tWjwecTO941zaSGzs2WQSzcpIOxUA5444NNn1lNLurbT4IBdrPGZ98EhZRk5OS3IOex6V7pqkbxwr9i06C6aSQRyK5ChVPVjxyBxkVHL4c0m5uFubnT7Y3IwzMq4BYdyBwcVv8A2gt2jsWZxavKP5f8A8vsoLyytX1dNJuRASqyMsWHPbOD1Hv0xXeNp8EmkxC9W7iilPEMUrO0hPr2xznGMV1XI656UE85HU/hXLUxsqlnaxyVcfKo07W9DzKy8DvYRK2kh5IoI1Cx3DFGkZW3BjjqwPQn3GK9ESNrvTRHeqytJHtkBODz1+lWqQ56cYPvWNXESq2v0MKld1LXWx5xrnw9ebVGubAwywvCYHE7lX2EYKkj7w9M9MU7xD4M1jURbTJqzQtbxrmKBQDORwN7kZYAcYr0ToQR/KqWm6fBp0MkVp5u2WZ5z5khc7nOTgnoPQdBWscZUsrvbyNFjJ6N2uvI8Rv7K78OyXM2uR6lNKZfNiSNA4I9E5wV9RntWdDPd29vD/Zrz3Qnk8yV9Qy86qQMoirgA/XgV9DywxypiWOOQejKGA/Os++0XT75ALi1iwFCgqu0gdcAjpXVDME9Jo645lBu84/czw++VLmJvt9zGbeGfzkidVCohG0BierHrn2wKbYztNrhtTbTuNhcXQjAiAPRSRycHnPrXpN34B0/fJLKk94DIGjiYqQg9uOxyc8msp/AWsu8sEWpQ2lo0gcNGSzFQclTxnJHHpXVHFUmtzrjjaNm07HNzRSWuow/Z1R55QsZilk2qwXkuCc/MAScY5rT0TxB4h0y6tbW8u5L5VgKb5/ukgjG/HO/ngg4wOea6/wb4bu9M0+VNVuGuJTO7xhsHy48/Knv9T615D4m1eTR/iHf6FqQmlsZQIlltE2GPzFzn5j82M9eMEVPtadaTg1cweIo1G4z6HURfF+6XWrqCfR4GtYZpIAkNwN5ZPmL7mwAqrnOe5GO9dheeNYH0d7jTIg148W+FJ8mPcRxuK9R9K+a/iFJJod5p8Okpcwac9rujeUZMu45dtx6kkc+nTpXd/BXxK/iCS5tNWt45JrdFKzINnmZJG0gcAjtjHSsHDD+09m07o5YwoX95fcesWHjeK4uY45bGSNW2qzo+4Ix9R6Z710dtqthcytHbXttLIp27UkBOfSuHu9CubhnS2stqSAg5JUYIwRms2DwVe6Do8P9gWsELRy+bPFKGkZwT820gkk8DH0onh6LejsXWo4d25Xb53PV1PBx264oB4rxR72+iu5JL6aQSW0rXFtHasd5JG3BB+8SCfl6Cug8PeJtWmVZHhvEeQ8W99CUY+49PzrOWCktmRPL5x1TR6OJEaTyldDIOqBssB9OtOB7EY/pXmmueGdQv7m4vhb3H2y4TypE8zagXsRyOnH1rR8OavqFnJaWV+zXMMcOJJNuZGfjjHYKAT3Jz7VLw3u3i7mU8N7vNB3Oy8WwLc+Co4jjnUB+H7pq8l1/SruDU7C/gusW4zHNBj7+R/8Aqr1XxEV1DwNaywu4Q6iG5BU4EbDpXLXFkssbK7Pk87s9COhrLDScE15sw5+Rq5y91qUGnxRPfXVtbhztAds4PcZ7kVqxzwNZRTWrJNbvw0wbdu7cdjXPeIPCn9trs1CN4Zd25ZomyOOM4P6iui8KaBb6Jpgs1JlUsWJfoenP6ZrofLa/U0qSilcj1S8t9OhgF9MkRf5URELOwHYKO3PWuB8QeAoL/Xf7Vv5JWt2ZCEUAZXsD39q9Pu9O83UILpBGzRnpIucD29KFgSa8kWX94qtuCkZwe1JSQQrRivzJtPszbwR+WREm0fu1XAXj07VBckJcgCZSFHK8A57mq3jTWbjQtClu7O3E86kAKTgKvVmP0Arkdc8QrZeFRqtyyw3Vyivg88t3/LtTUXbmexnSg6ju3uO8Z+JoYtPUCaRSx4EPVv8AOK8b8R6vLdPBullETZO1s+vU+tWtVnvnulmI+1Q3MZeKWOX5SMYO30IPY96cvg/UbjSluWulhRQSI5fmI/wrVqTj+7Vz0m4wjyR2OdFw7XASS1hBHIZcgkevWty31u4m0s27T3O/hQiSFT7c96w7iCS1njikPnnGN0fJx7fStC3uzY6W0bBbpZXBJcbRHjPGev8ASs6d1dSYozlF2Og8I2wXWLG+e4k8+3kO2K6bOPqRyB0NelW7aZ4sGo+Hb5pobzlvJONnHI2nr1wa8PikuHu5Lqydba3iX55eu/H15JJ7V6P4Rv7XUtdtr+1KpfW3yKZSVEg/u+x9PyrSNpXVv+COUVODUNGJo2rH4cwCK60Z7WK8uHgmdmLOdoGG+mGzx+teqiaLRdPzYxIZ5fmAdtgIz2z35zXM/EixbxNpVlaXsOxPtAxInzPExGM47jnke9ZupeHVi1+/bUvEaQadfLHHBay5MnmIqjIXpgYIz7496mz7aHPy81ufRPexDJZX83ja3ufD1lY2momXzLw4G5043bSeOmc45Oa9WtLeMXk9xCsQlYlGbaNwAPCk9elc/pt/pukWf2+RxLaYEcd0BkkDAIPvmtj7XFDcfbsTJazR/vC6EAY+63txRK70SMq6cneK0OY+LGoRWuiC0u5lje4IEJAOSe/6Zr54t4Ypr5ZbeQB1fcV6bue3ofavb/jG1uutaHdXnly2MUcgaNj98t0II7YryWf+yrh1trG2W3TeW3tKS59OvH5U4Quk2dVBfu4qx1UFxDFAjwzmKXoQB2PYium0zXrrV3S2uHjSWJfkkY/eA7D3rmP7Pje2WRbn96oHGMkj/Ira06az+zLb3FnEl2jZ8/cV+mO2frXoNNvVHXWhTkr2uzfnsXsrV5rR/MZVMrJJ0J77T/j3rDuILzVL2CS7ZbSPy8goM4Q89upPJ5qXVp5jDFHHdl1D/NAw6jPqO1RXur3AxcRWQiiiBO0PuwPbjpQlbcyowqKPMrN669vvLf8Awi+nOxYXpLg4JmUjd9D0H/1q5jXtGti88MCNcyRk5ZFLqox1yPrWfP8AEI3VwtubXyreQ7JHAyxX6dK9E03WLO0tUWK4T7KkeFRSA3vnHPNQuWonyu9jONerDf3vI8YtbZVvHit5RK0imFnHQA9/pX0r4Ct7m18G2tpcPuliQhN7Zwo+7n8q+bZJYTrkptjmA3JfJGBjOePpXvnwx8QyahpF/bXsWZLCQRg9TJEwBUn9a55xXs9DHFa07pdSv4w1WOG78J6xdRRqzTkeXIM7SeMj3wDzWz4lCImswvlo720Nwnf5kABA/DBqTUPD9prtrp7SqcWknmRgnAB7A/pU3iq1kbT4LiIhntyScjPBGD9fpUXVkvX/AIBnCpHnjH5fjdHzha2tydTjSL9+5bISXAb8B1rvG0vUbWNYpr3yWxu8tZTx7Y7GuMF/bWXij+0YDK00b4aMDPPQ9etd/F4sj1CD7NHpb3bFt6eYm2RF9CR0x611QtbQ9CU6kZNRV1/Xcr2WliQk3N7KWAwMDdgenPaitAaXrE6+bbaZiFjkKJlYj60VrzQQ/bvpNL5o+gQBnIxTwOnqKcUAP41IsYKA85r5ls8BIYARn/CnD6/XmnKg2g89M04qMipuBGo5PHAox/Op0jDcknNIUHB5pXERgUo6e9SCMbgMnrRGgPcilcCM/pS+5p6oCSOeKURj5uTxRcCI9eMZpe4p6qCx+tJt5x70XAaetGcYz3qRYx1564pAgxRcYz17ijtxTyoHr0BpfLGCcnjBoGRE49qbk4561IRk4pNuBjJP1phcjIOe/wBKQEEkd8VIFGe9AXtk96dwKcVu8d5cTG4lkWbbtibG2PA/h781N261KVGG68CkIwxHvTvcbk2REA9qy9S0HTNSn86+sbaa42bFmeMM6DqMEjjnnitZRu29aTAI5qoycXdMm5852/ws8Ty61rP9tWkN3ZMrNbeXdBY5ZQV2nBJKgjOeM9QMVzPhPwxJ4c+K2k6fd26XbLqCxma28wBG2huVx0G4H8D2r6vcDaD3zVa3sra1nuGtoI4nuZDNMyjBkcgAsffAArr+tc3xLVbGqqvW4iRncCXzjsR1NSjII9qm2AY68VGoHHHrXM3czbZAbeEvvMMe8dCUGR+NSEbsDqAPyp684B6EUD7pPocU7sLsj71AbK33u5gi3Scu20ZJ9frVsqMD6ZpuPkz74pqTWw02til4pc2fguzWAKFGpKoQ88eU2QPf/CsE9xgjHcV0Pim2S68Naajs6hNXVwUbBJET9fasFoBll3vgEAdP8PeqoK8X6sqorqJVulDR5Y42nj69Kgh3SzsN21VAwoPf1qxcRAMV3MQGxzRZwL9pnGWxvwPYYrYSjaJFqt9b6XYy3N3KkUSD7zHAz2FNs54xZRTuyJ55GwyMBuJGQB6n2FcL8brcXUvhrTnkkFtc3qpIFIBIJA/kTWl4/wBFtZfEXhrLSiGwjmnhgDDZuj2lcjGew79qrlsl5jjBNJdzkfFPiz7L4y1PTtf+bSUjRWjQfeJxgD/PY1wnjDxLFqJmgtoswxOFhjbmNUAI6dzXZ+ILGLWNIttSvtz3TXRYsMDOUNePahEtvdyxoTtDY5NVWlKEfwPRS9ktDRtV1TVoUWKKea3tl2r5KfLECc9unNdx4ei1vU7Sa2vb5YIIht3OMscjjj6etHwe1K5trXUIYXCxhgSMZ3ZHQ/lXX66iWf2HUoEVZ5cxyLj5HX3FdWFg1FSb3IjPXl6nI3PhttOv7C3S7ZxLuO8ptA9+e30rQ8J2enq13BLFBPqsRYTecituQ427c9OKtapcSDV7OEH5Yo3ZOeQSOv6VygRr3xTDO8skUs7JG5iO3IOBW0ko2fmb8sqlNIf8S9L06wSwbTojDPJkTRqwIx1DYHT6VzQ1GWza0bTYzbiJtzSb/vn1JPSvQ/Hfhiw06y8yBpy8mFYu+c9fb2FeXO5zJBx5QG7HriuWqmm2upCXLG6Z70vjiO1g0KOa3MsOpSCGW4RsGOXIwT2wcg/nS+J/BkGu6taahfzzwtDKQHjO7IDHqD0GR1FcX8JYY9et9U0zU1EtokPmIvQoycqQR0I/rXq3h67kubBZZgrPJuzx9Tmp/vEVIqN5LY5z4k6NqOqeHf7M0RUZoZEuIY4sJvXncB2znBr0jQDcS+HtNN+qi6NtGJlHQPtGR+dUZIVRdNlQlXZ1UkejHkVzfw/8Sajq/jzxdpl7IrWdg+23QDG0B9vXvxUNXOSu+aKfY85+M99d3WvXmn+Sv2XTxEsSjhiCCSwPr/QVyGkwW9wkiGPfIDuBdSMV6h8bIIpNUtwyDMkQDHvnJwc+tec2OQdjMz/7RPPX2ropJaM9XDxuoPyN6xtXuNsS3AifuB3/AArorGG7sEaNraK9iI+5Jkf5+lchdzSLcxRqxAK5z3robS6uF05XWeQEuFPPUV2RasdVanJ7PQuWKrcaoVgtltXk4MIO4D6emfStbdFYMLDVFe3jGfnVTuc/3SecDn/9VSfC5f7U1q5a6J3RQ/KVwCctzmt34i2McdjBOGcuHKckHjH51m568pxVKv79UHtoedy2vhmylkaL7LuDHLE5xVGa5spUdrFUBUcsvP8ALpRqWhWEt4Xmh81ic5ZjV21sLayGLSJYQVB+Qd8Hv1rZRaOmCcH5HnE4umvpZHAVmOfMHAA9uwr2/wCHanUPDPlRY3NtikmDcsofrkc8AkV5d4p0u3M4ncyOwXOGbIPGa7j4J3LzWWoW7hfLMbMMDG3tgVy2cFJM5ay5U7ep65YKbffCqq0MZPkn1HbNcj4C8VXPiXTdasNZtfs2p6ezpJGM/MhyAfqDx+Vda7GPRDKuN+0EE84NLDaxG4S+K/6S6bGb+8CO/wCVcr3Z5aa1b7/kfLniGGe2125M8EIDSfJIMD8/U10/gTxKumXEqarEmH6M4xk9sYrK+I7+R4xmgVVa3bLGJh8oPPT0rn9G1Ka8vY4J0iaFQdq7fu46Y71tTqKLt3PalGNRuL2Z7hDdvrJMmm6fK7HLMF+XPqee1FcVaa5qELrAk52LGMeo9s0V3pP7OxzywlRO0bW+Z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28265=[""].join("\n");
var outline_f27_38_28265=null;
var title_f27_38_28266="Vitamin D insufficiency and deficiency in children and adolescents";
var content_f27_38_28266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vitamin D insufficiency and deficiency in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/38/28266/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/38/28266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23365743\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D is an essential nutrient that plays an important role in calcium homeostasis and bone health. Severe deficiency of vitamin D causes rickets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypocalcemia in infants and children and osteomalacia in adults or adolescents after epiphysial closure; severe vitamin D deficiency may also be associated with hypocalcemia, which may cause tetany or seizures. These disorders occur with the highest frequency among children in malnourished populations and in children with chronic illnesses. Rickets also occurs in children in developed nations if sufficient vitamin D intake is not ensured through the use of supplements and fortified foods, particularly if exposure to sunlight is limited. The clinical evaluation and treatment of a child with rickets is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Nutritional rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical consequences of mild vitamin D deficiency are less well established. However, chronically low vitamin D levels are associated with the development of low bone mineral density and other measures of reduced bone health, even in the absence of rickets. The definition, causes, and prevention of vitamin D deficiency in children, and the treatment of vitamin D deficiency in the absence of rickets will be reviewed here.",
"   </p>",
"   <p>",
"    The causes and treatment of vitamin D deficiency in adults are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366428\">",
"    <span class=\"h1\">",
"     METABOLISM AND FORMS OF VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D is a prohormone that is synthesized in the skin after exposure to ultraviolet radiation. Less than 10 percent of vitamin D comes from dietary sources in the absence of food fortification or use of supplements. The prohormone is then converted to the metabolically active form in the liver and kidneys (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"UTD.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cholecalciferol",
"      </strong>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/4/33862?source=see_link\">",
"       vitamin D3",
"      </a>",
"      , is formed when ultraviolet-B (UV-B) radiation (wavelength 290 to 315 nm) converts 7-dehydrocholesterol in epidermal keratinocytes and dermal fibroblasts to pre-vitamin D, which subsequently isomerizes to vitamin D",
"      <sub>",
"       3",
"      </sub>",
"      . This is the form of vitamin D found in animal products and some vitamin D supplements.",
"     </li>",
"     <li>",
"      <strong>",
"       Ergocalciferol",
"      </strong>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=see_link\">",
"       vitamin D2",
"      </a>",
"      , is formed when ergosterol in plants is exposed to irradiation. This is the form of vitamin D found in plant dietary sources and in most vitamin D supplements.",
"     </li>",
"     <li>",
"      Vitamin D (cholecalciferol produced in the skin or ingested, or ergocalciferol ingested) is bound to vitamin D-binding protein (DBP) and transported to the liver, where it undergoes 25-hydroxylation to 25-hydroxyvitamin D [25(OH)D], the storage form of this vitamin, also known as",
"      <strong>",
"       calcidiol",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      In the kidney, 25(OH)D undergoes 1-&alpha;-hydroxylation to form 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      vitamin D [1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D], the active form of the vitamin, also known as",
"      <strong>",
"       calcitriol",
"      </strong>",
"      . This process is driven by parathyroid hormone (PTH) and other mediators, including hypophosphatemia and growth hormone. There are many sites of 1-&alpha;-hydroxylation, including lymph nodes, placenta, colon, breasts, osteoblasts, alveolar macrophages, activated macrophages, and keratinocytes, suggesting an autocrine-paracrine role for 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366564\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency in children in the United States and several other developed nations has been reported with increasing frequency since the mid 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In the United States, the overall prevalence of vitamin D deficiency or insufficiency (defined in these studies as 25(OH)D &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    in the pediatric age range is about 15 percent, according to large population-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Levels &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&lt;25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were found in 1 to 2 percent of the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the prevalence varies considerably among different countries and subpopulations because of differences in risk factors. Populations at increased risk include exclusively breast-fed infants, particularly when the mothers were vitamin D deficient during pregnancy, dark-skinned children, those living at higher latitudes, and those with limited sun exposure for a multitude of reasons (see",
"    <a class=\"local\" href=\"#H23365759\">",
"     'Causes of vitamin D deficiency'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D is an important mediator of active calcium absorption from the intestine, and deficiency of vitamin D causes rickets in growing children and osteomalacia in older adolescents and adults. Epidemiological studies also suggest that vitamin D deficiency may be associated with certain immunological conditions such as multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/9\">",
"     9",
"    </a>",
"    ], type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/10\">",
"     10",
"    </a>",
"    ], rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/11\">",
"     11",
"    </a>",
"    ], inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/12\">",
"     12",
"    </a>",
"    ], mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and cancers such as breast, prostate, and colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. A causal relationship between vitamin D levels and these extraskeletal disorders has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents in the United States, low serum vitamin D levels are associated with increased risk of hypertension, hyperglycemia, and the metabolic syndrome, even after controlling for",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    BMI, socioeconomic status, and physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/21\">",
"     21",
"    </a>",
"    ]. A higher risk of upper respiratory infections has also been associated with low vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/22\">",
"     22",
"    </a>",
"    ]. Associations with food allergies and asthma also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. While these data are intriguing, a causal association has not been established and the mechanism for the association is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365751\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant controversy has been associated with determining standards of vitamin D sufficiency, insufficiency, and deficiency. This is due to lack of consistency among vitamin D assays and inadequate data to determine whether vitamin D below a specific threshold causes significant biochemical alterations (such as in PTH or calcium levels) or clinical sequelae (rickets or low bone mineral density).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366584\">",
"    <span class=\"h2\">",
"     Vitamin D assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the various forms of vitamin D described above, the level of 25(OH)D is the best indicator of vitamin D status and stores. 25(OH)D is the main circulating form of vitamin D, and has a half life of two to three weeks. In contrast, 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D has a much shorter half life of about four hours, circulates in much lower concentrations than 25(OH)D, and is susceptible to fluctuations induced by PTH in response to subtle changes in calcium levels.",
"   </p>",
"   <p>",
"    The vitamin D assay in use should be able to measure both the D",
"    <sub>",
"     2",
"    </sub>",
"    and D",
"    <sub>",
"     3",
"    </sub>",
"    derivatives of 25(OH)D, because both derivatives are biologically active after 1-&alpha;-hydroxylation. The D",
"    <sub>",
"     3",
"    </sub>",
"    derivative (from cholecalciferol) is obtained from cutaneous synthesis and most natural dietary animal sources (particularly oil-rich fish such as salmon, mackerel, and herring), as well as some commercially available supplements (multivitamin preparations). The D",
"    <sub>",
"     2",
"    </sub>",
"    derivative (from ergocalciferol) is the form in most supplements available for pharmaceutical dosing and from dietary plant sources. Both the D",
"    <sub>",
"     2",
"    </sub>",
"    and D",
"    <sub>",
"     3",
"    </sub>",
"    forms are used for food fortification. Most commercial laboratories measure both derivatives and report the combined result as the 25(OH)D level, but variability among assays remains an important problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High performance liquid chromatography (HPLC) and liquid chromatography-mass spectroscopy (LC-MS) have been variably reported to be the gold standard for the vitamin D assay. Certain radioimmunoassays also perform well enough for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/29\">",
"     29",
"    </a>",
"    ]. A report from the UK National Diet and Nutrition Survey rated both HPLC and",
"    <span class=\"nowrap\">",
"     LC-MS/MS",
"    </span>",
"    very highly, while scores for immunoassay techniques were lower [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366630\">",
"    <span class=\"h2\">",
"     Defining vitamin D sufficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366807\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, thresholds for defining vitamin D status are based on associations with PTH levels, and studies of calcium absorption and bone density. Some controversy exists regarding optimal levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Many experts suggest maintaining 25(OH)D levels between 20 and 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50 to 72",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    while others suggest maintaining 25(OH)D levels between 30 and 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (75 to 125",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23366814\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standards for defining vitamin D sufficiency in children are not well established. In children, radiological changes of rickets and low bone density have been reported at 25(OH)D levels of &lt;16 to 18",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (40 to 45",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    and alkaline phosphatase (ALP) levels have been noted to rise at 25(OH)D levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. Among 500 immigrant children in Scotland during the 1970s, radiographic changes consistent with rickets were found in 32 children (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/41\">",
"     41",
"    </a>",
"    ]. The mean 25(OH)D level among children with subclinical rickets was 8.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (21",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    as compared to 16.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (41.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    among patients without radiographic changes; the positive predictive value of a 25(OH)D level &le;15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for rickets was 41 percent. In separate studies in adolescent girls in Finland and boys in Tasmania, 25(OH)D levels less than 16",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were associated with elevated markers of bone turnover and reduced bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/37,39,42\">",
"     37,39,42",
"    </a>",
"    ]. At this time, there is little evidence from studies in children to indicate that vitamin D levels above the threshold of 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    are necessary to optimize calcium absorption or bone density.",
"   </p>",
"   <p>",
"    Based on these considerations, currently accepted standards for defining vitamin D status in children and adolescents are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin D sufficiency: 25(OH)D &ge;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Vitamin D insufficiency: 25(OH)D between 15 and 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (37.5 and 50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Vitamin D deficiency: 25(OH)D &le;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (37.5",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cut-offs may need to be revised if future pediatric studies demonstrate efficacy of higher 25(OH)D levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365759\">",
"    <span class=\"h1\">",
"     CAUSES OF VITAMIN D DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency is common in infants who are dark skinned and exclusively breast-fed beyond three to six months of age, particularly if there are additional risk factors such as maternal vitamin D deficiency during pregnancy or prematurity. Vitamin D deficiency is also common among children who are dark skinned and on vegetarian and unusual diets, use anticonvulsant or antiretroviral medications, or those with malabsorptive conditions. Additional risk factors include residence at higher latitudes, winter season, and other causes of low sun exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365767\">",
"    <span class=\"h2\">",
"     Decreased synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to sunlight, specifically UV-B, is essential for cutaneous vitamin D synthesis, and this is reduced in children with increased skin pigmentation in whom melanin functions as a natural sunblock. More UV-B radiation is present in the midday sun than at other times of the day. During the spring, summer, and fall, 10 to 15 minutes of sun exposure between 1000 to 1500 hours (10:00 AM and 3:00 PM) is sufficient for adequate vitamin D synthesis in light skinned individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"     1",
"    </a>",
"    ]. However, most Asian Indians require three times as much sun exposure as a light-skinned individual to achieve equivalent vitamin D concentrations, and individuals with very dark skin pigmentation (eg, some with African ancestry) require 6 to 10 times as much exposure as a light-skinned individual [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/31,43\">",
"     31,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall prevalence of vitamin D deficiency among racial groups is generally correlated with differences in skin pigmentation. As examples, in studies from the UK, the highest prevalence of vitamin D deficiency rickets has been reported in Black children, followed by Asian Indians, and then White children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/44\">",
"     44",
"    </a>",
"    ]. Data reported in the United States and in Canada are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. One study reported that 36 percent of Black teenagers in Boston, Massachusetts, had 25(OH)D levels of &lt;15",
"    <span class=\"nowrap\">",
"     ng/",
"    </span>",
"    mL (37.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/49\">",
"     49",
"    </a>",
"    ], and other studies have reported that 83 to 91 percent of children with rickets are dark-skinned [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. Even in a state such as Georgia, where sun exposure is high, 22 percent of minority children were noted to have 25(OH)D levels of &lt;20",
"    <span class=\"nowrap\">",
"     ng/",
"    </span>",
"    mL (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/51\">",
"     51",
"    </a>",
"    ]. Proportions were higher in non-Hispanic Black compared with Hispanic children. Data from NHANES (2001-2006) indicate that 92 percent of non-Hispanic Blacks and 80 percent of Hispanics have 25(OH)D levels of &lt;30",
"    <span class=\"nowrap\">",
"     ng/",
"    </span>",
"    mL (75",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    compared with 59 percent of non-Hispanic Whites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/6\">",
"     6",
"    </a>",
"    ]. Additionally, data from NHANES III indicate that non-Hispanic Black adolescents have 20 times the risk of having 25(OH)D levels of &lt;20",
"    <span class=\"nowrap\">",
"     ng/",
"    </span>",
"    mL (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    compared with non-Hispanic Whites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/7\">",
"     7",
"    </a>",
"    ], and the risk is higher in females compared with males.",
"   </p>",
"   <p>",
"    The latitude of residence and season are also important determinants of cutaneous vitamin D synthesis. During the winter months at high latitudes there is greater scatter and absorption of UV-B because of the oblique angle at which sunlight traverses the atmosphere and its longer path through the atmosphere. As a consequence, beyond a latitude of 40&deg; and during winter, little or no UV-B radiation reaches the surface of the earth. Therefore, while vitamin D deficiency is relatively uncommon at the end of the summer months, it is very common at the end of winter. In the Northern hemisphere, vitamin D levels typically reach their nadir in February and March. Even in the summer, excessive use of sunblock can cause a persistence of low vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/52\">",
"     52",
"    </a>",
"    ]. One study from Iowa (41&deg;N) reported that 25(OH)D levels were less than 11",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (27.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in 78 percent of unsupplemented breast-fed infants during winter, compared to only 1 percent in the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/53\">",
"     53",
"    </a>",
"    ]. In Edmonton, Canada (52&deg;N), 34 percent of children presenting to an emergency department at the end of winter had 25(OH)D levels less than 16",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    and 6 percent had levels less than 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, the prevalence of low vitamin D levels (&lt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    is as high as 48 percent in white prepubertal girls in the northern state of Maine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the natural sunscreen of deeper skin pigmentation, UV-B absorption is blocked by artificial sunscreens, and sunblock with an SPF of 30 can decrease vitamin D synthetic capacity by as much as 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/56\">",
"     56",
"    </a>",
"    ]. Other factors that can affect UV-B exposure are altitude and cloud cover, and exposure is higher at greater altitudes and in areas where cloud cover is less. Staying indoors for long periods can also cause reduced vitamin D synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/57\">",
"     57",
"    </a>",
"    ], and this can cause low Vitamin D levels in disabled children and children who stay primarily indoors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16833051\">",
"    <span class=\"h2\">",
"     Decreased nutritional intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary natural (unfortified) dietary sources of vitamin D are oily fish (salmon, mackerel, sardines), cod liver oil, liver and organ meats, and egg yolk. Few of these natural dietary sources are typically consumed by children consistently. The vitamin D content of breast milk is also low, as discussed below. (See",
"    <a class=\"local\" href=\"#H28181902\">",
"     'Exclusive breast feeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the scarcity of natural dietary sources, vitamin D is fortified in many foods, particularly milk and milk products, orange juice, bread, and cereals. Infant formulas in the United States are required to contain 40 to 100 int. units of vitamin",
"    <span class=\"nowrap\">",
"     D/100",
"    </span>",
"    kcal (usually providing at least 400 int. units per liter), and milk and orange juice that are labeled vitamin D-fortified are required to contain at least 400 int. units of vitamin",
"    <span class=\"nowrap\">",
"     D/liter.",
"    </span>",
"   </p>",
"   <p>",
"    Despite these measures and the availability of vitamin D-fortified milk and other products, the dietary intake of vitamin D is often insufficient. Factors accounting for this include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efforts to promote exclusive breast feeding without coincident efforts to promote use of vitamin D supplements in these infants",
"     </li>",
"     <li>",
"      Inadequate consumption of fortified milk and dairy products by older children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/32,59,60\">",
"       32,59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absence of standard regulations for vitamin D fortification across countries",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181880\">",
"    <span class=\"h2\">",
"     Perinatal factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181888\">",
"    <span class=\"h3\">",
"     Maternal vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D is transferred from the mother to the fetus across the placenta, and reduced vitamin D stores in the mother are associated with lower vitamin D levels in the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/45\">",
"     45",
"    </a>",
"    ]. Vitamin D deficiency is particularly common in dark-skinned pregnant mothers, especially those living at higher latitudes and in the winter months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181895\">",
"    <span class=\"h3\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D levels are particularly low in premature infants, who have less time to accumulate vitamin D from the mother through transplacental transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/64\">",
"     64",
"    </a>",
"    ]. The third trimester is a critical time for vitamin D transfer, because this is when the fetal skeleton becomes calcified, requiring increased activation of 25(OH)D to 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D in the maternal kidneys and placenta. Vitamin D deficiency in the mother during this period can cause fetal vitamin D deficiency, and in severe cases, fetal rickets. (See",
"    <a class=\"local\" href=\"#H722963\">",
"     'Vitamin D supplementation of pregnant women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181902\">",
"    <span class=\"h3\">",
"     Exclusive breast feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitamin D content of breast milk is low (15 to 50 int.",
"    <span class=\"nowrap\">",
"     units/L)",
"    </span>",
"    even in a vitamin D sufficient mother, and exclusively breast-fed infants consuming an average of 750 mL of breast milk daily ingest only 10 to 40 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of vitamin D in the absence of sun exposure or supplement use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1,65,66\">",
"     1,65,66",
"    </a>",
"    ]. The vitamin D content of breast milk is lower in mothers with dark skin or other causes of maternal vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/67\">",
"     67",
"    </a>",
"    ]. One study that included Black and White infants estimates that most breast-fed infants need to be exposed to sunlight for at least 30",
"    <span class=\"nowrap\">",
"     minutes/week",
"    </span>",
"    while wearing only a diaper in order to maintain 25(OH)D levels at &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/45\">",
"     45",
"    </a>",
"    ]. This amount of sun exposure is unlikely given current recommendations to limit sun exposure in infants younger than six months old. (See",
"    <a class=\"local\" href=\"#H723631\">",
"     'Exposure to sunlight'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One study reviewed 166 published cases of rickets in children 4 to 54 months old between 1986 and 2003, and reported that 96 percent of the affected children were breast-fed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/2\">",
"     2",
"    </a>",
"    ]. In another study from Alaska, 98 percent of infants with 25(OH)D levels &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were exclusively breast-fed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/68\">",
"     68",
"    </a>",
"    ]. In a third report, 25(OH)D levels were &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in 50 percent of infants at birth and 65 percent of their mothers, despite maternal intake of about 600 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    through vitamin D supplements and milk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although vitamin D deficiency is uncommon in formula fed infants because of the fortification of infant formulas, it can still occur if the infant had low vitamin D stores at birth because of maternal vitamin D deficiency and if the vitamin D content of the formula is insufficient to compensate for this. In one study, 50 percent of children with rickets at 0 to 5 years old who presented with hypocalcemic convulsions had been formula fed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H723639\">",
"     'Vitamin D supplementation for infants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365781\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inverse association exists between obesity and 25(OH)D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/21,69,70\">",
"     21,69,70",
"    </a>",
"    ], that has been attributed to the sequestration of Vitamin D in fat. Vitamin D requirements are thus higher in obese compared with normal weight adolescents. The clinical significance of low serum 25(OH)D levels in this group of patients is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical evaluation of the obese child and adolescent\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365788\">",
"    <span class=\"h2\">",
"     Malabsorption and other medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that impair fat absorption are associated with inadequate Vitamin D absorption from the gut as this process is chylomicron dependent. Rickets can therefore occur in children with celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/71\">",
"     71",
"    </a>",
"    ], inflammatory bowel disease, exocrine pancreatic insufficiency (as in cystic fibrosis), cholestasis, and following gut resection or bariatric surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Vitamin D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H16#H16\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver and kidney disease may be associated with deficient 25-hydroxylation and 1-hydroxylation, and therefore cause rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365795\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medications increase the risk for vitamin D deficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain anticonvulsants and antiretroviral drugs used to treat HIV infection can precipitate vitamin D deficiency by enhancing catabolism of 25(OH)D and 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of vitamin D deficiency and resistance\", section on 'Drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link&amp;anchor=H4#H4\">",
"       \"Bone and calcium disorders in HIV-infected patients\", section on 'Effects of medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin D requirements are higher in patients on glucocorticoids because they inhibit intestinal vitamin D-dependent calcium absorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of vitamin D\", section on 'Deficiency and resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/10/34976?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      and some other antifungal agents increase vitamin D requirements because they block 1-hydroxylation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365809\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF VITAMIN D DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency causes rickets in growing children, and osteomalacia in adolescents and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28182152\">",
"    <span class=\"h2\">",
"     Rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickets refers to a failure of mineralization of growing bone and cartilage and, depending on the severity, the child may be asymptomatic, or present with varying degrees of pain and irritability, motor delays, poor growth, and increased susceptibility to infections. Younger children may manifest with delayed closure of fontanelles, craniotabes, frontal bossing, prominence of costochondral junctions, widening of wrists and ankles, and bow legs or knock knees (genu valgum or varum). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiological features of rickets include low bone density, loss of the demarcation between the metaphyses and growth plate and loss of the provisional zone of calcification, widening of the growth plate (from proliferation of uncalcified cartilage and osteoid), and metaphyseal widening, splaying, cupping, and fraying (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53635 \" href=\"UTD.htm?12/45/13022\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"UTD.htm?40/15/41206\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28182168\">",
"    <span class=\"h2\">",
"     Osteomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older adolescents and adults, growth is complete, epiphyseal plates are fused, and there is usually reserve mineral, all of which help prevent bony deformities. Impaired mineralization in older children and adults causes osteomalacia, which may be asymptomatic or manifest as isolated or generalized muscle and bone pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28182175\">",
"    <span class=\"h2\">",
"     Biochemical changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency reduces intestinal calcium and phosphorus absorption. Parathyroid hormone (PTH) increases, leading to mobilization of calcium from bone so that serum calcium levels remain normal or are moderately decreased.",
"   </p>",
"   <p>",
"    Biochemical changes that characterize early, moderate, and severe vitamin D deficiency are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef56687 \" href=\"UTD.htm?33/1/33820\">",
"     table 1",
"    </a>",
"    ). With more severe vitamin D deficiency, calcium and phosphorus levels are normal or moderately decreased, 25(OH)D levels decrease, and PTH and ALP levels increase. 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D levels initially increase in response to rising levels of PTH, but may subsequently decrease because its substrate 25(OH)D is limited.",
"   </p>",
"   <p>",
"    Low serum phosphorus levels may cause muscle weakness and discomfort, and children may have difficulty standing or walking. Low phosphorus also prevents apoptosis of hypertrophic chondrocytes, causing disorganization of the growth plate. The reduced serum levels of calcium and phosphorus lead to a lower calcium-phosphorus product and the subsequent mineralization defects in growing children that are characteristic of rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of rickets in children\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced vitamin D-deficient rickets may develop severe hypocalcemia especially during periods of very rapid growth, such as infancy and adolescence, when increased calcium mobilization from bone from rising levels of PTH and 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D is unable to keep pace with increased calcium needs. This can lead to seizures or tetany, or may present as apneic spells, stridor, wheezing, hypotonia, and hyperreflexia, particularly in very young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365817\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR VITAMIN D INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for vitamin D intake are endorsed by the Institute of Medicine, the Endocrine Society and the American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All infants, including those who are exclusively breast-fed &ndash; 400 International Units (10 micrograms) daily, beginning within a few days after birth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"       1",
"      </a>",
"      ]. This intake is considered sufficient to prevent rickets and to maintain 25(OH)D levels at &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in most infants [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1,77\">",
"       1,77",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Healthy children 1 to 18 years of age &ndash; 600 International Units (15 micrograms) daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations reflect an increase over previous guidelines, which recommended intake of 200 int. units daily in infants and children. The intake of 200 int. units daily was designed to ensure serum 25(OH)D levels &gt;11",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (27.5",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    However, this target serum level was considered inadequate because these levels are not sufficient for preventing all cases of florid rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/35,36,78\">",
"     35,36,78",
"    </a>",
"    ], and because the risk of rickets decreases substantially when 25(OH)D levels exceed 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (37.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23366814\">",
"     'Children'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is limited evidence that fracture risk is associated with low levels of vitamin D intake. However, one large observational study found that vitamin D intake was associated with reduced risk of stress fractures among preadolescent and adolescent girls, particularly those participating in at least one",
"    <span class=\"nowrap\">",
"     hour/day",
"    </span>",
"    of high-impact activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/79\">",
"     79",
"    </a>",
"    ]. After adjusting for confounders, the risk of developing a stress fracture among girls in the highest quintile of vitamin D intake (mean intake 663 int. units daily) was 50 percent lower than the risk in girls with the lowest quintile of vitamin D intake (mean intake 107 int.",
"    <span class=\"nowrap\">",
"     units/day).",
"    </span>",
"    Although this study does not establish a causal association between vitamin D intake and fracture risk, the findings lend support to the recommended daily intake level of 600 int. units daily. Children who are obese and those on anticonvulsants, glucocorticoids, and on medications for HIV infection may require higher doses of vitamin D to maintain their vitamin D levels in the sufficient range (see",
"    <a class=\"local\" href=\"#H23365781\">",
"     'Obesity'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23365795\">",
"     'Medications'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722827\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723639\">",
"    <span class=\"h2\">",
"     Vitamin D supplementation for infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;All exclusively breast-fed infants should receive 400 int. units per day of Vitamin D supplements, as outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1,74,75\">",
"     1,74,75",
"    </a>",
"    ]. This recommendation is based on the low vitamin D content of breast milk, the inconsistency and unpredictability of cutaneous vitamin D synthesis from sun exposure, and the disproportionately high frequency of rickets among exclusively breast-fed infants (see",
"    <a class=\"local\" href=\"#H28181902\">",
"     'Exclusive breast feeding'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Many formula-fed infants should also receive vitamin D supplements. Currently, fortification practices in the United States ensure that infant formulas contain 40 to 100 int. units of vitamin D per 100 kcal of formula, providing at least 400 int. units per liter. Thus, formula-fed infants who consume at least 1 liter (33 oz) of formula daily meet the current AAP standards for vitamin D intake. However, most infants who are only partially formula-fed, and many infants who are fully formula-fed will consume less than this amount of formula, and should therefore receive supplemental vitamin D.",
"   </p>",
"   <p>",
"    Of concern, it appears that few infants in the United States are receiving sufficient vitamin D to meet the AAP recommendations. This is partly because pediatric health care providers in the United States are not routinely advising Vitamin D supplements for predominantly breast-fed infants. In one study, only 36 percent of responding clinicians indicated that they routinely recommended Vitamin D supplementation in predominantly breastfed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, an even smaller percentage of parents are actually giving vitamin D supplements to their infants. In the study cited above, 67 percent of parents indicated that they believed breast milk has all necessary nutrients, and only 3 percent gave supplements to their children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/80\">",
"     80",
"    </a>",
"    ]. Another study from the United States concluded that only 1 to 13 percent of infants received supplements per AAP recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/81\">",
"     81",
"    </a>",
"    ]. In this study, only 5 to 13 percent of breast-fed infants, 9 to 14 percent of mixed-fed infants, and 20 to 35 percent of formula fed infants met the 2008 AAP recommendations for intake of Vitamin D supplements.",
"   </p>",
"   <p>",
"    Awareness of and adherence to national recommendations for vitamin D supplementation also appears to be a problem in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Adherence is better in some other countries. In a Canadian study, 74 percent of mothers who exclusively breast-fed their infants indicated compliance with Canadian recommendations for vitamin D intake (also 400 int. units daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/86\">",
"     86",
"    </a>",
"    ]. Other reports describe that supplements are given as recommended to 59 percent of breast fed infants in Norway and 64 percent of those in Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, vitamin D supplementation may rarely trigger idiopathic infantile hypercalcemia (IIH), which is characterized by hypercalcemia, failure to thrive, vomiting, dehydration, and nephrocalcinosis. The disorder has been attributed to mutations in the gene encoding CYP24A1, an enzyme involved in vitamin D metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/89\">",
"     89",
"    </a>",
"    ]. The effect is dose-related, and the disorder is uncommon among infants given standard supplement doses of vitamin D. The risk and speed of developing symptomatic IIH appears to be greater in infants given bolus dosing of vitamin D (eg, 600,000 int. units every three months, as has been done in some countries).",
"   </p>",
"   <p>",
"    The current lack of information about the frequency of CYP24A1 mutations precludes a universal screening recommendation for IIH in infants given standard doses of vitamin D. However, infants should be evaluated for the possibility of IIH if they develop suspicious symptoms or have a family history of hypercalcemia. The first step in the evaluation is to measure serum 25(OH)D and calcium levels. If these levels are elevated (eg, 25(OH)D&gt;50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [72",
"    <span class=\"nowrap\">",
"     nmol/L],",
"    </span>",
"    calcium &gt;the upper limit of normal for age), then vitamin D supplements should be stopped and the infant should be further evaluated for evidence of IIH, which includes suppressed parathyroid hormone, hypercalcuria, and nephrocalcinosis.",
"   </p>",
"   <p>",
"    Another strategy to raise vitamin D levels in exclusively breast-fed infants without feeding them supplements is to administer high doses of vitamin D (4000 to 6400 int. units per day) to the lactating mother [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/77,90\">",
"     77,90",
"    </a>",
"    ]. This intervention sufficiently increases the vitamin D content of breast milk to allow sufficient vitamin D intake by the infant without causing hypervitaminosis D in the mother. More moderate vitamin D doses (eg, maternal intake of 1500 to 2000 int. units daily during pregnancy and lactation) are generally sufficient to maintain blood levels of vitamin D of &gt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the mother and will improve the infant's vitamin D status at birth. However, these doses may not result in sufficient vitamin D in breast milk to meet the infant&rsquo;s needs, and supplementation may still be necessary for the infant (see",
"    <a class=\"local\" href=\"#H722963\">",
"     'Vitamin D supplementation of pregnant women'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722841\">",
"    <span class=\"h2\">",
"     Vitamin D fortification of food",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, milk and orange juice are fortified with 400 int. units of vitamin D per liter. Consumption of at least one liter of fortified formula or beverages daily is usually sufficient to meet at least two-thirds of the current guidelines for daily vitamin D intake (600 int. units daily for children one year and older). However, many children do not consume this quantity of fortified beverages and may need supplementation to meet guidelines for vitamin D intake. This is particularly true if juice intake is limited because of its high content of sugar and calories, which have been implicated in the development of childhood obesity.",
"   </p>",
"   <p>",
"    Even 600 int. units per day of vitamin D may be insufficient to meet the needs of high risk populations. For example, studies from Mediterranean and Middle Eastern regions indicate that as much as 2000 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of vitamin D may be necessary to raise 25(OH)D levels to &gt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (75",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and maintain these levels over a year long period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The Canadian Pediatric Society recommends supplementation with 800 int. units daily of vitamin D for breast-fed infants living in northern communities during the winter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/93\">",
"     93",
"    </a>",
"    ]. The requirement for vitamin D may be even higher for infants of dark skinned mothers (unless these mothers received adequate vitamin D supplementation through pregnancy), and those who live in the higher latitudes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722963\">",
"    <span class=\"h2\">",
"     Vitamin D supplementation of pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;To optimize an infant&rsquo;s vitamin D status and bone health at birth, it is important to ensure that the pregnant mother has sufficient vitamin D intake throughout pregnancy. This is because maternal vitamin D crosses the placental barrier and builds up fetal stores of vitamin D, particularly during the third trimester. This is of greater concern in dark skinned women, those living in higher latitudes, and those whose cultural and religious practices include complete skin cover.",
"   </p>",
"   <p>",
"    In pregnant and lactating women, the recommended dietary allowance for vitamin D is 600 int. units daily, which is the same as for women who are not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/74\">",
"     74",
"    </a>",
"    ]. However, some studies suggest that this intake may not be adequate: One study of pregnant women in Finland found that 71 percent were vitamin D deficient (25(OH)D levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    despite an average vitamin D intake of almost 600 int. units daily; lower maternal 25(OH)D levels were also associated with some indicators of reduced fetal bone health [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/94\">",
"     94",
"    </a>",
"    ]. Other studies suggest that doses of vitamin D in excess of 1000 int. units per day are necessary to achieve 25(OH)D concentrations of &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in pregnant women, particularly in dark skinned women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/95-101\">",
"     95-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723631\">",
"    <span class=\"h2\">",
"     Exposure to sunlight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun exposure allows for cutaneous Vitamin D synthesis. During most seasons, 10 to 15 minutes of sun exposure near midday is sufficient for adequate vitamin D synthesis in light-skinned individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"     1",
"    </a>",
"    ]. However, darker skin pigmentation, winter season, or northern latitudes can markedly reduce skin synthesis of vitamin D and increase the need for dietary sources. (See",
"    <a class=\"local\" href=\"#H23365767\">",
"     'Decreased synthesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The advantage of sun exposure in providing vitamin D needs to be balanced against the potential risk for skin cancer from excessive exposure to ultraviolet radiation, particularly melanoma, which is one of the most common forms of cancer among young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/102\">",
"     102",
"    </a>",
"    ]. The latter is particularly concerning in light skinned individuals during the summer months, especially if there is a family history of skin cancer. These concerns have led to recommendations that direct sunlight exposure should be avoided for infants younger than six months old, and that sun exposure should be limited in older children, through the use of protective clothing and sunscreen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Deliberate exposure to sun or artificial sources of ultraviolet radiation should be avoided; outdoor activities should be encouraged for their value in providing exercise, but sun-safety should be emphasized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/104\">",
"     104",
"    </a>",
"    ]. Studies are necessary to assess the impact of these recommendations in dark skinned children, and it is possible that relaxation of these measures in dark skinned children will allow for sufficient cutaneous Vitamin D synthesis in the summer months, particularly in lower latitudes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365824\">",
"    <span class=\"h1\">",
"     SCREENING FOR VITAMIN D DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is recommended in populations at risk for vitamin D deficiency, but not for the population at large. We suggest screening the following patient groups, each of which has increased likelihood of rickets or osteopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and young children with nonspecific symptoms such as poor growth, gross motor delays, and unusual irritability (See",
"      <a class=\"local\" href=\"#H28182152\">",
"       'Rickets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dark-skinned infants and children who live at higher latitudes in the winter and spring months, particularly infants with a history of prematurity (See",
"      <a class=\"local\" href=\"#H23365767\">",
"       'Decreased synthesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28181880\">",
"       'Perinatal factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children on anticonvulsants or chronic glucocorticoids (See",
"      <a class=\"local\" href=\"#H23365795\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with chronic diseases that are associated with malabsorption, such as cystic fibrosis and inflammatory bowel disease (See",
"      <a class=\"local\" href=\"#H23365788\">",
"       'Malabsorption and other medical conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with low dietary intake of vitamin D, who are not taking supplements (See",
"      <a class=\"local\" href=\"#H16833051\">",
"       'Decreased nutritional intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with elevated levels of serum alkaline phosphatase (ALP) (eg, &gt;500 int.",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      in neonates or &gt;1000 int.",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      in children up to 9 years of age; ALP levels tend to decrease after puberty) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/105\">",
"       105",
"      </a>",
"      ] (See",
"      <a class=\"local\" href=\"#H28182175\">",
"       'Biochemical changes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some centers also routinely screen obese children for vitamin D deficiency. The best test for assessing vitamin D status is to measure 25(OH)D levels using a reliable assay. This may be a radioimmunoassay, HPLC, or",
"    <span class=\"nowrap\">",
"     LC-MS/MS.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H23366584\">",
"     'Vitamin D assays'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10577016\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"   </p>",
"   <p>",
"    The possibility of rickets should be considered in growing children with vitamin D levels below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    For these children who are at higher risk for rickets, the evaluation should include measurements of serum calcium, phosphorus, ALP, and parathyroid hormone (PTH) (",
"    <a class=\"graphic graphic_table graphicRef56687 \" href=\"UTD.htm?33/1/33820\">",
"     table 1",
"    </a>",
"    ). Radiographic evaluation for rickets should be performed if the child is young or if there is a high clinical suspicion of rickets, based on risk factors or physical signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of rickets in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rickets can be further classified as calcipenic (hypocalcemic) or hypophosphatemic rickets. Isolated vitamin D deficiency typically causes calcipenic rickets, but other causes of rickets may coexist in the same patient and should be considered. The detailed evaluation of a patient with rickets is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365861\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10576904\">",
"    <span class=\"h2\">",
"     Dosing and forms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16834525\">",
"    <span class=\"h3\">",
"     Vitamin D deficiency or insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D replacement therapy is necessary for children presenting with low vitamin D levels (25(OH)D &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L))",
"    </span>",
"    or rickets. A variety of dosing schemes are used in clinical practice for vitamin D replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/1,75\">",
"     1,75",
"    </a>",
"    ]. In our practice, we use the following doses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &lt;1 month old: 1000 int.",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      for six weeks, followed by maintenance dosing of at least 400 int.",
"      <span class=\"nowrap\">",
"       units/day.",
"      </span>",
"      Commonly available preparations are Calciferol or Drisdol oral solution, 8000 int.",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Infants 1 to 12 months old: 1000 to 2000 int.",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      for six weeks, followed by maintenance dosing of at least 400 int.",
"      <span class=\"nowrap\">",
"       units/day.",
"      </span>",
"     </li>",
"     <li>",
"      Children &gt;12 months old: 2000 int.",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      for six weeks, or 50,000 int. units per week for six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/106\">",
"       106",
"      </a>",
"      ], followed by maintenance dosing of 600 to 1000 int.",
"      <span class=\"nowrap\">",
"       units/day.",
"      </span>",
"     </li>",
"     <li>",
"      Children with obesity, malabsorptive diseases, or those on medications that impact vitamin D metabolism may require higher replacement doses (two to three times higher than in children without these conditions), followed by higher maintenance dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23365781\">",
"       'Obesity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23365788\">",
"       'Malabsorption and other medical conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23365795\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with elevated levels of parathyroid hormone (PTH) or clinical evidence of rickets, calcium should be supplemented along with vitamin D. This is because vitamin D replacement and a normalization of PTH levels can precipitate hypocalcemia by suppressing bone resorption and from increased bone mineralization, also referred to as the \"hungry bone\" syndrome. Hence, calcium replacement is necessary along with vitamin D replacement and should be given at doses of 30 to 75",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of elemental calcium given in two to three divided doses for two to four weeks, until vitamin D doses have been reduced to maintenance levels of 600 to 1000 int. units daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with symptomatic hypocalcemia (including seizures or tetany), one or more intravenous boluses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    may be necessary at a dose of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental calcium administered slowly intravenously over 5 to 10 minutes (1 to 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 10 percent calcium gluconate) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D may be administered as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=see_link\">",
"     vitamin D2 (ergocalciferol)",
"    </a>",
"    or as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/4/33862?source=see_link\">",
"     vitamin D3 (cholecalciferol)",
"    </a>",
"    . The potency of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/4/33862?source=see_link\">",
"     vitamin D3",
"    </a>",
"    in relation to vitamin D",
"    <sub>",
"     2",
"    </sub>",
"    remains somewhat controversial. Typically, the two forms of vitamin D are used interchangeably, although some studies indicate that vitamin D3 may be more potent than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=see_link\">",
"     vitamin D2",
"    </a>",
"    and cause two to three-fold greater storage of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Liquid vitamin D preparations containing 8000 int.",
"    <span class=\"nowrap\">",
"     units/",
"    </span>",
"    mL of Vitamin D2 are available, as are gelatin capsules containing 50,000 int. units.",
"   </p>",
"   <p>",
"    Short-term administration of high dose vitamin D, known as &ldquo;stoss therapy&rdquo;, is an effective alternative. A single dose of 600,000 int. units of vitamin D as an intramuscular injection is an excellent solution for persistent non-compliance; however, this vitamin D preparation is no longer available in the US. Some studies have reported administering 100,000 to 600,000 int. units of vitamin D orally over a period of one to five days for infants and children older than one month of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/38/28266/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], followed by maintenance dosing. If such an approach is chosen, it is important to use oral preparations that do not contain propylene glycol because this can be toxic in high concentrations. Tablets containing 25,000 to 50,000 int. units of vitamin D may be crushed, or a 50,000 int. units capsule soaked in water to soften this before administering the softened capsule in blended food. Liquid preparations often contain propylene glycol, and should be avoided for &ldquo;stoss&rdquo; dosing.",
"   </p>",
"   <p>",
"    Administration of calcitriol (1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D) is not necessary, except in conditions of severe vitamin D deficiency with severe symptomatic hypocalcemia. In such situations, calcitriol administration at a dose of 20 to 100",
"    <span class=\"nowrap\">",
"     ng/kg/day",
"    </span>",
"    with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    and high doses of vitamin D may normalize plasma calcium levels more rapidly than standard vitamin D treatments. However, calcitriol plays no role in building up vitamin D stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16834539\">",
"    <span class=\"h3\">",
"     Borderline vitamin D levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, vitamin D levels above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have not been associated with adverse clinical effects in children. However, studies in adults have shown impaired calcium absorption and lower bone density at 25(OH)D levels between 20 and 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50 to 75",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    and additional studies are needed to examine these issues more carefully in children (see",
"    <a class=\"local\" href=\"#H23366630\">",
"     'Defining vitamin D sufficiency'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Based on currently available data, we do not usually give vitamin D replacement therapy to infants or children for low-normal vitamin D levels (25(OH)D between 20 and 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50 to 75",
"    <span class=\"nowrap\">",
"     nmol/L)),",
"    </span>",
"    unless there are other signs of vitamin D deficiency or important risk factors (eg, very low nutritional intake or perinatal risk factors) (see",
"    <a class=\"local\" href=\"#H23365759\">",
"     'Causes of vitamin D deficiency'",
"    </a>",
"    above). However, the diets of such children should be reviewed, and vitamin D supplements should be given as needed to meet current intake recommendations. We also suggest monitoring 25(OH)D levels in these children periodically, and initiating treatment if levels fall below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H23365817\">",
"     'Recommendations for vitamin D intake'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10576931\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rickets require close follow-up to document radiographic healing, normalization of serum 25(OH)D, PTH, calcium and phosphorus levels, and long-term maintenance of vitamin D sufficiency. Recovery is associated with an initial increase in serum phosphate, alkaline phosphatase (ALP) and 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D levels, followed by a gradual normalization of ALP; PTH; 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D; and 25(OH)D levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without rickets but with low vitamin D levels and biochemical changes such as elevated ALP levels or PTH levels should also be monitored to ensure treatment adherence. We generally check serum 25(OH)D levels and other chemistries after six to eight weeks of high-dose therapy, then again after several months of maintenance therapy, then annually thereafter. It is important to monitor 25(OH)D levels to ensure that vitamin D requirements continue to be met after vitamin D deficiency has been treated, particularly in high risk population groups.",
"   </p>",
"   <p>",
"    Patients presenting with only low levels of vitamin D and no other biochemical changes or evidence of rickets require less intense monitoring. In our practice, we generally check 25(OH)D levels after two to three months, then as needed thereafter, depending on the adequacy of the patient&rsquo;s intake and adherence to maintenance supplements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=see_link\">",
"       \"Patient information: Vitamin D for babies and children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23365869\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Groups at risk for vitamin D deficiency include premature infants or exclusively breast-fed infants (unless they are reliably taking supplements of 400 int. units daily), dark-skinned children on vegetarian and unusual diets, children living at higher latitudes, and children with conditions of malabsorption or those who are taking certain medications. (See",
"      <a class=\"local\" href=\"#H23365759\">",
"       'Causes of vitamin D deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants and children with the above risk factors, we suggest laboratory screening for vitamin D deficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Screening is accomplished by measuring 25(OH)D levels. (See",
"      <a class=\"local\" href=\"#H23365824\">",
"       'Screening for vitamin D deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standards for defining vitamin D status in children are not well established. The most common definitions are: (See",
"      <a class=\"local\" href=\"#H23366630\">",
"       'Defining vitamin D sufficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vitamin D sufficiency: 25(OH)D &ge;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Vitamin D insufficiency: 25(OH)D between 16 and 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (40 to 50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Vitamin D deficiency: 25(OH)D &le;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (37.5",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All infants and children (including adolescents) should receive at least 400 International Units (int. units; IU) daily of vitamin D beginning soon after birth. The Institute of Medicine now recommends a higher intake of 600 int. units of vitamin D daily for healthy children between 1 and 18 years of age. High risk groups may have a higher requirement of vitamin D to maintain 25(OH)D levels in the sufficient range. (See",
"      <a class=\"local\" href=\"#H23365817\">",
"       'Recommendations for vitamin D intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For exclusively breast-fed infants we recommend vitamin D supplementation providing 400 int. units daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Infants who are partially formula-fed usually also require supplementation unless their formula intake is &gt;1000 mL (33 oz) daily. Use of supplements in purely breast-feeding neonates and infants may be avoided if maternal intake of vitamin D is 4000 to 6000 int.",
"      <span class=\"nowrap\">",
"       units/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H723639\">",
"       'Vitamin D supplementation for infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants and children with 25(OH)D levels below 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we recommend vitamin D repletion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In our practice, we use a six-week course of vitamin D replacement at doses ranging from 1000 to 2000 int. units per day, depending on the degree of deficiency and the age of the individual, followed by maintenance dosing of 600 to 1000 int.",
"      <span class=\"nowrap\">",
"       units/day.",
"      </span>",
"      Some children may require higher doses. Either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) may be used. A variety of other dosing schemes are also effective for children older than one year, including use of 50,000 int. units weekly for six weeks. (See",
"      <a class=\"local\" href=\"#H10576904\">",
"       'Dosing and forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After treatment for vitamin D deficiency, follow-up laboratory testing is important to verify response and adherence to treatment, and that normal vitamin D levels are sustained on maintenance dosing. (See",
"      <a class=\"local\" href=\"#H10576931\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/1\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/2\">",
"      Weisberg P, Scanlon KS, Li R, Cogswell ME. Nutritional rickets among children in the United States: review of cases reported between 1986 and 2003. Am J Clin Nutr 2004; 80:1697S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/3\">",
"      McAllister JC, Lane AT, Buckingham BA. Vitamin D deficiency in the San Francisco Bay Area. J Pediatr Endocrinol Metab 2006; 19:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/4\">",
"      Mylott BM, Kump T, Bolton ML, Greenbaum LA. Rickets in the Dairy State. WMJ 2004; 103:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/5\">",
"      Shah M, Salhab N, Patterson D, Seikaly MG. Nutritional rickets still afflict children in north Texas. Tex Med 2000; 96:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/6\">",
"      Mansbach JM, Ginde AA, Camargo CA Jr. Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: do children need more vitamin D? Pediatrics 2009; 124:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/7\">",
"      Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial us adolescent population: the National Health and Nutrition Examination Survey III. Pediatrics 2009; 123:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/8\">",
"      Gordon CM, Feldman HA, Sinclair L, et al. Prevalence of vitamin D deficiency among healthy infants and toddlers. Arch Pediatr Adolesc Med 2008; 162:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/9\">",
"      Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/10\">",
"      Willis JA, Scott RS, Darlow BA, et al. Seasonality of birth and onset of clinical disease in children and adolescents (0-19 years) with type 1 diabetes mellitus in Canterbury, New Zealand. J Pediatr Endocrinol Metab 2002; 15:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/11\">",
"      Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/12\">",
"      Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/13\">",
"      Mersch PP, Middendorp HM, Bouhuys AL, et al. Seasonal affective disorder and latitude: a review of the literature. J Affect Disord 1999; 53:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/14\">",
"      R&auml;s&auml;nen P, Hakko H, J&auml;rvelin MR. Prenatal and perinatal risk factors for psychiatric diseases of early onset. Results are different if seasons are categorised differently. BMJ 1999; 318:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/15\">",
"      Bodiwala D, Luscombe CJ, French ME, et al. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 2003; 24:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/16\">",
"      Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/17\">",
"      Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990; 19:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/18\">",
"      Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002; 94:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/19\">",
"      Pritchard RS, Baron JA, Gerhardsson de Verdier M. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev 1996; 5:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/20\">",
"      Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/21\">",
"      Reis JP, von M&uuml;hlen D, Miller ER 3rd, et al. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009; 124:e371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/22\">",
"      Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/23\">",
"      Fox AT, Du Toit G, Lang A, Lack G. Food allergy as a risk factor for nutritional rickets. Pediatr Allergy Immunol 2004; 15:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/24\">",
"      Allen KJ, Koplin JJ, Ponsonby AL, et al. Vitamin D insufficiency is associated with challenge-proven food allergy in infants. J Allergy Clin Immunol 2013; 131:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/25\">",
"      Muehleisen B, Gallo RL. Vitamin D in allergic disease: shedding light on a complex problem. J Allergy Clin Immunol 2013; 131:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/26\">",
"      Camargo CA Jr, Clark S, Kaplan MS, et al. Regional differences in EpiPen prescriptions in the United States: the potential role of vitamin D. J Allergy Clin Immunol 2007; 120:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/27\">",
"      Brehm JM, Celed&oacute;n JC, Soto-Quiros ME, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009; 179:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/28\">",
"      Gupta A, Bush A, Hawrylowicz C, Saglani S. Vitamin D and asthma in children. Paediatr Respir Rev 2012; 13:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/29\">",
"      Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/30\">",
"      de la Hunty A, Wallace AM, Gibson S, et al. UK Food Standards Agency Workshop Consensus Report: the choice of method for measuring 25-hydroxyvitamin D to estimate vitamin D status for the UK National Diet and Nutrition Survey. Br J Nutr 2010; 104:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/31\">",
"      Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/32\">",
"      Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/33\">",
"      Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/34\">",
"      Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003; 88:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/35\">",
"      Kreiter SR, Schwartz RP, Kirkman HN Jr, et al. Nutritional rickets in African American breast-fed infants. J Pediatr 2000; 137:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/36\">",
"      Spence JT, Serwint JR. Secondary prevention of vitamin D-deficiency rickets. Pediatrics 2004; 113:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/37\">",
"      Outila TA, K&auml;rkk&auml;inen MU, Lamberg-Allardt CJ. Vitamin D status affects serum parathyroid hormone concentrations during winter in female adolescents: associations with forearm bone mineral density. Am J Clin Nutr 2001; 74:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/38\">",
"      Jones G, Blizzard C, Riley MD, et al. Vitamin D levels in prepubertal children in Southern Tasmania: prevalence and determinants. Eur J Clin Nutr 1999; 53:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/39\">",
"      Jones G, Dwyer T, Hynes KL, et al. Vitamin D insufficiency in adolescent males in Southern Tasmania: prevalence, determinants, and relationship to bone turnover markers. Osteoporos Int 2005; 16:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/40\">",
"      Pettifor JM, Isdale JM, Sahakian J, Hansen JD. Diagnosis of subclinical rickets. Arch Dis Child 1980; 55:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/41\">",
"      Goel KM, Sweet EM, Logan RW, et al. Florid and subclinical rickets among immigrant children in Glasgow. Lancet 1976; 1:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/42\">",
"      Cheng S, Tylavsky F, Kr&ouml;ger H, et al. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr 2003; 78:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/43\">",
"      Holick MF. Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. Fed Proc 1987; 46:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/44\">",
"      Callaghan AL, Moy RJ, Booth IW, et al. Incidence of symptomatic vitamin D deficiency. Arch Dis Child 2006; 91:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/45\">",
"      Specker BL, Valanis B, Hertzberg V, et al. Sunshine exposure and serum 25-hydroxyvitamin D concentrations in exclusively breast-fed infants. J Pediatr 1985; 107:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/46\">",
"      Stein EM, Laing EM, Hall DB, et al. Serum 25-hydroxyvitamin D concentrations in girls aged 4-8 y living in the southeastern United States. Am J Clin Nutr 2006; 83:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/47\">",
"      Harkness L, Cromer B. Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos Int 2005; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/48\">",
"      Binet A, Kooh SW. Persistence of Vitamin D-deficiency rickets in Toronto in the 1990s. Can J Public Health 1996; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/49\">",
"      Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/50\">",
"      Cosgrove L, Dietrich A. Nutritional rickets in breast-fed infants. J Fam Pract 1985; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/51\">",
"      Cole CR, Grant FK, Tangpricha V, et al. 25-hydroxyvitamin D status of healthy, low-income, minority children in Atlanta, Georgia. Pediatrics 2010; 125:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/52\">",
"      Sullivan S, Rosen C, Chen T, et al. Seasonal changes in serum 25(OH)D in adolescent girls in Maine [meeting abstract]. J Bone Mineral Res 2003; 18(Suppl 2):S407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/53\">",
"      Ziegler EE, Hollis BW, Nelson SE, Jeter JM. Vitamin D deficiency in breastfed infants in Iowa. Pediatrics 2006; 118:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/54\">",
"      Roth DE, Martz P, Yeo R, et al. Are national vitamin D guidelines sufficient to maintain adequate blood levels in children? Can J Public Health 2005; 96:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/55\">",
"      Sullivan SS, Rosen CJ, Halteman WA, et al. Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc 2005; 105:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/56\">",
"      Matsuoka LY, Ide L, Wortsman J, et al. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 1987; 64:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/57\">",
"      Tangpricha V, Turner A, Spina C, et al. Tanning is associated with optimal vitamin D status (serum 25-hydroxyvitamin D concentration) and higher bone mineral density. Am J Clin Nutr 2004; 80:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/58\">",
"      Del Arco C, Riancho JA, Luzuriaga C, et al. Vitamin D status in children with Down's syndrome. J Intellect Disabil Res 1992; 36 ( Pt 3):251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/59\">",
"      Bowman SA. Beverage choices of young females: changes and impact on nutrient intakes. J Am Diet Assoc 2002; 102:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/60\">",
"      Greer FR, Krebs NF, American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/61\">",
"      Hollis BW, Wagner CL. Vitamin D deficiency during pregnancy: an ongoing epidemic. Am J Clin Nutr 2006; 84:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/62\">",
"      Lee JM, Smith JR, Philipp BL, et al. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr (Phila) 2007; 46:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/63\">",
"      van der Meer IM, Karamali NS, Boeke AJ, et al. High prevalence of vitamin D deficiency in pregnant non-Western women in The Hague, Netherlands. Am J Clin Nutr 2006; 84:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/64\">",
"      Greer FR. Fat-soluble vitamin supplements for enterally fed preterm infants. Neonatal Netw 2001; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/65\">",
"      Henderson A. Vitamin D and the breastfed infant. J Obstet Gynecol Neonatal Nurs 2005; 34:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/66\">",
"      SECTION ON BREASTFEEDING. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/67\">",
"      Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child 1985; 139:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/68\">",
"      Gessner BD, Plotnik J, Muth PT. 25-hydroxyvitamin D levels among healthy children in Alaska. J Pediatr 2003; 143:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/69\">",
"      Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/70\">",
"      Harel Z, Flanagan P, Forcier M, Harel D. Low vitamin D status among obese adolescents: prevalence and response to treatment. J Adolesc Health 2011; 48:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/71\">",
"      Pazianas M, Butcher GP, Subhani JM, et al. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos Int 2005; 16:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/72\">",
"      Lehmann B, Rudolph T, Pietzsch J, Meurer M. Conversion of vitamin D3 to 1alpha,25-dihydroxyvitamin D3 in human skin equivalents. Exp Dermatol 2000; 9:97.",
"     </a>",
"    </li>",
"    <li>",
"     Pettifor JM. Nutritional and drug-induced rickets and osteomalacia. In: Primer on the Metabolic and Bone Diseases and Disorders of Bone Metabolism, 6th ed, Favus MJ (Ed), American Society for Bone and Mineral Research, Washington, DC 2006. p.399.",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. National Academy Press, Washington, DC 2010. Available at: file://books.nap.edu/openbook.php?record_id=13050. (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/75\">",
"      Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/76\">",
"      Dietary reference intakes for calcium and vitamin d. Pediatrics 2012; 130:e1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/77\">",
"      Wagner CL, Hulsey TC, Fanning D, et al. High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study. Breastfeed Med 2006; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/78\">",
"      Greer FR. Issues in establishing vitamin D recommendations for infants and children. Am J Clin Nutr 2004; 80:1759S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/79\">",
"      Sonneville KR, Gordon CM, Kocher MS, et al. Vitamin d, calcium, and dairy intakes and stress fractures among female adolescents. Arch Pediatr Adolesc Med 2012; 166:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/80\">",
"      Taylor JA, Geyer LJ, Feldman KW. Use of supplemental vitamin d among infants breastfed for prolonged periods. Pediatrics 2010; 125:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/81\">",
"      Perrine CG, Sharma AJ, Jefferds ME, et al. Adherence to vitamin D recommendations among US infants. Pediatrics 2010; 125:627.",
"     </a>",
"    </li>",
"    <li>",
"     Update on Vitamin D: Position statement by the Scientific Advisory Committee on Nutrition. The Stationery Office, London, 2007. Available at: file://www.sacn.gov.uk/pdfs/sacn_position_vitamin_d_2007_05_07.pdf (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/83\">",
"      Williamson S, Greene S. Rickets: Prevention message is not getting through. BMJ 2007; 334:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/84\">",
"      Ahmed SF, Franey C, McDevitt H, et al. Recent trends and clinical features of childhood vitamin D deficiency presenting to a children's hospital in Glasgow. Arch Dis Child 2011; 96:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/85\">",
"      Davies JH, Shaw NJ. Preventable but no strategy: vitamin D deficiency in the UK. Arch Dis Child 2011; 96:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/86\">",
"      Gallo S, Jean-Philippe S, Rodd C, Weiler HA. Vitamin D supplementation of Canadian infants: practices of Montreal mothers. Appl Physiol Nutr Metab 2010; 35:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/87\">",
"      Lande B, Andersen LF, Baerug A, et al. Infant feeding practices and associated factors in the first six months of life: the Norwegian infant nutrition survey. Acta Paediatr 2003; 92:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/88\">",
"      Dratva J, Merten S, Ackermann-Liebrich U. Vitamin D supplementation in Swiss infants. Swiss Med Wkly 2006; 136:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/89\">",
"      Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011; 365:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/90\">",
"      Basile LA, Taylor SN, Wagner CL, et al. The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants. Breastfeed Med 2006; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/91\">",
"      El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006; 91:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/92\">",
"      Maalouf J, Nabulsi M, Vieth R, et al. Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab 2008; 93:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/93\">",
"      Vitamin D supplementation: Recommendations for Canadian mothers and infants. Paediatr Child Health 2007; 12:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/94\">",
"      Viljakainen HT, Saarnio E, Hytinantti T, et al. Maternal vitamin D status determines bone variables in the newborn. J Clin Endocrinol Metab 2010; 95:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/95\">",
"      Brooke OG, Brown IR, Bone CD, et al. Vitamin D supplements in pregnant Asian women: effects on calcium status and fetal growth. Br Med J 1980; 280:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/96\">",
"      Cockburn F, Belton NR, Purvis RJ, et al. Maternal vitamin D intake and mineral metabolism in mothers and their newborn infants. Br Med J 1980; 281:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/97\">",
"      Delvin EE, Salle BL, Glorieux FH, et al. Vitamin D supplementation during pregnancy: effect on neonatal calcium homeostasis. J Pediatr 1986; 109:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/98\">",
"      Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/99\">",
"      Mallet E, G&uuml;gi B, Brunelle P, et al. Vitamin D supplementation in pregnancy: a controlled trial of two methods. Obstet Gynecol 1986; 68:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/100\">",
"      Maxwell JD, Ang L, Brooke OG, Brown IR. Vitamin D supplements enhance weight gain and nutritional status in pregnant Asians. Br J Obstet Gynaecol 1981; 88:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/101\">",
"      Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/102\">",
"      Balk SJ, Council on Environmental Health, Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:e791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/103\">",
"      Ultraviolet light: a hazard to children. American Academy of Pediatrics. Committee on Environmental Health. Pediatrics 1999; 104:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/104\">",
"      Council on Environmental Health, Balk SJ. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/105\">",
"      Wharton B, Bishop N. Rickets. Lancet 2003; 362:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/106\">",
"      Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351:805.",
"     </a>",
"    </li>",
"    <li>",
"     Root AW, Diamone FB. Disorders of mineral homeostasis in the newborn, infant, child, and adolescent. In: Pediatric Endocrinology, 3rd ed, Sperling MA (Ed), Saunders, Philadelphia 2008. p.699.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/108\">",
"      Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/109\">",
"      Heaney RP, Recker RR, Grote J, et al. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011; 96:E447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/110\">",
"      Hochberg Z, Bereket A, Davenport M, et al. Consensus development for the supplementation of vitamin D in childhood and adolescence. Horm Res 2002; 58:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/38/28266/abstract/111\">",
"      Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr 1994; 125:487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14590 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28266=[""].join("\n");
var outline_f27_38_28266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23365869\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365743\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23366428\">",
"      METABOLISM AND FORMS OF VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23366564\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365751\">",
"      MEASUREMENT OF VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23366584\">",
"      Vitamin D assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23366630\">",
"      Defining vitamin D sufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23366807\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23366814\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365759\">",
"      CAUSES OF VITAMIN D DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23365767\">",
"      Decreased synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16833051\">",
"      Decreased nutritional intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28181880\">",
"      Perinatal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28181888\">",
"      - Maternal vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28181895\">",
"      - Prematurity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28181902\">",
"      - Exclusive breast feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23365781\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23365788\">",
"      Malabsorption and other medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23365795\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365809\">",
"      CLINICAL MANIFESTATIONS OF VITAMIN D DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28182152\">",
"      Rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28182168\">",
"      Osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28182175\">",
"      Biochemical changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365817\">",
"      RECOMMENDATIONS FOR VITAMIN D INTAKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H722827\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723639\">",
"      Vitamin D supplementation for infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722841\">",
"      Vitamin D fortification of food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722963\">",
"      Vitamin D supplementation of pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723631\">",
"      Exposure to sunlight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365824\">",
"      SCREENING FOR VITAMIN D DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10577016\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365861\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10576904\">",
"      Dosing and forms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16834525\">",
"      - Vitamin D deficiency or insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16834539\">",
"      - Borderline vitamin D levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10576931\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23365869\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14590|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/45/13022\" title=\"diagnostic image 1\">",
"      Vit D deficiency rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/15/41206\" title=\"diagnostic image 2\">",
"      Rickets wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14590|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/23/20862\" title=\"figure 1\">",
"      Vit D metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/1/33820\" title=\"table 1\">",
"      Laboratory findings in vitamin D deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=related_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_38_28267="Comparison Dx tests Hirschsprun";
var content_f27_38_28267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of sensitivity and specificity for rectal suction biopsy, contrast enema, and anorectal manometry in the diagnosis of Hirschsprung disease in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Rectal suction biopsy",
"       </td>",
"       <td>",
"        93 percent",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (95% CI, 77 - 98 percent)",
"       </td>",
"       <td>",
"        (95% CI, 96 - 100 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Contrast enema",
"       </td>",
"       <td>",
"        76 percent",
"       </td>",
"       <td>",
"        97 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (95% CI, 57 - 89 percent)",
"       </td>",
"       <td>",
"        (95% CI, 91 - 99 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Anorectal manometry",
"       </td>",
"       <td>",
"        83 percent",
"       </td>",
"       <td>",
"        93 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (95% CI, 63 - 93 percent)",
"       </td>",
"       <td>",
"        (95% CI, 85 - 97 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Diagnosis was confirmed by full-thickness rectal biopsy and exluded by clinical follow-up for at least six months.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: De Lorijn, F, Reitsma, JB, Voskuijl, WP, et al. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. J Pediatr 2005; 146:787.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28267=[""].join("\n");
var outline_f27_38_28267=null;
var title_f27_38_28268="Rush fire ant immunotherapy";
var content_f27_38_28268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of fire ant rush protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Day",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dilution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Color vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        Silver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        Silver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This protocol (Willford Hall protocol) was developed for administration of immunotherapy using whole body extract of imported fire ants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109:556.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28268=[""].join("\n");
var outline_f27_38_28268=null;
var title_f27_38_28269="Mortality in VT after MI";
var content_f27_38_28269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stable VT after acute MI predicts mortality sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 222px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial curves for sudden cardiac death (SCD) and total mortality after electrophysiologically-guided pharmacologic therapy or electrophysiologic map-guided surgery in 124 patients with stable SMVT two weeks or more after a myocardial infarction (MI). The patients had a high annual total mortality (11 percent) but a relatively low annual SCD mortality (2.4 percent); there was no difference between the medical and surgical groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sarter BH, Finkle JK, Gerszten RE, et al. J Am Coll Cardiol 1996; 28:122.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28269=[""].join("\n");
var outline_f27_38_28269=null;
var title_f27_38_28270="Influenza hospitalization by age";
var content_f27_38_28270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Cumulative rate of hospitalizations during three influenza seasons, by age group - Emerging Infections Program, United States, 2007-2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 365px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 2009 pandemic influenza A (H1N1) hospitalization data from September 1, 2009-January 21, 2010.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Per 10,000 population.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28270=[""].join("\n");
var outline_f27_38_28270=null;
var title_f27_38_28271="Anatomic etiologic risk";
var content_f27_38_28271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Anatomic etiologic risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sidhartha Tan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_38_28271=[""].join("\n");
var outline_f27_38_28271=null;
